0001932393-24-000013 | 10-K | XBRL Viewer | GE Healthcare Technologies INC

Print Document View Excel Document

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Other Income (Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net interest and investment income (expense)	$ 26	$ (9)	$ 34
Equity method income (loss)	11	13	27
Change in fair value of assumed obligations	(32)	0	0
Other items, net	81	58	62
Total other income (expense) – net	$ 86	$ 62	$ 123

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Current and Non Current Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Employee compensation and benefit liabilities	$ 1,518	$ 853
Sales allowances and related liabilities	228	243
Uncertain and other income taxes and related liabilities	260	237
Product warranties	192	193
Accrued freight and utilities	132	150
Operating lease liabilities	110	104
Derivative instruments	128	86
Interest payable on borrowings	87	52
Environmental and asset retirement obligations	21	34
Other	335	238
Contract liabilities, noncurrent	705	630
Operating lease liabilities	273	243
Environmental and asset retirement obligations	265	251
Uncertain and other income taxes and related liabilities	208	182
Derivative instruments	136	119
Finance lease obligations	$ 38	$ 39
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	All other non-current liabilities	All other non-current liabilities
Sales allowances and related liabilities	$ 27	$ 26
Other	225	113
All other non-current liabilities	1,877	1,603
Nonrelated party
Related Party Transaction [Line Items]
All other current liabilities	$ 3,011	$ 2,190

LEASES - Schedule of Lease, Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Long-term (fixed)	$ 121	$ 115	$ 114
Long-term (variable)	106	98	67
Short-term	2	4	4
Total operating lease expense	$ 229	$ 217	$ 185

RELATED PARTIES

12 Months Ended

Dec. 31, 2023

RELATED PARTIES

PRIOR TO SPIN-OFF.

Prior to the Spin-Off, GE provided the Company with significant corporate infrastructure and shared services. Some of these services continue to be provided by GE to the Company on a temporary basis under the Transition Services Agreement, as discussed below. The following disclosures summarize related party activity between GE HealthCare and GE. This activity, which occurred prior to the Spin-Off, is included in the combined financial statements.

Pensions, Benefit, and Contribution Plans

As discussed in Note 10, “Postretirement Benefit Plans”, employees of the Company participated in pensions, benefit, and contribution plans that were sponsored by GE. The Company was charged $207 million and $237 million for the years ended December 31, 2022 and 2021, respectively, related to employee participation in these plans. In connection with the Spin-Off, a portion of the plans was transferred to the Company.

Share-based Compensation

GE granted various employee benefits to its group employees, including those of the Company, under the GE Long-Term Incentive Plan. These benefits primarily included stock options and restricted stock units. Compensation expense allocated to the Company was $67 million and $76 million for the years ended December 31, 2022 and 2021, respectively, and is primarily recognized within SG&A in the Combined Statements of Income.

Corporate Overhead and Other Allocations from GE

GE provided certain services described below that were charged to the Company based on employee headcount, revenue, or other allocation methodologies.


Corporate Allocations from GE	For the years ended
	December 31, 2022		December 31, 2021
Costs for centralized services(1)	$	42	$	56
Costs associated with employee medical insurance(2)	122		132
Costs for corporate and shared services(3)	457		455

(1) Costs for centralized services such as public relations, treasury and cash management, and other services were recognized within SG&A in the Combined Statements of Income.

(2) Costs associated with employee medical insurance were recognized within Cost of products, Cost of services, SG&A, and R&D in the Combined Statements of Income based on the employee population.

(3) Costs for corporate and shared services such as information technology, finance and other services were primarily recognized in SG&A and R&D in the Combined Statements of Income.

Management believes that the expense and cost allocations have been determined on a basis that is a reasonable reflection of the utilization of services provided or the benefit received by the Company during the years ended December 31, 2022 and 2021. The amounts that would have been, or will be, incurred on a stand-alone basis could materially differ from the amounts allocated due to economies of scale, difference in management judgment, a requirement for more or fewer employees, or other factors.

AFTER SPIN-OFF.

In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE, including, but not limited to, the following which had activity during the year ended December 31, 2023:

•Separation and Distribution Agreement – sets forth the principal actions to be taken in connection with the Spin-Off, including the transfer of assets and assumption of liabilities, and establishes certain rights and obligations between the Company and GE following the Distribution, including procedures with respect to claims subject to indemnification and related matters.

•Transition Services Agreement – governs all matters relating to the provision of services between the Company and GE on a transitional basis. The services the Company receives include support for information technology, human resources, supply chain, finance, and facilities services, among others. Some of these costs were included in the Corporate allocations from GE prior to Spin-Off. The services generally commenced on the date of the Spin-Off and will terminate up to 24 months following the Distribution Date depending upon the related transitional service. For the year ended December 31, 2023, we incurred $372 million, net, which represents fees charged from GE to the Company primarily for information technology, human resources, and R&D and is net of fees charged from the Company to GE for facilities and other shared services.

•Tax Matters Agreement – governs the respective rights, responsibilities, and obligations between the Company and GE with respect to all tax matters (excluding employee-related taxes covered under the Employee Matters Agreement), in addition to certain restrictions which generally prohibit us from taking or failing to take any action in the two-year period following the Distribution that would prevent the Distribution from qualifying as tax-free for U.S. federal income tax purposes, including limitations on our ability to pursue certain strategic transactions. The Tax Matters Agreement specifies the portion of tax liability for which the Company will bear contractual responsibility, and the Company and GE will each agree to indemnify each other against any amounts for which such indemnified party is not responsible.

Current amounts due from and to GE under the various agreements described above are recognized within Due from related parties or Due to related parties, as applicable, in the Consolidated and Combined Statements of Financial Position. Non-current amounts due from GE were $81 million and due to GE were $33 million, and were recognized within All other assets and All other liabilities, respectively, in the Consolidated Statement of Financial Position as of December 31, 2023. These amounts primarily relate to tax and other indemnities.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Dec. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ESTIMATES AND ASSUMPTIONS. The preparation of the consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the consolidated and combined financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows. Estimates are used for, but are not limited to, determining the following: revenue from contracts with customers, recoverability of long-lived assets and inventory, valuation of goodwill and intangible assets, useful lives used in depreciation and amortization, asset retirement obligations, income taxes and related valuation allowances, accruals for contingencies including legal and product warranties, actuarial assumptions used to determine costs of pension and other postretirement benefits, valuation of pension assets, valuation and recoverability of receivables, valuation of derivatives, and valuation of assets acquired, liabilities assumed, and contingent consideration as a result of acquisitions. There have been no material impacts to our accounting estimates as of December 31, 2023 and 2022, or the results for the years ended December 31, 2023, 2022, and 2021, from the COVID-19 pandemic. The federal COVID-19 Public Health Emergency declaration in the U.S. ended in May 2023, and COVID-19 restrictions have been lifted in many locations globally. REVENUE RECOGNITION. Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as related parts and labor, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services. The Company recognizes a contract with a customer when there is a legally enforceable agreement between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on the consideration specified in the contract with each customer net of any sales incentives, discounts, returns, chargebacks, group purchasing organization fees, rebates, or credits, as well as taxes collected from customers that are remitted to government authorities. Our estimates for these deductions, which are accounted for as variable consideration, are based on historical experience and consider current and forecasted market trends. We record these estimated amounts as a reduction to revenue when we recognize the related product or service sales. Payment terms are generally within 12 months. Payment terms within 12 months are not treated as significant financing components. Contracts for the sale of products and services often include multiple distinct performance obligations, usually involving an upfront deliverable of equipment and future performance obligations such as installation, training, or the future delivery of products or services. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative stand-alone selling price. Stand-alone selling price is obtained from sources such as the separate selling price for that or a similar item if reasonably available. If such evidence is not reasonably available, we use our best estimate of selling price, which is established consistent with the pricing strategy of the Company and considers product configuration, geography, customer type, and other market-specific factors. Revenue is recognized in the period in which the customer obtains control of the underlying products or services, allowing them the ability to direct the use of, and obtain substantially all of, the remaining benefits of such product or service. This may occur at a point in time or over time. Shipping and handling costs to deliver products to customers are expensed as incurred and recognized within Cost of products or Cost of services in our Consolidated and Combined Statements of Income. For standard, assurance-type warranties that are provided with products, we estimate the cost that may be incurred during the warranty period and record a liability at the time the revenue is recognized. The provision recorded reflects the estimated costs of replacement and free-of-charge services that will be incurred related to the products sold. Service-type warranties or extended warranties sold with products are considered separate performance obligations. As such, a portion of the overall transaction price is allocated to these performance obligations and recognized in revenue over time, as the performance obligations are satisfied. The Company capitalizes certain direct incremental costs incurred to obtain a contract, primarily commissions. Costs to obtain a contract are classified within Contract and other deferred assets or All other assets in the Consolidated and Combined Statements of Financial Position and are recognized based on the timing of when the Company expects to earn related revenues. Management assesses these costs for impairment based on periodic assessments of recoverability. Performance Obligations Satisfied at a Point in Time We primarily recognize revenue from sales of products at the point in time that the customer obtains control, which is generally no earlier than when the customer has physical possession. Where arrangements include customer acceptance provisions based on seller- or customer-specified criteria, we recognize revenue when we have concluded that the customer has control of the products, which is typically at the point of acceptance. Our billing terms for these point-in-time product contracts generally coincide with delivery to the customer and customer acceptance; however, periodically, we receive customer advances and deposits from customers. These are recognized as contract liabilities in the Consolidated and Combined Statements of Financial Position. Any differences between the timing of our revenue recognition and customer billings (based on contractual terms) result in changes to our contract asset or contract liability positions. Performance Obligations Satisfied Over Time We recognize revenue from the sale of certain service contracts, including preventative maintenance, corrective services, and extended warranties over time on a ratable basis consistent with the nature, timing, and extent of our services, which primarily relate to routine maintenance and as-needed product repairs. Our billing terms for these contracts vary and can occur in advance of or following the period of service; however, we generally invoice periodically as services are provided. The differences between the timing of our revenue recognized and customer billings (based on contractual terms) result in changes to our contract asset or contract liability positions. See Note 3, “Revenue Recognition” for further information. CASH, CASH EQUIVALENTS, AND RESTRICTED CASH. Cash deposits, short-term investments, and high-liquidity mutual funds with original maturities of three months or less are included in Cash, cash equivalents, and restricted cash. Restricted cash primarily relates to funds restricted in connection with escrow accounts and other contractual and legal restrictions. For the period prior to the Spin-Off, the cash presented in the Combined Statement of Financial Position represents cash not subject to the GE centralized cash management process. Cash held in commingled accounts with GE, or its affiliates, is presented within Net parent investment in the Combined Statement of Financial Position. See Note 18, “Supplemental Financial Information” for further information. INVESTMENT SECURITIES. Publicly traded equity securities for which we do not have the ability to exercise significant influence are recorded at fair value with changes in fair value recognized in Other (income) expense – net in the Consolidated and Combined Statements of Income. Privately held equity securities for which we do not have the ability to exercise significant influence are accounted for using the measurement alternative approach and are recorded at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, with changes in the measurement recognized through Other (income) expense – net in the Consolidated and Combined Statements of Income. Equity investments without readily determinable fair value as of December 31, 2023 and 2022 were $156 million and $117 million, respectively. Investment securities are recognized within All other assets in the Consolidated and Combined Statements of Financial Position. EQUITY METHOD INVESTMENTS. Equity method investments are investments in entities in which we do not have a controlling financial interest, but over which we have significant influence. Equity method investments are assessed for other-than-temporary impairment when events occur or circumstances change that indicate it is more likely than not the fair value of the asset is below its carrying value. Equity method investments are recognized within All other assets in the Consolidated and Combined Statements of Financial Position. Our share of the results of equity method investments is recognized within Other (income) expense – net in the Consolidated and Combined Statements of Income. See Note 18, “Supplemental Financial Information” for further information. RECEIVABLES. Amounts due from customers arising from the sales of products and services are recorded at the outstanding amount, less allowances for credit losses, chargebacks, and other credits. We regularly monitor the recoverability of our receivables. See Note 5, “Receivables” for further information. FINANCING RECEIVABLES. Our financing receivables portfolio consists of a variety of loans and leases, including both larger-balance, non-homogeneous loans and leases, and smaller-balance homogeneous loans and leases. Loans Loans represent term loans that are collateralized by equipment and other assets. Loans are classified as either held for sale or held for investment (“HFI”) based on management’s intent and ability to hold the loans for the foreseeable future. Loans which the Company does not have the ability and intent to hold for investment purposes and those which the Company intends to hold for sale in the foreseeable future are accounted for as loans held for sale. Loans held for sale are recorded at the lower of historical cost or current fair value with any fair value write-down (or change to the write-down) recorded as a valuation allowance through current period earnings in the period in which the change occurs. Loans classified as HFI are recorded at amortized cost. Investment in Finance Leases Finance leases include mostly sales-type leases of equipment and represent net unpaid rentals and estimated unguaranteed residual values of leased equipment, less related deferred income and less the allowance for credit losses. See Note 7, “Leases” for further information. See “Allowance for credit losses” below for the Company’s policy regarding allowances on financing receivables. Credit Quality Indicators We manage our financing receivables portfolio using delinquency and nonaccrual data as key performance indicators. We assess the overall quality of the portfolio based on a potential risk of loss measure. The metric incorporates both the borrower’s credit quality along with any related collateral protection. Financing receivables are considered past due if default on a contractual principal or interest payment exists for a period of 30 days or more. We stop accruing interest on financing receivables at the earlier of when collection of an account becomes doubtful or the account becomes 90 days past due. Although we stop accruing interest in advance of payments, we recognize income within Other (income) expense – net in the Consolidated and Combined Statements of Income when we determine that the account is returned to accrual status, provided that the amount does not exceed that which would have been earned at the historical effective interest rate. See Note 6, “Financing Receivables” for further information. ALLOWANCE FOR CREDIT LOSSES. When we record customer receivables, contract assets, and financing receivables, we maintain an allowance for credit losses for the current expected credit losses. Each period, the allowance for credit losses is adjusted through earnings to reflect expected credit losses over the remaining lives of the assets. The credit losses are recognized within Selling, general, and administrative (“SG&A”) in the Consolidated and Combined Statements of Income. For financing receivables, expected credit losses are calculated based on the gross carrying amount of the financial asset, multiplied by a factor reflecting the probability of default and the loss in the event of default. We routinely evaluate our entire portfolio for potential specific credit or collection issues that might indicate an impairment. We estimate expected credit losses based on relevant information from past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. When measuring expected credit losses, we pool assets with similar credit risk characteristics. Changes in the relevant information may significantly affect the estimates of expected credit losses. INVENTORIES. Inventories are stated at lower of cost or net realizable values. Cost of inventories is determined on a first-in, first-out basis. Inventories are generally classified as current, however, based on age or historical consumption certain inventories are considered non-current and are recognized, net of related reserves, within All other assets in the Consolidated and Combined Statements of Financial Position. As necessary, we record provisions and write-downs for excess, slow moving, and obsolete inventory. To determine these amounts, we regularly review inventory quantities on hand and compare them to historical utilization and estimates of future product demand, market conditions and technological developments. See Note 18, “Supplemental Financial Information” for further information. PROPERTY, PLANT, AND EQUIPMENT. The cost of property, plant, and equipment is depreciated on a straight-line basis over its estimated useful life. Equipment leased to others under operating leases is depreciated on a straight-line basis over the term of the lease. Repair and maintenance costs are expensed as incurred. See Note 18, “Supplemental Financial Information” for further information. LEASES. Lessee Arrangements At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. ROU assets are recognized within Property, plant, and equipment – net and lease liabilities are recognized within All other current liabilities and All other liabilities in the Consolidated and Combined Statements of Financial Position. Options to extend a lease are included as part of the ROU lease asset and liability at commencement when it is reasonably certain the Company will exercise the option. We have elected to combine lease and non-lease components in determining our lease liability for all leased assets except our vehicle leases. Non-lease components are generally related to services that the lessor performs for the Company associated with the leased asset. As the Company’s leases typically do not provide an implicit rate, the present value of our lease liability is determined using our incremental collateralized borrowing rate at lease commencement for leases that commenced post-Spin-Off and GE’s incremental collateralized borrowing rate at lease commencement for leases that commenced pre-Spin-Off. For leases with an initial term of 12 months or less, an ROU asset and lease liability are not recognized, and lease expense is recognized on a straight-line basis over the lease term. Certain of our leases include provisions for variable lease payments which are based on, but not limited to, maintenance, insurance, taxes, index escalations, and usage-based amounts. The Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. We review ROU assets for impairment annually or when events occur or circumstances change that indicate that the asset may be impaired. Lessor Arrangements Equipment leased to others under operating leases is recognized within Property, plant, and equipment – net in the Consolidated and Combined Statements of Financial Position. Leases classified as sales-type leases or direct financing leases are recognized within All other current assets and All other assets, respectively, in the Consolidated and Combined Statements of Financial Position. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term or purchase the underlying asset, vary by customer. Finance lease receivables are tested for impairment as described in the “Financing Receivables” section above. See Note 6, “Financing Receivables” and Note 7, “Leases” for further information. GOODWILL AND OTHER INTANGIBLE ASSETS. Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We test goodwill for impairment at the reporting unit level annually in the fourth quarter of each year as of October 1st, or more frequently when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. When testing goodwill for impairment, the Company may first assess qualitative factors. If an initial qualitative assessment identifies that it is more likely than not that the fair value of a reporting unit is less than its carrying value, additional quantitative testing is performed. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. If the quantitative testing indicates that goodwill is impaired, an impairment charge is recognized based on the difference between the reporting unit’s carrying value and its fair value. When performing a quantitative test, the market approach is typically used for estimating the fair values for our reporting units. Under the market approach, we estimate the fair value based on market multiples of earnings derived from comparable publicly traded companies with operating and investment characteristics similar to the reporting unit. Depending on the specific reporting unit circumstances, we may also consider performing a valuation based on an income approach. It is reasonably possible that the judgments and estimates used could change in future periods. In-process research and development (“IPR&D”) acquired as part of a business acquisition is capitalized at fair value when acquired and is considered an indefinite-lived intangible asset. We test indefinite-lived intangible assets for impairment annually in the third quarter of each year or when events occur or circumstances change that indicate it is more likely than not the fair value of the asset is below its carrying value. When testing IPR&D for impairment, the Company may first assess qualitative factors. If an initial qualitative assessment identifies that it is more likely than not that the fair value of the IPR&D is less than its carrying value, additional quantitative testing is performed. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. If the quantitative testing indicates that the IPR&D is impaired, an impairment charge is recognized based on the difference between the IPR&D’s carrying value and its fair value. When the IPR&D project is complete, the asset is considered a finite-lived intangible asset and subject to an impairment test at that date. Thereafter, the resulting asset is amortized over its estimated useful life and is subject to impairment assessment in the same manner as all amortizing intangible assets. For other intangible assets that are not deemed indefinite-lived, the cost of the intangible asset is amortized on a straight-line basis over the asset’s estimated useful life. Amortizable intangible assets are reviewed for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. In such circumstances, they are tested for impairment based on undiscounted cash flows and, if impaired, written down to estimated fair value based on either discounted cash flows or appraised values. Internal-Use Software Internal-use software is software that is developed, purchased, or modified to meet internal needs and for which no substantive plan exists to sell, lease, or otherwise market the software externally. All costs associated with project tasks classified in the preliminary project development or post-implementation/operation stage are expensed as incurred. Capitalization of application development stage costs begins after both of the following occur: (1) the preliminary project development stage is completed and (2) management authorizes and commits to funding the software project and it is probable that the project will be completed and the software will be used for the purpose for which it was intended. Capitalization ceases when the project is substantially complete. Capitalized amounts are recognized within Other intangible assets – net in the Consolidated and Combined Statements of Financial Position and are amortized on a straight-line basis over the asset’s estimated useful life. External Use Software External use software relates to software that is (1) intended to be sold, licensed, or marketed to our customers or (2) embedded and integral to our tangible products for which research and development (“R&D”) has been completed. Costs that are related to the conceptual formulation and design of software are expensed as incurred. Costs that are incurred after technological feasibility has been established until general release of the product are capitalized as an intangible asset and recognized within Other intangible assets – net in the Consolidated and Combined Statements of Financial Position. Capitalized costs for software to be sold, leased, or otherwise marketed are amortized on an individual product basis using straight-line amortization over the estimated useful life of the product. The Company performs regular reviews to assess whether unamortized capitalized external use software program costs remain recoverable through future revenue. See Note 8, “Acquisitions, Goodwill, and Other Intangible Assets” for further information. DERIVATIVES AND HEDGING. We use derivative contracts to reduce the volatility of earnings and cash flows associated with risks related to foreign currency exchange rates, interest rates, equity prices, and commodity prices. Our policy is to use derivatives solely for managing risks and not for speculative purposes. We employ the following hedge types: (1) cash flow hedges of foreign currency risk associated with third-party and intercompany foreign currency-denominated forecasted transactions and firm commitments, (2) net investment hedges of foreign currency risk associated with investments in foreign operations, (3) fair value hedges of interest rate risk associated with long-term borrowings, and (4) economic hedges not designated as qualifying hedging relationships of foreign currency risk associated with monetary assets and liabilities, including intercompany balances, equity price risk, and commodity price risk. For net investment hedges, changes in the fair value of the components of the hedging derivatives excluded from the assessment of hedge effectiveness are deferred and amortized to earnings in the Consolidated and Combined Statements of Income using a systematic and rational method over the life of the derivative transaction. Contracts that do not in their entirety meet the definition of a derivative instrument and are not measured at fair value may contain embedded features affecting some or all of the cash flows or value of other exchanges that would otherwise be considered derivatives when assessed separately from the host contract. Such embedded features are separated from the hybrid contract and accounted for as a derivative measured at fair value if their economic characteristics and risks are not clearly and closely related to those of the host contract. See Note 13, “Financial Instruments and Fair Value Measurements” for further information. INCOME TAXES. For the years ended December 31, 2022 and 2021, the Company’s income tax provision was prepared using the separate return method. The calculation of income taxes on a separate return basis requires a considerable amount of judgment and use of both estimates and allocations. As a result, actual transactions included in the consolidated financial statements of GE may not be included in these combined financial statements. Similarly, the tax treatment of certain items reflected in the combined financial statements may not be reflected in the consolidated financial statements and tax returns of GE. Therefore, items such as net operating losses, credit carryforwards, and valuation allowances may exist in the stand-alone combined financial statements that may or may not exist in GE’s consolidated financial statements. For post-Spin-Off periods, as a stand-alone entity, GE HealthCare will file tax returns on its own behalf, and its deferred taxes and actual income tax rate differ from those in the historical periods. For the years prior to the Spin-Off, all income taxes due to or due from GE that had not been settled or recovered by the end of the period are recognized within Net parent investment in the Combined Statement of Financial Position. Any differences between actual amounts paid or received by the Company and taxes accrued under the separate return method are deemed to be settled and are recognized within Net parent investment in the Combined Statement of Financial Position. Current obligations for tax in jurisdictions where the Company did not file a consolidated tax return with GE in the pre-Spin-Off period, including certain foreign and certain U.S. state tax jurisdictions, are recorded as accrued liabilities and recognized within All other liabilities in the Combined Statement of Financial Position. The effects of tax adjustments and settlements with taxing authorities are presented in the consolidated and combined financial statements in the period to which they relate. Uncertain tax positions that meet the more likely than not recognition threshold are measured to determine the amount of tax benefit to recognize in the consolidated and combined financial statements. An uncertain tax position is measured at the largest amount of benefit that the Company believes has a greater than 50% likelihood of realization upon settlement. Tax benefits not meeting the measurement or realization criteria represent unrecognized tax benefits. Penalties related to income tax matters are recognized within Benefit (provision) for income taxes in the Consolidated and Combined Statements of Income. Our policy is to adjust these reserves when facts and circumstances change, such as the actual settlement or effective settlement of positions with the relevant taxing authorities. Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their respective tax bases, as well as from net operating loss and tax credit carryforwards. The deferred income tax balances are stated at enacted tax rates expected to be in effect when those taxes are paid or recovered. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years. We evaluate the recoverability of these future tax deductions and credits by evaluating all available positive and negative evidence, specifically assessing the adequacy of future expected taxable income from all sources, including reversal of existing taxable temporary differences, forecasted operating earnings, and available tax planning strategies. To the extent we consider it more likely than not that a deferred tax asset will not be recovered, a valuation allowance is established to reduce the carrying value of the deferred asset to its more likely than not realizable value. Deferred taxes are provided for our investment in non-U.S. affiliates and associated companies based upon our evaluation of the undistributed earnings of such entities. See Note 11, “Income Taxes” for further information. POSTRETIREMENT BENEFIT PLANS. Prior to the Spin-Off, GE sponsored plans were accounted for as multiemployer plans. Therefore, the related assets and liabilities are not reflected in the Combined Statement of Financial Position for the year ended December 31, 2022. The Combined Statements of Income reflect a proportionate allocation of net periodic benefit costs for the multiemployer plans associated with the Company for the years ended December 31, 2022 and 2021. In connection with the Spin-Off, on January 1, 2023, GE HealthCare assumed a portion of former GE pension and postretirement obligations and assets. The pension and postretirement obligations assumed relate to benefits owed to current GE HealthCare employees, former GE HealthCare employees, and certain GE legacy plan participants. The pension plans are now sponsored by GE HealthCare. For the postretirement plans, GE HealthCare is now a participant in a multiple-employer plan with GE. Management accounts for the pension and postretirement plans as defined benefit plans. We measure our plan assets at fair value and categorize plan assets for disclosure purposes in accordance with the fair value hierarchy. Certain assets for which the fair value is measured using the net asset value (“NAV”) per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The components of net periodic benefit costs, other than the service cost component, are recognized within Non-operating benefit (income) costs in the Consolidated and Combined Statements of Income for plans sponsored by the Company. We engage third-party actuaries to assist in the determination of pension obligations and related plan costs. We develop significant long-term assumptions including discount rates and the expected rate of return on assets in connection with our pension accounting. We recognize differences between the expected long-term return on plan assets, the actual return, and net actuarial gains and losses for the pension plan liabilities annually in the fourth quarter of each fiscal year and whenever a plan is determined to qualify for a remeasurement within the Consolidated and Combined Statements of Comprehensive Income (Loss). We amortize gains and losses, as well as the effects of changes in actuarial assumptions and plan provisions, that exceed 10% of the greater of plan assets or benefit obligations. The period over which gains and losses are amortized is generally over the average remaining service of employees. See Note 10, “Postretirement Benefit Plans” for further information. LOSS CONTINGENCIES. Loss contingencies are uncertain and unresolved matters that arise in the ordinary course of business and result from events that have the potential to result in a future loss. Such contingencies include, but are not limited to, product warranties, claims, litigation, environmental obligations, regulatory investigations and proceedings, product quality, and losses resulting from other events and developments. When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the loss. When there appears to be a range of possible losses with equal likelihood, liabilities are based on the low end of such range. Disclosure is provided for material loss contingencies when a loss is probable and an estimate can be made, when a loss is probable but a reasonable estimate cannot be made, and when it is reasonably possible that a loss will be incurred or the amount of a loss will exceed the recorded provision. We regularly review contingencies to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. Legal costs incurred in connection with loss contingencies are expensed as incurred. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information. SUPPLY CHAIN FINANCE PROGRAMS. The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables as borrowings. In connection with the supply chain finance programs, payment terms normally range from 30 to 150 days, not exceeding 180 days, depending on the underlying supplier agreements. FAIR VALUE MEASUREMENTS. The following sections describe the valuation methodologies we use to measure financial and non-financial instruments at fair value including certain assets within our postretirement benefit plans. Observable inputs for fair value measurements reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. These inputs establish the following fair value hierarchy: •Level 1 — Quoted prices for identical instruments in active markets. •Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. •Level 3 — Significant inputs to the valuation model are unobservable. See Note 13, “Financial Instruments and Fair Value Measurements” for further information. RECURRING FAIR VALUE MEASUREMENTS. For financial assets and liabilities measured at fair value on a recurring basis, primarily investment securities, derivatives, and contingent consideration, fair value is the price we would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. In the absence of active markets for the identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date. Investment Securities Publicly traded equity securities are valued using Level 1 quoted price inputs. Derivatives The majority of our derivatives are valued using model-derived offers received from financial institutions for similar over-the-counter instruments without an active market or internal models. The models maximize observable inputs including interest rates and both forward and spot prices for currencies and commodities. As of December 31, 2023 and 2022, foreign currency contracts, interest rate contracts, commodity exchange contracts, embedded derivatives, and the equity-linked total return swap were valued using Level 2 inputs. Contingent Consideration When an acquisition involves a contingent consideration arrangement, we record on the date of acquisition a liability for the fair value of the estimated additional consideration we may be obligated to pay in the future. The fair value is based upon estimates of future financial projections under various potential scenarios using a probability-weighted expected payment model discounted to present value. The estimates used to determine the fair value are subject to significant judgement and as such are considered Level 3 inputs. We subsequently remeasure such liabilities at the end of each reporting period and record changes in the fair value within SG&A in the Consolidated and Combined Statements of Income. Investments in private equity, real estate and collective funds held within our postretirement benefit plans Most investments are generally valued using the NAV per share as a practical expedient for fair value provided certain criteria are met. The NAVs are determined based on the fair values of the underlying investments in the funds. Investments that are measured at fair value using the NAV practical expedient are not required to be classified in the fair value hierarchy. Investments classified within Level 3 primarily relate to real estate and private equities which are valued using unobservable inputs, primarily by discounting expected future cash flows, using comparative market multiples, third-party pricing sources, or a combination of these approaches as appropriate. See Note 10, “Postretirement Benefit Plans” for further information. Debt securities held within our postretirement benefit plans When available, we use quoted market prices to determine the fair value of debt securities which are Level 1 inputs. For our remaining debt securities, we obtain pricing information from an independent pricing vendor. The inputs and assumptions to the pricing vendor’s models are derived from market observable sources including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and other market-related data. These investments are classified within Level 2. See Note 10, “Postretirement Benefit Plans” for further information. There were no transfers between Levels 1, 2, and 3 of the fair value hierarchy during the years ended December 31, 2023 and 2022. See Note 13, “Financial Instruments and Fair Value Measurements” for further information. NON-RECURRING FAIR VALUE MEASUREMENTS. Certain assets and liabilities are measured at fair value on a non-recurring basis. These items may include financing receivables and long-lived assets reduced to fair value upon classification as held for sale and impaired equity method investments and long-lived assets, which, when written down to fair value upon an impairment, are not subsequently adjusted to fair value unless further impairment occurs. The following sections describe the valuation methodologies the Company uses to measure these assets not measured on a recurring fair value basis. Equity Method Investments Equity method investments are initially recorded at cost and are adjusted in each period for the Company’s share of the investee’s income or loss and dividends paid. In instances of impairment, equity method investments are written down to fair value using market observable data such as quoted prices when available. When market observable data is unavailable, investments are valued using either a discounted cash flow model, comparative market multiples, third-party pricing sources, or a combination of these approaches, as appropriate. These investments are generally valued using Level 3 inputs. Equity Investments Without Readily Determinable Fair Value Equity investments without readily determinable fair value, subject to a policy choice on a transaction-by-transaction basis, are accounted for under the measurement alternative at cost less impairment and adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. In the instance of impairment, if any, equity investments are adjusted to fair value using market observable data if available. If market observable data is not available, fair values are estimated using discounted cash flow models, comparative market multiples, or a combination of these approaches using Level 3 inputs. Financing Receivables We generally use market data, including pricing on recently closed market transactions, to value financing receivables that are held for sale. Such financing receivables are valued using Level 2 inputs. When the data is unobservable, we use valuation methodologies based on current market interest rate data adjusted for inherent credit risk. Such financing receivables are valued using Level 3 inputs. Long-Lived Assets Fair values of long-lived assets are primarily developed internally and are corroborated by available external appraisal information, as applicable. These assets are generally valued using Level 3 inputs. FOREIGN CURRENCY. We have determined that the functional currency for many of our international operations is the local currency, and for other international operations the functional currency is the USD. The basis of this determination is the currency in which each of the international operations primarily generates and expends cash. When the functional currency is not the USD, asset and liability accounts are translated at period-end exchange rates. The Company translates functional currency income and expense amounts to their USD equivalents using average exchange rates for the period. These translation gains and losses are recognized within Accumulated other comprehensive income (loss) – net (“AOCI”) in the Consolidated and Combined Statements of Financial Position. Gains and losses from foreign currency transactions, such as those resulting from the settlement of monetary items in the non-functional currency and those resulting from remeasurements of monetary items, are included in Cost of products, Cost of services, SG&A, and R&D in the Consolidated and Combined Statements of Income, depending on the underlying nature of the item. Net gains (losses) from foreign currency transactions were $16 million, $(88) million, and $130 million for the years ended December 31, 2023, 2022, and 2021, respectively. BUSINESS COMBINATIONS. Our consolidated and combined financial statements include the operations of acquired businesses from the date of acquisition. The Company accounts for acquired businesses using the acquisition method of accounting in accordance with U.S. GAAP, which requires that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date. When we acquire the remaining equity ownership of a company in which we hold an equity interest, we remeasure our equity interest to fair value. Any excess of the purchase price over the assigned values of the net assets acquired is recorded as Goodwill. Transaction costs are expensed as incurred. For those arrangements that involve potential future contingent consideration, on the date of acquisition we record a liability equal to the fair value of the estimated additional consideration we may be obligated to pay in the future. See Note 8, “Acquisitions, Goodwill, and Other Intangible Assets” and Note 13, “Financial Instruments and Fair Value Measurements” for further information. DISCONTINUED OPERATIONS. Certain of our operations have been presented as discontinued. We present businesses whose disposal represents a strategic shift that has, or will have, a major effect on our operations and financial results as discontinued operations when the components meet the criteria for held for sale, are sold, or spun-off. Presentation as discontinued operations is consistent for all periods presented. See Note 20, “Discontinued Operations” for further information. RESTRUCTURING COSTS. We record liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee termination costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period. See Note 15, “Restructuring and Other Activities – Net” for further information. RESEARCH AND DEVELOPMENT. The Company conducts R&D activities to create new products, develop new applications for existing products, and enhance existing products. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. R&D costs are expensed as incurred. In certain instances, R&D activities may be funded by third parties, including government entities. These R&D funding arrangements may include upfront payments, R&D cost sharing payments, and future milestone payments that may be based upon the occurrence of future R&D or commercialization events. Payments received as part of the R&D funding arrangements are generally presented as an offset to R&D expense. COLLABORATIVE ARRANGEMENTS. We enter into collaborative arrangements primarily related to development of new products. A collaborative arrangement is a contractual arrangement that involves two or more parties who are active participants in the activity, and are exposed to significant risks and rewards dependent on the commercial success of the activity. The assessment for a collaborative arrangement is performed throughout the life of the arrangement based on changes in the responsibilities of all parties. Amounts that are owed by collaboration partners related to R&D activities are generally presented as an offset to R&D expense. See Note 18, “Supplemental Financial Information” for further information. ACCOUNTING CHANGES. Accounting Standards Codification (“ASC”) Topic 740, Income Taxes, provides that interest and penalties related to unrecognized income tax benefits may either be classified as income tax expense or interest expense in the consolidated statements of operations. In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions. The interest was previously presented within Interest and other financial charges – net and has changed to being presented within Benefit (provision) for income taxes. The Company believes this presentation is preferable because the cost is related to income tax matters and this presentation enhances comparability with our peers. The effects of the change in accounting have been prospectively applied to periods beginning in the first quarter of 2023 and were not material to any previously reported periods prior to March 31, 2023. Recent Accounting Pronouncements Reflected in These Consolidated and Combined Financial Statements In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50). The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted this guidance on January 1, 2023. See Note 18, “Supplemental Financial Information” for further information. In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The ASU requires companies to apply the definition of a performance obligation under ASC 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities relating to contracts with customers acquired in a business combination. Prior to the adoption of this ASU, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. The ASU results in the acquirer recording acquired contract assets and contract liabilities from contracts with customers on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance on January 1, 2023 using a prospective method, and the adoption did not have a material impact on the consolidated financial statements. Other Recent Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The provisions of ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07. In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09.

SUPPLEMENTAL FINANCIAL INFORMATION - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Original Cost	$ 5,208	$ 4,989
Accumulated Depreciation	(3,064)	(2,988)
Net Carrying Value	2,144	2,001
Operating lease ROU assets	356	313
Property, plant, and equipment – net	$ 2,500	2,314
Land and improvements
Property, Plant and Equipment [Line Items]
Depreciable lives (in years)	8 years
Original Cost	$ 70	70
Accumulated Depreciation	(1)	(1)
Net Carrying Value	69	69
Buildings, structures and related equipment
Property, Plant and Equipment [Line Items]
Original Cost	1,956	1,889
Accumulated Depreciation	(1,167)	(1,109)
Net Carrying Value	$ 789	780
Buildings, structures and related equipment \| Minimum
Property, Plant and Equipment [Line Items]
Depreciable lives (in years)	8 years
Buildings, structures and related equipment \| Maximum
Property, Plant and Equipment [Line Items]
Depreciable lives (in years)	40 years
Machinery and equipment
Property, Plant and Equipment [Line Items]
Original Cost	$ 2,617	2,541
Accumulated Depreciation	(1,802)	(1,791)
Net Carrying Value	815	750
Equipment leased, net	$ 38	39
Machinery and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Depreciable lives (in years)	4 years
Machinery and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Depreciable lives (in years)	20 years
Leasehold costs and manufacturing plants under construction
Property, Plant and Equipment [Line Items]
Original Cost	$ 565	489
Accumulated Depreciation	(94)	(87)
Net Carrying Value	$ 471	$ 402
Leasehold costs and manufacturing plants under construction \| Minimum
Property, Plant and Equipment [Line Items]
Depreciable lives (in years)	1 year
Leasehold costs and manufacturing plants under construction \| Maximum
Property, Plant and Equipment [Line Items]
Depreciable lives (in years)	40 years

RECEIVABLES - Allowance for Credit Losses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 91	$ 107	$ 93
Additions charged to costs and expenses	16	2	12
Write-offs	(11)	(13)	(10)
Foreign currency exchange and other	2	(5)	12
Ending balance	$ 98	$ 91	$ 107

Cover - USD ($) $ in Billions	12 Months Ended
Cover - USD ($) $ in Billions	Dec. 31, 2023	Jan. 30, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-41528
Entity Registrant Name	GE HEALTHCARE TECHNOLOGIES INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2515116
Entity Address, Address Line One	500 W. Monroe Street
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60661
City Area Code	833
Local Phone Number	735-1139
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	GEHC
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction	false
Entity Shell Company	false
Entity Public Float			$ 32
Entity Common Stock, Shares Outstanding		455,357,229
Documents Incorporated by Reference	The definitive proxy statement relating to the registrant’s Annual Meeting of Shareholders, to be held May 21, 2024, is incorporated by reference into Part III of this Annual Report on Form 10-K to the extent described therein.
Amendment Flag	false
Entity Central Index Key	0001932393
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023

INCOME TAXES - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Current
U.S. Federal	$ 171	$ 396	$ 141
Non – U.S.	345	324	422
U.S. State	42	97	55
Deferred
U.S. Federal	0	(213)	82
Non – U.S.	103	7	(101)
U.S. State	82	(48)	1
Total	$ 743	$ 563	$ 600

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax


Income Before Income Taxes
	For the years ended December 31
	2023		2022		2021
U.S. income	$	816	$	1,090	$	1,587
Non-U.S. income	1,545		1,422		1,288
Total	$	2,361	$	2,512	$	2,875

Schedule of Provision for Income Taxes


Provision for Income Taxes
	For the years ended December 31
	2023		2022		2021
Current
U.S. Federal	$	171	$	396	$	141
Non – U.S.	345		324		422
U.S. State	42		97		55
Deferred
U.S. Federal	—		(213)		82
Non – U.S.	103		7		(101)
U.S. State	82		(48)		1
Total	$	743	$	563	$	600

Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate


Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate
	For the years ended December 31
	2023		2022		2021
Income before taxes	$	2,361	$	2,512	$	2,875
Tax expected at 21%	496		528		604
Foreign operations	63		43		(54)
Withholding taxes	28		4		11
U.S. tax on foreign operations	(35)		(36)		(23)
Uncertain tax positions	11		6		11
R&D benefits	(33)		(33)		(32)
State taxes, net of federal benefit	24		39		45
Valuation allowance	19		8		33
Spin-Off and separation costs	184		—		—
Other	(14)		4		5
Provision for income taxes	$	743	$	563	$	600
Actual income tax rate	31.5%		22.4%		20.9%

Schedule of Unrecognized Tax Benefits Roll Forward

The balance of unrecognized tax benefits, the amount of related interest and penalties, and what we believe to be the range of reasonably possible changes in the next 12 months are as follows.


	2023		2022		2021
Balance at beginning of period	$	465	$	365	$	684
Additions for tax positions of the current year	—		9		9
Additions for tax positions of prior years	156		137		14
Reductions for tax positions of prior years	(203)		(41)		(78)
Settlements with tax authorities	(6)		(1)		(262)
Expiration of the statute of limitations	(3)		(4)		(2)
Balance at end of period	$	409	$	465	$	365

Schedule of Unrecognized Tax Benefits


Unrecognized Tax Benefits
	For the years ended December 31
	2023		2022		2021
Unrecognized tax benefits	$	409	$	465	$	365
Accrued interest on unrecognized tax benefits	72		56		53
Reasonably possible reduction to the balance of unrecognized tax benefits in succeeding 12 months	29		45		36
Portion that, if recognized, would reduce tax expense and effective tax rate	157		153		111

Schedule of Deferred Tax Assets and Liabilities


Deferred Income Taxes
	As of
	December 31, 2023		December 31, 2022
Total assets	$	4,474	$	1,550
Total liabilities	(68)		(370)
Net deferred income tax asset (liability)	$	4,406	$	1,180


Components of the Net Deferred Income Tax Asset (Liability)
	As of
	December 31, 2023		December 31, 2022
Deferred tax assets:
Employee benefits	$	1,418	$	222
Contract liabilities	171		193
Inventories	95		84
Operating loss carryforwards	648		176
Other accrued expenses	68		70
Receivables	45		42
Lease liabilities	75		57
Tax credit carryforwards	59		128
Contract assets	79		99
U.S. interest restriction carryforwards	61		—
Goodwill and other intangible assets	1,461		—
Property, plant, and equipment	261		338
Capitalized R&D	547		554
Other	8		—
Total deferred income tax asset	4,996		1,963
Valuation allowances	(540)		(272)
Total deferred income tax asset after valuation allowance	4,456		1,691
Deferred tax liabilities:
Goodwill and other intangible assets	—		(458)
ROU assets	(50)		(47)
Other	—		(6)
Total deferred income tax liability	(50)		(511)
Net deferred income tax asset (liability)	$	4,406	$	1,180

Summary of Valuation Allowance

Valuation allowances primarily relate to non-U.S. deferred taxes where there were historical losses and U.S. federal and state credit carryforwards. Activity in the valuation allowance for the years ended December 31, 2023, 2022, and 2021 consists of the following:


Valuation Allowances

Balance at December 31, 2020	$	250
Provision for income taxes	39
Foreign currency exchange and other	(10)
Balance at December 31, 2021	$	279
Provision for income taxes	(5)
Foreign currency exchange and other	(2)
Balance at December 31, 2022	$	272
Provision for income taxes	(12)
Foreign currency exchange and other	280
Balance at December 31, 2023	$	540

RECEIVABLES - Current Receivables (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses	$ (98)	$ (91)	$ (107)	$ (93)
Chargebacks	144	157
Nonrelated party
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current customer receivables	3,339	3,112
Non-income based tax receivables	166	174
Other sundry receivables	118	100
Sundry receivables	284	274
Allowance for credit losses	(98)	(91)
Total current receivables – net	$ 3,525	$ 3,295

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Equity Method Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Equity method investment balance	$ 170	$ 182
Equity method income (loss)	$ 11	13	$ 27
Nihon Medi-Physics Co., Ltd
Schedule of Equity Method Investments [Line Items]
Ownership Percentage	50.00%
Equity method investment balance	$ 150	162
Equity method income (loss)	10	16	22
Other
Schedule of Equity Method Investments [Line Items]
Equity method investment balance	20	20
Equity method income (loss)	$ 1	$ (3)	$ 5

POSTRETIREMENT BENEFIT PLANS - Assumptions (Details)	12 Months Ended
POSTRETIREMENT BENEFIT PLANS - Assumptions (Details)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Pension Plans \| Principal Pension Plans
Weighted-average benefit obligations assumptions
Discount rate	5.20%
Compensation increases	3.90%
Weighted-average benefit cost assumptions
Discount rate	5.50%
Expected rate of return on plan assets	7.00%
Pension Plans \| Other Pension Plans
Weighted-average benefit obligations assumptions
Discount rate	4.50%	4.30%	1.90%
Compensation increases	3.10%	3.00%	2.80%
Weighted-average benefit cost assumptions
Discount rate	4.90%	1.90%	1.40%
Expected rate of return on plan assets	5.60%	6.30%	5.40%
OPEB Plans
Weighted-average benefit obligations assumptions
Discount rate	5.10%
Compensation increases	3.60%
Weighted-average benefit cost assumptions
Discount rate	5.40%
Expected rate of return on plan assets	0.00%

LEASES - Schedule of Maturity of Operating Leases (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Operating Lease
2024	$ 124
2025	100
2026	79
2027	48
2028	23
Thereafter	52
Total	426
Less: imputed interest	43
Total operating lease liabilities	$ 383	$ 347

POSTRETIREMENT BENEFIT PLANS (Tables)

12 Months Ended

Dec. 31, 2023

Retirement Benefits [Abstract]

Schedule of Defined Benefit Plans

The total assets and liabilities for all plans assumed by GE HealthCare on January 1, 2023, are shown in the tables below.


Accumulated Benefit Obligations and Unrecognized Gain
	As of January 1, 2023
	Defined benefit plans(1)		Other postretirement plans(2)		Total
Accumulated benefit obligations	$	21,696	$	1,210	$	22,906

Unrecognized gain recorded in AOCI	1,258		1,223		2,481


Net Benefit Liability
	As of January 1, 2023
	Defined benefit plans(1)		Other postretirement plans(2)		Total
Projected benefit obligations	$	21,743	$	1,210	$	22,953
Fair value of assets	18,908		—		18,908
Net liability	$	2,835	$	1,210	$	4,045

(1) Defined benefit plans are comprised of both Principal Pension Plans and Other Pension Plans, as defined below.
(2) Other postretirement plans (“OPEB Plans”) are comprised of other post-employment benefits, as defined below.


Pre-Tax Amounts Recorded in AOCI
	As of
	December 31, 2023						December 31, 2022
	Principal Pension Plans		Other Pension Plans		OPEB Plans			Other Pension Plans
Net loss (gain)	$	(1,213)	$	1,075	$	(482)		$	60
Prior service cost (credit)	(43)		(18)		(533)			(5)
Total recorded in AOCI	$	(1,256)	$	1,057	$	(1,015)		$	55


Plan Obligations in Excess of Plan Assets
	As of
	December 31, 2023		December 31, 2022
Accumulated benefit obligation	$	23,841	$	687
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	$	20,774	$	390
Fair value of plan assets	15,433		63
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	$	20,808	$	406
Fair value of plan assets	15,433		63

Schedule of Net Funded Status


Plan Funded Status
	As of
	December 31, 2023						December 31, 2022
	Principal Pension Plans		Other Pension Plans		OPEB Plans			Other Pension Plans
Change in projected benefit obligations
Balance at January 1	$	—	$	640	$	—		$	940
Transfers from GE at Spin-Off	17,997		3,707		1,149			—
Service cost	32		23		6			19
Interest cost	952		209		59			17
Participant contributions	4		1		18			1
Plan amendments	53		2		—			—
Actuarial loss (gain) – net	493		221		50			(193)
Benefits paid	(1,341)		(359)		(149)			(38)
Curtailments	(30)		—		—			—

Exchange rate adjustments	—		144		—			(43)
Balance at December 31	$	18,160	$	4,588	$	1,133		$	703
Change in plan assets
Balance at January 1	$	—	$	382	$	—		$	553
Transfers from GE at Spin-Off	14,838		4,046		—			—
Actual gain (loss) on plan assets	1,057		189		—			(101)
Employer contributions	142		84		131			18
Participant contributions	4		1		18			1
Benefits paid	(1,341)		(359)		(149)			(38)
Acquisitions/Divestitures/Mergers	—		1		—			—
Exchange rate adjustments	—		174		—			(8)
Balance at December 31	$	14,700	$	4,518	$	—		$	425
Funded status – surplus (deficit)	$	(3,460)	$	(70)	$	(1,133)		$	(278)

Schedule of Amounts Recognized in Balance Sheet


Amounts Recorded in Consolidated and Combined Statements of Financial Position
	As of
	December 31, 2023						December 31, 2022
	Principal Pension Plans		Other Pension Plans		OPEB Plans		Other Pension Plans
All other assets	$	—	$	712	$	—	$	65
All other current liabilities	(143)		(47)		(130)		(16)
Compensation and benefits	(3,317)		(735)		(1,003)		(327)
Net amount recorded	$	(3,460)	$	(70)	$	(1,133)	$	(278)

Components of Net Periodic Expense


Components of Expense (Income)
	For the years ended December 31
	Principal Pension Plans		Other Pension Plans					OPEB Plans

	2023			2023		2022		2021		2023
Service cost – Operating	$	32		$	23	$	19	$	24	$	6
Interest cost	952			209		17		15		59
Expected return on plan assets	(1,170)			(256)		(27)		(27)		—
Amortization of net loss (gain)	(125)			10		5		17		(64)
Amortization of prior service cost (credit)	4			(3)		(5)		(4)		(87)
Curtailment loss (gain)	17			—		—		—		—
Settlement loss (gain)	—			61		—		—		—
Non-operating	$	(322)		$	21	$	(10)	$	1	$	(92)
Net periodic expense (income)	$	(290)		$	44	$	9	$	25	$	(86)

Schedule of Pre-tax Cost of Postretirement Benefit Plans and Changes in Other Comprehensive Income


Pre-tax Cost of Postretirement Benefit Plans and Changes in Other Comprehensive Income
	For the years ended December 31
	2023						2022			2021
	Principal Pension Plans		Other Pension Plans		OPEB Plans			Other Pension Plans			Other Pension Plans
Cost of postretirement benefit plans	$	(290)	$	44	$	(86)		$	9		$	23
Changes in other comprehensive loss (income):
Transfers from GE at Spin-Off	(1,989)		740		(1,216)			—			—
Plan amendments	53		—		—			—			—
Net loss (gain) – current year	606		287		50			(74)			(86)
Reclassifications out of AOCI:
Curtailment / settlement gain (loss)	(47)		(61)		—			—			—

Amortization of net loss (gain)	125		(10)		64			(5)			(16)
Amortization of prior service credit	(4)		3		87			5			4
Total changes in other comprehensive loss (income)	$	(1,256)	$	959	$	(1,015)		$	(74)		$	(98)
Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)	$	(1,546)	$	1,003	$	(1,101)		$	(65)		$	(75)

Schedule of Assumptions


Assumptions
	For the years ended December 31
	2023						2022			2021
	Principal Pension Plans		Other Pension Plans		OPEB Plans			Other Pension Plans			Other Pension Plans
Weighted-average benefit obligations assumptions
Discount rate	5.2	%	4.5	%	5.1	%		4.3	%		1.9	%
Compensation increases	3.9	%	3.1	%	3.6	%		3.0	%		2.8	%
Weighted-average benefit cost assumptions
Discount rate	5.5	%	4.9	%	5.4	%		1.9	%		1.4	%
Expected rate of return on plan assets	7.0	%	5.6	%	—	%		6.3	%		5.4	%

Schedule of Expected Benefit Payments


Expected Future Benefit Payments of Our Benefit Plans
	Principal Pension Plans		Other Pension Plans		OPEB Plans
2024	$	1,277	$	226	$	130
2025	1,289		239		124
2026	1,300		239		119
2027	1,307		243		114
2028	1,310		254		110
2029-2033	6,449		1,334		454

Schedule of Allocation of Plan Assets

The following tables summarize our pension plan financial instruments that are measured at fair value on a recurring basis. There are no plan assets associated with our OPEB Plans. The inputs and valuation techniques used to measure the fair value of the assets are consistent with the valuation methodologies we use to measure financial assets at fair value on a recurring basis, as described in Note 2, “Summary of Significant Accounting Policies.”


Composition of Plan Assets as of December 31, 2023
	Principal Pension Plans										Other Pension Plans
			Basis of fair value measurement										Basis of fair value measurement
	Balance as of December 31, 2023		Level 1		Level 2		Level 3		Measured at NAV(1)		Balance as of December 31, 2023		Level 1		Level 2		Level 3		Measured at NAV(1)
Global equity securities	$	2,609	$	954	$	—	$	—	$	1,655	$	467	$	51	$	1	$	—	$	415
Debt securities (including cash and cash equivalents)	8,121		866		6,309		—		946		2,977		239		2,203		—		535
Real estate	912		—		—		382		530		508		—		—		20		488
Private equities and other investments	3,058		—		9		213		2,836		566		—		1		11		554
Fair value of plan assets	$	14,700	$	1,820	$	6,318	$	595	$	5,967	$	4,518	$	290	$	2,205	$	31	$	1,992

(1) Certain assets that are measured at fair value using the NAV per share (or its equivalent), as a practical expedient, have not been classified in the fair value hierarchy.


Composition of Plan Assets as of December 31, 2022
	Other Pension Plans
			Basis of fair value measurement
	Balance as of December 31, 2022		Level 1		Level 2		Level 3		Measured at NAV(1)
Global equity securities	$	67	$	33	$	—	$	—	$	34
Debt securities (including cash and cash equivalents)	205		24		150		—		31
Real estate	25		—		—		12		13
Private equities and other investments	128		3		7		49		69
Fair value of plan assets	$	425	$	60	$	157	$	61	$	147

(1) Certain assets that are measured at fair value using the NAV per share (or its equivalent), as a practical expedient, have not been classified in the fair value hierarchy.


Weighted Average Asset Allocation of Pension Plans
	2023 Target				2023 Actual
	Principal Pension Plans		Other Pension Plans			Principal Pension Plans		Other Pension Plans
Global equity securities	18	%	11	%		18	%	10	%
Debt securities (including cash and cash equivalents)	54	%	58	%		55	%	66	%
Real estate	7	%	17	%		6	%	11	%
Private equities and other instruments	21	%	14	%		21	%	13	%

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 2,494	$ 1,440
Short-term restricted cash	10	5
Total Cash, cash equivalents, and restricted cash as presented on the Consolidated and Combined Statements of Financial Position	2,504	1,445
Long-term restricted cash	2	6
Total Cash, cash equivalents, and restricted cash as presented on the Consolidated and Combined Statements of Cash Flows	$ 2,506	$ 1,451	$ 561	$ 1,012

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Schedule of Unrecognized Contractual Obligations (Details) $ in Millions	Dec. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2024	$ 308
2025	195
2026	142
2027	79
2028	72
Thereafter	79
Total	$ 875

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
	Jan. 03, 2023	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period			$ 230	$ 220	$ 223
Net income attributable to redeemable noncontrolling interests			41	47	39
Redemption value adjustments	$ 183		183	0	0
Distributions to and exercise of redeemable noncontrolling interests and other			(289)	(37)	(42)
Balance at end of period			165	230	220
Noncontrolling interest redemption payment		$ 211	$ 211	$ 0	$ 0

LEASES - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
LEASES - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Finance lease income	$ 13	$ 12	$ 16

EARNINGS PER SHARE - Narrative (Details) - shares	Dec. 31, 2023	Jan. 03, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Common stock, outstanding (in shares)	455,342,290	454,000,000	100

SEGMENT AND GEOGRAPHICAL INFORMATION

12 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHICAL INFORMATION

GE HealthCare’s operations are organized and managed through four reportable segments: Imaging, Ultrasound, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”). The Company’s organizational structure is based upon the availability of separate financial information that is evaluated regularly by the Company’s Chief Operating Decision Maker (“CODM”) for the purpose of assessing performance and allocating resources. The Company’s CODM is its Chief Executive Officer. These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments. A description of our reportable segments has been provided in the “Business” section of this Annual Report on Form 10-K.

The performance of these segments is principally measured based on Total revenues and an earnings metric defined as “Segment EBIT.” Segment EBIT is calculated as Income from continuing operations before income taxes in our Consolidated and Combined Statements of Income excluding the impact of the following: Interest and other financial charges – net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and investment revaluation gain (loss).


Total Revenues by Segment
	For the years ended December 31

		2023		2022		2021
Imaging:
Radiology		$	8,944	$	8,395	$	8,019
Interventional Guidance		1,637		1,590		1,414
Total Imaging		10,581		9,985		9,433
Total Ultrasound		3,457		3,422		3,172
PCS:
Monitoring Solutions		2,283		2,092		2,119
Life Support Solutions		859		824		796
Total PCS		3,142		2,916		2,915
Total PDx		2,306		1,958		2,018
Other(1)		66		60		47
Total revenues		$	19,552	$	18,341	$	17,585

(1) Financial information not presented within the reportable segments, shown within the Other category, represents the HealthCare Financial Services (“HFS”) business which does not meet the definition of an operating segment.

No single customer accounted for more than 10% of the Company’s revenues for the years ended December 31, 2023, 2022, or 2021. Additionally, no single customer accounted for more than 10% of accounts receivable as of December 31, 2023 or 2022.


Segment EBIT
	For the years ended December 31
		2023		2022		2021
Segment EBIT
Imaging		$	1,124	$	1,100	$	1,240
Ultrasound		821		908		885
PCS		383		341		356
PDx		617		520		693
Other(1)		11		(8)		(2)
		2,956		2,861		3,172
Restructuring costs		(54)		(146)		(155)
Acquisition and disposition-related benefits (charges)		15		34		(14)
Gain (loss) on business and asset dispositions		—		1		2
Spin-Off and separation costs		(270)		(14)		—
Amortization of acquisition-related intangible assets		(127)		(121)		(90)
Investment revaluation gain (loss)		1		(31)		3
Interest and other financial charges – net		(542)		(77)		(40)
Non-operating benefit income (costs)		382		5		(3)
Income from continuing operations before income taxes		$	2,361	$	2,512	$	2,875

(1) Financial information not presented within the reportable segments, shown within the Other category, represents the HFS business and certain other business activities which do not meet the definition of an operating segment.

The Company does not report total assets by segment for internal or external reporting purposes as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

GEOGRAPHIC INFORMATION.

Revenues are classified according to the country in which products and services are sold.


Total Revenues by Country
	For the years ended December 31
	2023		2022		2021
United States	$	8,228	$	7,819	$	7,060
China	2,560		2,325		2,510
All other countries	8,764		8,197		8,015
Total revenues	$	19,552	$	18,341	$	17,585

Long-lived assets represent Property, plant, and equipment – net, and are classified according to the country where the asset is located.


Long-Lived Assets – Net by Country
	As of
	December 31, 2023		December 31, 2022
United States	$	913	$	860
China	391		393
Norway	286		249
All other countries	910		812
Total long-lived assets – net	$	2,500	$	2,314

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

+ Details

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Pre-tax Amortization Expense for Intangible Assets (Details) $ in Millions	Dec. 31, 2023 USD ($)
Estimated Intangible Pre-tax Amortization
2024	$ 303
2025	259
2026	207
2027	122
2028	$ 71

LEASES

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

LEASES

OPERATING LEASES.

As a lessee, the Company leases certain logistics, office, and manufacturing facilities, as well as vehicles and other equipment. Certain of the Company’s leases may include options to extend. Our ROU operating lease assets are recognized within Property, plant, and equipment – net in the Consolidated and Combined Statements of Financial Position. Our operating lease liabilities are recognized within All other current liabilities and All other liabilities in the Consolidated and Combined Statements of Financial Position, as detailed below.


Operating Lease Assets and Liabilities
	As of
	December 31, 2023		December 31, 2022
Operating lease ROU assets	$	356	$	313
Current operating lease liabilities	110		104
Non-current operating lease liabilities	273		243
Total operating lease liabilities	$	383	$	347


Operating Lease Expense
	For the years ended December 31
	2023		2022		2021
Long-term (fixed)	$	121	$	115	$	114
Long-term (variable)	106		98		67
Short-term	2		4		4
Total operating lease expense	$	229	$	217	$	185


Maturity of Lease Liabilities
	2024		2025		2026		2027		2028		Thereafter		Total
Undiscounted lease payments	$	124	$	100	$	79	$	48	$	23	$	52	$	426
Less: imputed interest													43
Total lease liability as of December 31, 2023													$	383


Supplemental Information Related to Operating Leases
	For the years ended December 31
	2023			2022			2021
Operating cash flows used for operating leases	$	130		$	113		$	128
Right-of-use assets obtained in exchange for new lease liabilities	154			98			94
Weighted-average remaining lease term (in years)	4.7			4.4			4.7
Weighted-average discount rate	4.4		%	3.8		%	3.3		%

FINANCE LEASES.

The Company leases equipment manufactured or sold by the Company to customers through sales-type leases. Sales-type leases are included in financing receivables and are recognized within All other current assets and All other assets in the Consolidated and Combined Statements of Financial Position.

Finance lease income was $13 million, $12 million, and $16 million for the years ended December 31, 2023, 2022, and 2021, respectively, and is recognized within Other (income) expense – net in the Consolidated and Combined Statements of Income.


Net Investment in Financing Leases
	As of
	December 31, 2023		December 31, 2022
Total minimum lease payments receivable	$	236	$	248
Less: deferred income	(30)		(30)
Discounted lease receivable	206		218
Estimated unguaranteed residual value of leased assets, net of deferred income	11		12
Investment in financing leases, net of deferred income	$	217	$	230


Contractual Maturities

Due In	2024		2025		2026		2027		2028		Thereafter		Total
Net minimum lease payments receivable	$	80	$	61	$	41	$	25	$	15	$	14	$	236

We expect actual maturities to differ from contractual maturities, primarily as a result of prepayments.

LEASES

OPERATING LEASES.


Operating Lease Assets and Liabilities
	As of
	December 31, 2023		December 31, 2022
Operating lease ROU assets	$	356	$	313
Current operating lease liabilities	110		104
Non-current operating lease liabilities	273		243
Total operating lease liabilities	$	383	$	347


Operating Lease Expense
	For the years ended December 31
	2023		2022		2021
Long-term (fixed)	$	121	$	115	$	114
Long-term (variable)	106		98		67
Short-term	2		4		4
Total operating lease expense	$	229	$	217	$	185


Maturity of Lease Liabilities
	2024		2025		2026		2027		2028		Thereafter		Total
Undiscounted lease payments	$	124	$	100	$	79	$	48	$	23	$	52	$	426
Less: imputed interest													43
Total lease liability as of December 31, 2023													$	383


Supplemental Information Related to Operating Leases
	For the years ended December 31
	2023			2022			2021
Operating cash flows used for operating leases	$	130		$	113		$	128
Right-of-use assets obtained in exchange for new lease liabilities	154			98			94
Weighted-average remaining lease term (in years)	4.7			4.4			4.7
Weighted-average discount rate	4.4		%	3.8		%	3.3		%

FINANCE LEASES.


Net Investment in Financing Leases
	As of
	December 31, 2023		December 31, 2022
Total minimum lease payments receivable	$	236	$	248
Less: deferred income	(30)		(30)
Discounted lease receivable	206		218
Estimated unguaranteed residual value of leased assets, net of deferred income	11		12
Investment in financing leases, net of deferred income	$	217	$	230


Contractual Maturities

Due In	2024		2025		2026		2027		2028		Thereafter		Total
Net minimum lease payments receivable	$	80	$	61	$	41	$	25	$	15	$	14	$	236

We expect actual maturities to differ from contractual maturities, primarily as a result of prepayments.

ORGANIZATION AND BASIS OF PRESENTATION	12 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION ORGANIZATION. GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our,” or “we”) is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator. We operate at the center of the healthcare ecosystem, helping enable precision care by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients’ demand for greater efficiency, access, and personalized medicine. Our products, services, and solutions are designed to enable clinicians to make more informed decisions quickly and efficiently, improving patient care from diagnosis to therapy to monitoring. On January 3, 2023 (the “Distribution Date”), the General Electric Company (“GE”) completed the previously announced spin-off of GE HealthCare Technologies Inc. (the “Spin-Off”). The Spin-Off was completed through a distribution of approximately 80.1% of the Company’s outstanding common stock to holders of record of GE’s common stock as of the close of business on December 16, 2022 (the “Distribution”), which resulted in the issuance of approximately 454 million shares of common stock. Prior to the Distribution, the Company issued 100 shares of common stock in exchange for $1.00, all of which were held by GE as of December 31, 2022. As a result of the Distribution, the Company became an independent public company. As of December 31, 2023, GE’s beneficial ownership was approximately 13.5% of the Company’s outstanding common stock. In connection with the Spin-Off, certain adjustments were recorded to reflect transfers from GE, the draw-down of the Term Loan Facility and settlement of Spin-Off transactions with GE, which resulted in the net reduction in Total equity of $2,849 million. These items substantially consisted of the transfer of: (1) certain pension plan liabilities and assets as described in Note 10, “Postretirement Benefit Plans,” (2) certain deferred income taxes as described in Note 11, “Income Taxes,” (3) deferred compensation liabilities of $548 million, and (4) employee termination obligations as described in Note 15, “Restructuring and Other Activities – Net.” In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE. See Note 19, “Related Parties” for more information on these agreements. Unless the context otherwise requires, references to “GE HealthCare,” “we,” “us,” “our,” and the “Company” refer to (1) GE’s healthcare business prior to the Spin-Off as a carve-out business of GE with related combined financial statements and (2) GE HealthCare Technologies Inc. and its subsidiaries following the Spin-Off with related consolidated financial statements. BASIS OF PRESENTATION. The consolidated and combined financial statements have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) and present the historical results of operations, comprehensive income (loss), and cash flows for the years ended December 31, 2023, 2022, and 2021, and the financial position as of December 31, 2023 and 2022. All intercompany balances and transactions within the Company have been eliminated in the consolidated and combined financial statements. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position and operating results. The following tables are presented in millions of U.S. dollars (“USD”) unless otherwise stated. Prior to the Spin-Off, the combined financial statements were derived from the consolidated financial statements and accounting records of GE including the historical cost basis of assets and liabilities comprising the Company, as well as the historical revenues, direct costs, and allocations of indirect costs attributable to the operations of the Company, using the historical accounting policies applied by GE. The combined financial statements do not purport to reflect what the results of operations, comprehensive income (loss), financial position, or cash flows would have been had the Company operated as a separate, stand-alone entity prior to the Spin-Off. The financial statements include certain transactions with GE, which are disclosed as related party transactions. See Note 19, “Related Parties” for further information. Following the Spin-Off, certain prior year amounts in the financial statements and notes thereto have been reclassified to conform to the current year presentation, which provides additional detail to readers of our financial statements. Amounts in the Consolidated and Combined Statements of Cash Flows that were previously included within the All other operating activities line have been reclassified to separate lines including Net periodic postretirement benefit plan (income) expense, Postretirement plan contributions, and Share-based compensation.

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

12 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

GUARANTEES.

The Company has off-balance sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 9, “Borrowings” for further information. In addition, prior to Spin-Off, GE had provided performance guarantees in certain jurisdictions where we lacked the legal structure to issue the requisite guarantees required on certain projects.

Following the Spin-Off, which was completed pursuant to a Separation and Distribution Agreement (the “Separation and Distribution Agreement”), the Company has remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE is obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees.

Until such termination or replacement, in the event of non-fulfillment of contractual obligations by the relevant obligors, the Company could be obligated to make payments under the applicable instruments for which GE is obligated to reimburse and indemnify the Company. As of December 31, 2023 the Company’s maximum aggregate exposure, subject to GE reimbursement, is approximately $114 million.

PRODUCT WARRANTIES.

We provide warranty coverage to our customers as part of customary practices in the market to provide assurance that the products we sell comply with agreed-upon specifications. We provide estimated product warranty expenses when we sell the related products. Warranty accruals are estimates that are based on the best available information, mostly historical claims experience, therefore claims costs may differ from amounts provided. An analysis of changes in the liability for product warranties follows.


Product Warranties
	For the years ended December 31
	2023		2022		2021
Balance at beginning of period	$	193	$	161	$	157
Current-year provisions	216		238		228
Expenditures	(218)		(199)		(221)
Other changes	1		(7)		(3)
Balance at end of period	$	192	$	193	$	161

Product warranties are recognized within All other current liabilities in the Consolidated and Combined Statements of Financial Position.

LEGAL MATTERS.

In the normal course of our business, we are involved from time to time in various arbitrations; class actions; commercial, intellectual property, and product liability litigation; government investigations; investigations by competition/antitrust authorities; and other legal, regulatory, or governmental actions, including the significant matters described below that could have a material impact on our results of operations and cash flows. In many proceedings, including the specific matters described below, it is inherently difficult to determine whether any loss is probable or even reasonably possible or to estimate the size or range of the possible loss, and accruals for legal matters are not recorded until a loss for a particular matter is considered probable and reasonably estimable. Given the nature of legal matters and the complexities involved, it is often difficult to predict and determine a meaningful estimate of loss or range of loss until we know, among other factors, the particular claims involved, the likelihood of success of our defenses to those claims, the damages or other relief sought, how discovery or other procedural considerations will affect the outcome, the settlement posture of other parties, and other factors that may have a material effect on the outcome. For such matters, unless otherwise specified, we do not believe it is possible to provide a meaningful estimate of loss at this time. Moreover, it is not uncommon for legal matters to be resolved over many years, during which time relevant developments and new information must be continuously evaluated.

Contracts with Iraqi Ministry of Health

In 2017, a number of U.S. Service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia (the “District Court”) against a number of pharmaceutical and medical device companies, including GE HealthCare and certain affiliates, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all of the judges on the U.S. Court of Appeals for the District of Columbia Circuit (the “D.C. Circuit”). In February 2023, the D.C. Circuit denied this request. In June 2023, defendants petitioned the Supreme Court to review the D.C. Circuit’s decision. On October 2, 2023, the Supreme Court invited the Solicitor General to file a brief in this case expressing the views of the United States. The proceedings in the District Court are stayed.

Government Disclosures

From time to time, we make self-disclosures regarding our compliance with the Foreign Corrupt Practices Act (“FCPA”) and similar laws to relevant authorities who may pursue or decline to pursue enforcement proceedings against us. We, with the assistance of outside counsel, made voluntary self-disclosures to the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice (“DOJ”) beginning in 2018 regarding tender irregularities and other potential violations of the FCPA relating to our activities in certain provinces in China. We have been engaged in ongoing discussions with each of the SEC and the DOJ regarding these matters. We are fully cooperating with the reviews by these agencies and have implemented, and continue to implement, enhancements to our compliance policies and practices. At this time, we are unable to predict the duration, scope, result, or related costs associated with these disclosures to the SEC and the DOJ. We also are unable to predict what, if any, action may be taken by the SEC or the DOJ or what penalties or remedial actions they may seek. Any determination that our operations or activities are not in compliance with existing laws or regulations, including applicable foreign laws, could result in the imposition of fines, penalties, disgorgement, equitable relief, or other losses.

ENVIRONMENTAL AND ASSET RETIREMENT OBLIGATIONS.

Our operations, like operations of other companies engaged in similar businesses, involve the use, disposal, and cleanup of substances regulated under environmental protection laws and nuclear decommissioning regulations. We have obligations for ongoing and future environmental remediation activities. Liabilities for environmental remediation and nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. Our environmental remediation liabilities, which are measured on an undiscounted basis, were $19 million and $11 million as of December 31, 2023 and 2022, respectively, and are recognized within All other current liabilities and All other liabilities in the Consolidated and Combined Statements of Financial Position.

We record asset retirement obligations, which primarily relate to nuclear decommissioning, associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives. Our asset retirement obligations were $267 million and $274 million at December 31, 2023 and 2022, respectively, and are recognized within All other current liabilities and All other liabilities in the Consolidated and Combined Statements of Financial Position. Changes in the liability balance were mainly due to foreign exchange rates, settlement, accretion, and revisions in fair value, and were not material for the years ended December 31, 2023, 2022, and 2021.

OTHER UNRECOGNIZED CONTRACTUAL OBLIGATIONS.

We have future contractual obligations and other minimum commercial commitments which represent take-or-pay contracts as well as purchase orders for goods and services utilized in the normal course of business such as capital expenditures, inventory, and services under contracts.

As of December 31, 2023, we had the following purchase commitments that are legally binding and specify minimum purchase quantities or spending amounts. These purchase commitments do not exceed our projected requirements and the amounts below exclude open purchase orders with a remaining term of less than one year.


Other Unrecognized Contractual Obligations
	2024		2025		2026		2027		2028		Thereafter		Total
Other Unrecognized Contractual Obligations	$	308	$	195	$	142	$	79	$	72	$	79	$	875

SHARE-BASED COMPENSATION - Summary of Other Share-Based Compensation Data (Details) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Share-Based Payment Arrangement [Abstract]
Unrecognized compensation expense as of September 30, 2023	$ 149
Cash received from stock options exercised in the year ended December 31, 2023	34
Intrinsic value of stock options exercised and RSU/PSUs vested in the year ended December 31, 2023	$ 106
Weighted average period of recognition	1 year 10 months 24 days

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Inventory (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 961	$ 1,053
Work in process	91	91
Finished goods	908	1,011
Inventories	$ 1,960	$ 2,155

SHARE-BASED COMPENSATION - Summary of Stock Option Activity (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Stock options, shares
Outstanding at beginning of period (in shares) \| shares	3,738
Granted (in shares) \| shares	2,155
Exercised (in shares) \| shares	(561)
Forfeited (in shares) \| shares	(159)
Expired (in shares) \| shares	(210)
Outstanding at end of period (in shares) \| shares	4,963
Exercisable (in shares) \| shares	2,810
Expected to vest (in shares) \| shares	1,755
Stock options, weighted average exercise price
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 90
Granted (in dollars per share) \| $ / shares	72
Exercised (in dollars per share) \| $ / shares	60
Forfeited (in dollars per share) \| $ / shares	71
Expired (in dollars per share) \| $ / shares	127
Outstanding at end of period (in dollars per share) \| $ / shares	84
Exercisable (in dollars per share) \| $ / shares	94
Expected to vest (in dollars per share) \| $ / shares	$ 72
Stock options, weighted average contractual term (in years)
Stock options, weighted average remaining contractual term, outstanding	6 years 1 month 6 days
Stock options, weighted average remaining contractual term, exercisable	3 years 9 months 18 days
Stock options, weighted average remaining contractual term, expected to vest	9 years
Stock options, intrinsic value
Stock options, intrinsic value, outstanding \| $	$ 35
Stock options, intrinsic value, exercisable \| $	23
Stock options, intrinsic value, expected to vest \| $	$ 10

SEGMENT AND GEOGRAPHICAL INFORMATION - Narrative (Details)	12 Months Ended
	Dec. 31, 2023 segment
Segment Reporting [Abstract]
Number of operating segments	4
Number of reportable segments	4

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill


Goodwill
	Imaging		Ultrasound		PCS		PDx		Total
Balance at December 31, 2021	$	4,433	$	3,876	$	2,049	$	2,534	$	12,892
Acquisitions	—		—		—		—		—
Foreign currency exchange and other(1)	(24)		(41)		(13)		(1)		(79)
Balance at December 31, 2022	4,409		3,835		2,036		2,533		12,813
Acquisitions(2)	16		94		—		—		110
Foreign currency exchange and other	6		4		2		1		13
Balance at December 31, 2023	$	4,431	$	3,933	$	2,038	$	2,534	$	12,936

(1) Other includes purchase accounting adjustments for prior year acquisitions.

(2) Includes the acquisition of IMACTIS SAS in the second quarter of 2023.

Schedule of Finite-Lived Intangible Assets


Intangible Assets
	As of December 31, 2023						As of December 31, 2022
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Customer-related	$	60	$	(16)	$	44	$	60	$	(10)	$	50
Patents and technology	2,541		(1,867)		674		2,544		(1,815)		729
Capitalized software	1,963		(1,509)		454		2,309		(1,638)		671
Trademarks and other	33		(27)		6		35		(27)		8
Indefinite-lived assets(1)	75		—		75		62		—		62
Total	$	4,672	$	(3,419)	$	1,253	$	5,010	$	(3,490)	$	1,520

(1) Indefinite-lived intangible assets relate to acquired IPR&D prior to project completion and are not amortized.

Schedule of Indefinite-Lived Intangible Assets


Intangible Assets
	As of December 31, 2023						As of December 31, 2022
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Customer-related	$	60	$	(16)	$	44	$	60	$	(10)	$	50
Patents and technology	2,541		(1,867)		674		2,544		(1,815)		729
Capitalized software	1,963		(1,509)		454		2,309		(1,638)		671
Trademarks and other	33		(27)		6		35		(27)		8
Indefinite-lived assets(1)	75		—		75		62		—		62
Total	$	4,672	$	(3,419)	$	1,253	$	5,010	$	(3,490)	$	1,520

(1) Indefinite-lived intangible assets relate to acquired IPR&D prior to project completion and are not amortized.

Schedule of Pre-tax Amortization Expense for Intangible Assets

Estimated annual pre-tax amortization expense for intangible assets as of December 31, 2023 over the next five calendar years is as follows.


Estimated Intangible Pre-tax Amortization
	2024		2025		2026		2027		2028
Estimated annual pre-tax amortization	$	303	$	259	$	207	$	122	$	71

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

LEASES - Schedule of Operating Lease Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease ROU assets	$ 356	$ 313
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, plant, and equipment – net	Property, plant, and equipment – net
Current operating lease liabilities	$ 110	$ 104
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	All other current liabilities	All other current liabilities
Non-current operating lease liabilities	$ 273	$ 243
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	All other liabilities	All other liabilities
Total operating lease liabilities	$ 383	$ 347

DISCONTINUED OPERATIONS (Details) $ in Millions	Mar. 31, 2020 USD ($)
BioPharma business \| Disposed of by sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operation, consideration	$ 20,718

Consolidated and Combined Statements of Financial Position - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Cash, cash equivalents, and restricted cash	$ 2,504	$ 1,445
Inventories	1,960	2,155
Contract and other deferred assets	1,000	989
All other current assets	389	417
Current assets	9,410	8,318
Property, plant, and equipment – net	2,500	2,314
Goodwill	12,936	12,813
Other intangible assets – net	1,253	1,520
Deferred income taxes	4,474	1,550
All other assets	1,881	1,024
Total assets	32,454	27,539
Short-term borrowings	1,006	15
Accounts payable	2,947	2,944
Contract liabilities	1,918	1,896
Current liabilities	8,981	7,191
Long-term borrowings	8,436	8,234
Compensation and benefits	5,782	549
Deferred income taxes	68	370
All other liabilities	1,877	1,603
Total liabilities	25,144	17,947
Commitments and contingencies
Redeemable noncontrolling interests	165	230
Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 455,342,290 shares issued and outstanding as of December 31, 2023; 100 shares issued and outstanding as of December 31, 2022	5	0
Additional paid-in capital	6,493	0
Retained earnings	1,326	0
Net parent investment	0	11,235
Accumulated other comprehensive income (loss) – net	(691)	(1,878)
Total equity attributable to GE HealthCare	7,133	9,357
Noncontrolling interests	12	5
Total equity	7,145	9,362
Total liabilities, redeemable noncontrolling interests, and equity	32,454	27,539
Nonrelated party
Receivables, net	3,525	3,295
All other current liabilities	3,011	2,190
Related party
Receivables, net	32	17
All other assets	81
All other current liabilities	99	$ 146
All other liabilities	$ 33

INCOME TAXES - Summary of Valuation Allowance (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred Tax Asset, Valuation Allowance [Roll Forward]
Beginning Balance	$ 272	$ 279	$ 250
Provision for income taxes	(12)	(5)	39
Foreign currency exchange and other	280	(2)	(10)
Ending Balance	$ 540	$ 272	$ 279

EARNINGS PER SHARE - Schedule of Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net income from continuing operations	$ 1,618	$ 1,949	$ 2,275
Net (income) loss attributable to noncontrolling interests	(46)	(51)	(46)
Net income from continuing operations attributable to GE HealthCare	1,572	1,898	2,229
Deemed preferred stock dividend of redeemable noncontrolling interest	(183)	0	0
Net income from continuing operations attributable to GE HealthCare common stockholders	1,389	1,898	2,229
Income (loss) from discontinued operations, net of taxes	(4)	18	18
Net income attributable to GE HealthCare common stockholders	$ 1,385	$ 1,916	$ 2,247
Denominator:
Basic weighted-average shares outstanding	455	454	454
Dilutive effect of common stock equivalents (in shares)	3	0	0
Diluted weighted-average shares outstanding	458	454	454
Basic Earnings Per Share:
Continuing operations (in dollars per share)	$ 3.06	$ 4.18	$ 4.91
Discontinued operations (in dollars per share)	(0.01)	0.04	0.04
Attributable to GE HealthCare common stockholders (in dollars per share)	3.05	4.22	4.95
Diluted Earnings Per Share:
Continuing operations (in dollars per share)	3.04	4.18	4.91
Discontinued operations (in dollars per share)	(0.01)	0.04	0.04
Attributable to GE HealthCare common stockholders (in dollars per share)	$ 3.03	$ 4.22	$ 4.95
Antidilutive securities (in shares)	4	0	0

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Schedule of Product Warranties (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance at beginning of period	$ 193	$ 161	$ 157
Current-year provisions	216	238	228
Expenditures	(218)	(199)	(221)
Other changes	1	(7)	(3)
Balance at end of period	$ 192	$ 193	$ 161

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Cumulative Basis Adjustment for Fair value Hedges (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Long-term borrowings designated in fair value hedges	$ 1,023
Hedged Liability, Statement of Financial Position [Extensible Enumeration]	Long-term borrowings
Cumulative basis adjustment included in the carrying amount	$ 25	$ 0

BORROWINGS (Tables)

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Schedule of Long-Term Borrowings


Borrowings Composition
	As of
	December 31, 2023		December 31, 2022
5.550% senior notes due November 15, 2024	$	1,000	$	1,000
5.600% senior notes due November 15, 2025	1,500		1,500
5.650% senior notes due November 15, 2027	1,750		1,750
5.857% senior notes due March 15, 2030	1,250		1,250
5.905% senior notes due November 22, 2032	1,750		1,750
6.377% senior notes due November 22, 2052	1,000		1,000
Floating rate Term Loan Facility due January 2, 2026	1,150		—
Other	52		46
Total principal debt issued	9,452		8,296
Less: Unamortized debt issuance costs and discounts	35		47
Add: Cumulative basis adjustment for fair value hedges	25		—
Total borrowings	9,442		8,249
Less: Short-term borrowings (net of debt issuance costs)	1,006		15
Long-term borrowings	$	8,436	$	8,234

Schedule of Maturities of Long-Term Debt

Scheduled maturities of borrowings, excluding amortization of discounts and debt issuance costs, are as follows.



2024		2025		2026		2027		2028		Thereafter		Total
$	1,008	$	1,541	$	1,152	$	1,751	$	—	$	4,000	$	9,452

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482949/835-30-55-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480848/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-7

+ Details

INCOME TAXES - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of period	$ 465	$ 365	$ 684
Additions for tax positions of the current year	0	9	9
Additions for tax positions of prior years	156	137	14
Reductions for tax positions of prior years	(203)	(41)	(78)
Settlements with tax authorities	(6)	(1)	(262)
Expiration of the statute of limitations	(3)	(4)	(2)
Balance at end of period	409	465	365
Unrecognized tax benefits	409	465	365
Accrued interest on unrecognized tax benefits	72	56	53
Reasonably possible reduction to the balance of unrecognized tax benefits in succeeding 12 months	29	45	36
Portion that, if recognized, would reduce tax expense and effective tax rate	$ 157	$ 153	$ 111

POSTRETIREMENT BENEFIT PLANS - Narrative (Details)	3 Months Ended		12 Months Ended
POSTRETIREMENT BENEFIT PLANS - Narrative (Details)	Dec. 31, 2023 USD ($) payment_installment benefit_plan	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) payment_installment	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jan. 01, 2023 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Plan asset or obligation reporting threshold			$ 50,000,000	$ 20,000,000	$ 20,000,000
Defined benefit plan, number of annual installments upon retirement \| payment_installment	10		10
Fair value of assets						$ 18,908,000,000
Projected benefit obligations						22,953,000,000
Defined benefit plan, expected future employer contributions, next fiscal year	$ 336,000,000		$ 336,000,000
Number of plans with employee termination payment \| benefit_plan	2
Weighted average health care cost trend rate assumed, initial rate	6.50%		6.50%
Weighted average health care cost trend rate assumed, ultimate rate	5.00%		5.00%
Expected amortization of net actuarial gain, next fiscal year	$ (116,000,000)		$ (116,000,000)
Expected amortization of prior service credit, next fiscal year	(81,000,000)		(81,000,000)
Defined contribution plan, employer contribution amount			122,000,000	123,000,000	119,000,000
U.S.
Defined Benefit Plan Disclosure [Line Items]
Cost of postretirement benefit plans				73,000,000	96,000,000
Non U.S.
Defined Benefit Plan Disclosure [Line Items]
Cost of postretirement benefit plans				11,000,000	22,000,000
Level 3 \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	626,000,000		626,000,000	61,000,000
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets						18,908,000,000
Projected benefit obligations						21,743,000,000
Pension Plans \| Principal Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan asset	0		0
Cost of postretirement benefit plans			(290,000,000)
Fair value of assets	14,700,000,000		14,700,000,000	0
Projected benefit obligations	18,160,000,000		18,160,000,000	0
Defined benefit plan, employer contribution amount			142,000,000
Loss due to curtailment			17,000,000
Benefit obligation, increase for curtailment			(30,000,000)
AOCI, decrease due to remeasurement			(47,000,000)
Settlement charge			0
Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	14,700,000,000		14,700,000,000
Pension Plans \| GE HealthCare Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	14,700,000,000		14,700,000,000
Projected benefit obligations	$ 16,138,000,000		$ 16,138,000,000
Funded percentage	91.00%		91.00%
Loss due to curtailment		$ 17,000,000
Benefit obligation, increase for curtailment		23,000,000
AOCI, decrease due to remeasurement		$ 305,000,000
Pension Plans \| GE HealthCare Supplemental Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Projected benefit obligations	$ 2,022,000,000		$ 2,022,000,000
Defined benefit plan, employer contribution amount			142,000,000
Pension Plans \| Other Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan asset	712,000,000		712,000,000	65,000,000
Cost of postretirement benefit plans			44,000,000	9,000,000	25,000,000
Fair value of assets	4,518,000,000		4,518,000,000	382,000,000
Projected benefit obligations	4,588,000,000		4,588,000,000	640,000,000
Defined benefit plan, employer contribution amount			84,000,000
Loss due to curtailment			0	0	0
Benefit obligation, increase for curtailment			0
AOCI, decrease due to remeasurement			(61,000,000)	0	0
Settlement charge	61,000,000		61,000,000	0	$ 0
Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	4,518,000,000		4,518,000,000	425,000,000
Pension Plans \| Level 3 \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	595,000,000		595,000,000
Pension Plans \| Level 3 \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	31,000,000		31,000,000	61,000,000
OPEB Plans
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan asset	0		0
Cost of postretirement benefit plans			(86,000,000)
Fair value of assets	0		0	0		0
Projected benefit obligations	$ 1,133,000,000		1,133,000,000	0		$ 1,210,000,000
Defined benefit plan, employer contribution amount			131,000,000
Loss due to curtailment			0
Benefit obligation, increase for curtailment			0
AOCI, decrease due to remeasurement			0
Settlement charge			$ 0
GE Sponsored Pension And Retiree Health And Life Plans
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan liability				0
Defined benefit plan asset				$ 0

SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Expense (Details) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Share-Based Payment Arrangement [Abstract]
Share-based compensation expense (pre-tax)	$ 114
Income tax benefits	(23)
Share-based compensation expense (after-tax)	$ 91

EARNINGS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Schedule of Earnings per Share


Earnings Per Share
	For the years ended December 31
(In millions, except per share amounts)		2023		2022		2021
Numerator:
Net income from continuing operations		$	1,618	$	1,949	$	2,275
Net (income) loss attributable to noncontrolling interests		(46)		(51)		(46)
Net income from continuing operations attributable to GE HealthCare		1,572		1,898		2,229
Deemed preferred stock dividend of redeemable noncontrolling interest		(183)		—		—
Net income from continuing operations attributable to GE HealthCare common stockholders		1,389		1,898		2,229
Income (loss) from discontinued operations, net of taxes		(4)		18		18
Net income attributable to GE HealthCare common stockholders		$	1,385	$	1,916	$	2,247
Denominator:
Basic weighted-average shares outstanding		455		454		454
Dilutive effect of common stock equivalents		3		—		—
Diluted weighted-average shares outstanding		458		454		454
Basic Earnings Per Share:
Continuing operations		$	3.06	$	4.18	$	4.91
Discontinued operations		(0.01)		0.04		0.04
Attributable to GE HealthCare common stockholders		3.05		4.22		4.95
Diluted Earnings Per Share:
Continuing operations		$	3.04	$	4.18	$	4.91
Discontinued operations		(0.01)		0.04		0.04
Attributable to GE HealthCare common stockholders		3.03		4.22		4.95
Antidilutive securities(1)		4		—		—

(1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of All Other Current and Noncurrent Assets (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid expenses and deferred costs	$ 147	$ 163
Financing receivables – net	97	97
Derivative instruments	84	63
Other	61	94
All other current assets	389	417
Prepaid pension asset	716	70
Equity method and other investments	357	322
Financing receivables – net	178	196
Long-term receivables – net	124	145
Inventories	147	104
Contract and other deferred assets	168	119
Other	191	68
All other non-current assets	$ 1,881	$ 1,024

RESTRUCTURING AND OTHER ACTIVITIES - NET - Narrative (Details) - USD ($) $ in Millions		12 Months Ended
	Jan. 03, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring expenses, net		$ 54	$ 146	$ 155
Expected restructuring expense remaining		20
Restructuring liabilities		68	$ 75
Spin-Off
Restructuring Cost and Reserve [Line Items]
Accrual adjustment	$ 31
Restructuring liabilities		$ 4

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (3,419)	$ (3,490)
Indefinite-lived assets	75	62
Gross Carrying Amount	4,672	5,010
Net	1,253	1,520
Customer-related
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	60	60
Accumulated Amortization	(16)	(10)
Finite-lived assets, net	44	50
Patents and technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	2,541	2,544
Accumulated Amortization	(1,867)	(1,815)
Finite-lived assets, net	674	729
Capitalized software
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	1,963	2,309
Accumulated Amortization	(1,509)	(1,638)
Finite-lived assets, net	454	671
Trademarks and other
Finite-Lived Intangible Assets [Line Items]
Finite-lived assets, gross	33	35
Accumulated Amortization	(27)	(27)
Finite-lived assets, net	$ 6	$ 8

Consolidated and Combined Statements of Changes in Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2023 $ / shares
Statement of Stockholders' Equity [Abstract]
Dividends declared per common share (in dollars per share)	$ 0.12

REVENUE RECOGNITION - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Capitalized contract costs	$ 213	$ 204
Capitalized contract period	2 years
Contract liabilities	$ 2,623	2,526
Contract liabilities, noncurrent	705	630
Increase in contract liabilities, increase in extended warranty contracts	97
Contract liabilities, revenue recognized	1,554	$ 1,562
Remaining performance obligation, amount	14,655
Products
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 4,930
Products \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	98.00%
Remaining performance obligation, period	2 years
Services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 9,725
Services \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| Period one
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	65.00%
Remaining performance obligation, period	2 years
Services \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| Period two
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	93.00%
Remaining performance obligation, period	5 years

SUBSEQUENT EVENTS (Details) - USD ($) $ in Millions		3 Months Ended
SUBSEQUENT EVENTS (Details) - USD ($) $ in Millions	Jan. 22, 2024	Dec. 31, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Derivative, notional amount		$ 9,591	$ 8,488
Fair value hedges \| Designated as hedging instrument
Subsequent Event [Line Items]
Derivative, notional amount		1,000	0
Interest rate swaps \| Fair value hedges \| Designated as hedging instrument
Subsequent Event [Line Items]
Derivative, notional amount		1,000	$ 0
Unsecured debt \| Floating Rate Term Loan Facility due 2026 \| Line of credit
Subsequent Event [Line Items]
Debt repayments		$ 850
Subsequent event \| Interest rate swaps \| Fair value hedges \| Designated as hedging instrument
Subsequent Event [Line Items]
Derivative, notional amount	$ 700
Subsequent event \| Unsecured debt \| Floating Rate Term Loan Facility due 2026 \| Line of credit
Subsequent Event [Line Items]
Debt repayments	$ 150

BORROWINGS

12 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

BORROWINGS

The Company’s borrowings include the following senior unsecured notes and credit agreements:

Senior Unsecured Notes

The Company’s long-term borrowings include $8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2024 through 2052 (collectively, the “Notes”). Interest payments on the Notes are due semi-annually until maturity. In the event of a change in control and a related downgrade of the ratings of the Notes below investment grade, the indenture governing the Notes requires that the Company make an offer to each holder of the Notes to repurchase all or any part of that holder’s notes at a repurchase price equal to 101% of the aggregate principal amount of the Notes repurchased, plus any accrued and unpaid interest. The indenture also includes a limitation on liens incurred by the Company and its wholly owned U.S. subsidiaries. The indenture does not restrict the Company or its subsidiaries from incurring indebtedness, nor does it require any financial covenants. All covenants are subject to a number of exceptions, limitations, and qualifications. Refer to the table below for further information about the Notes.

Credit Facilities

The Company has credit agreements providing for:

•a five-year senior unsecured revolving credit facility in an aggregate committed amount of $2,500 million;

•a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $1,000 million; and

•a three-year senior unsecured term loan credit facility in an aggregate principal amount of $2,000 million (the “Term Loan Facility” and, together with the five-year revolving credit facility and the 364-day revolving credit facility, the “Credit Facilities”).

There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility as of December 31, 2023 or 2022. In the fourth quarter of 2023, we entered into a new 364-day senior unsecured revolving credit facility to replace the 364-day senior unsecured revolving credit facility that was scheduled to mature in January 2024.

On January 3, 2023, the Company completed a $2,000 million drawdown of the floating rate Term Loan Facility in connection with the Spin-Off from GE. In the fourth quarter of 2023, we repaid $850 million of the outstanding Term Loan Facility. We had no principal debt repayments on the Notes for the year ended December 31, 2023.

The Company pays a facility fee to each lender, which accrues at a rate equal to an applicable margin specified in the revolving credit facility agreements on the daily commitments of the lenders. The borrowings under the Credit Facilities will bear interest at variable interest rates equal to: (i) the alternate base rate or (ii) the Secured Overnight Financing Rate, in each case plus an applicable margin specified in the credit agreement. The Credit Facilities contain affirmative and negative covenants customary to financings of this type that, among other things, limit the Company and its subsidiaries’ ability to incur additional liens and to make certain fundamental changes. In addition, the Credit Facilities contain a financial covenant that requires the Company to not exceed a maximum consolidated net leverage ratio. The Company was in compliance with the financial covenant at each reporting period during 2023. The Credit Facilities will be used for general corporate purposes.

Interest expense associated with long-term debt was $616 million and $54 million for the years ended December 31, 2023 and 2022, respectively, and is included in Interest and other financial charges – net in the Consolidated and Combined Statements of Income. Interest expense for borrowings was not significant for the year ended December 31, 2021. The weighted average interest rate for the Notes and our Credit Facilities for the years ended December 31, 2023 and 2022 was 6.03% and 5.97%, respectively.


Borrowings Composition
	As of
	December 31, 2023		December 31, 2022
5.550% senior notes due November 15, 2024	$	1,000	$	1,000
5.600% senior notes due November 15, 2025	1,500		1,500
5.650% senior notes due November 15, 2027	1,750		1,750
5.857% senior notes due March 15, 2030	1,250		1,250
5.905% senior notes due November 22, 2032	1,750		1,750
6.377% senior notes due November 22, 2052	1,000		1,000
Floating rate Term Loan Facility due January 2, 2026	1,150		—
Other	52		46
Total principal debt issued	9,452		8,296
Less: Unamortized debt issuance costs and discounts	35		47
Add: Cumulative basis adjustment for fair value hedges	25		—
Total borrowings	9,442		8,249
Less: Short-term borrowings (net of debt issuance costs)	1,006		15
Long-term borrowings	$	8,436	$	8,234

Scheduled maturities of borrowings, excluding amortization of discounts and debt issuance costs, are as follows.



2024		2025		2026		2027		2028		Thereafter		Total
$	1,008	$	1,541	$	1,152	$	1,751	$	—	$	4,000	$	9,452

See Note 13, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated derivatives contracts.

LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS.

As of December 31, 2023 and 2022, the Company had bank guarantees and surety bonds of approximately $751 million and $657 million, respectively, related to certain commercial contracts. Additionally, we have approximately $39 million and $43 million of guarantees as of December 31, 2023 and 2022, respectively, primarily related to residual and credit guarantees on equipment sold to third-party finance companies. Our Consolidated and Combined Statements of Financial Position reflect a liability of $4 million as of December 31, 2023 and 2022 related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Consolidated and Combined Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income attributable to GE HealthCare	$ 1,568	$ 1,916	$ 2,247
Net (income) loss attributable to noncontrolling interests	46	51	46
Net income	1,614	1,967	2,293
Other comprehensive income (loss):
Currency translation adjustments – net of taxes	74	(878)	(326)
Benefit plans – net of taxes	(897)	58	80
Cash flow hedges – net of taxes	(27)	(23)	48
Other comprehensive income (loss)	(850)	(843)	(198)
Comprehensive income (loss)	764	1,124	2,095
Less: Comprehensive income (loss) attributable to noncontrolling interests	9	51	46
Comprehensive income attributable to GE HealthCare	$ 755	$ 1,073	$ 2,049

SEGMENT AND GEOGRAPHICAL INFORMATION (Tables)

12 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Schedule of Segment Reporting Information


Total Revenues by Segment
	For the years ended December 31

		2023		2022		2021
Imaging:
Radiology		$	8,944	$	8,395	$	8,019
Interventional Guidance		1,637		1,590		1,414
Total Imaging		10,581		9,985		9,433
Total Ultrasound		3,457		3,422		3,172
PCS:
Monitoring Solutions		2,283		2,092		2,119
Life Support Solutions		859		824		796
Total PCS		3,142		2,916		2,915
Total PDx		2,306		1,958		2,018
Other(1)		66		60		47
Total revenues		$	19,552	$	18,341	$	17,585


Segment EBIT
	For the years ended December 31
		2023		2022		2021
Segment EBIT
Imaging		$	1,124	$	1,100	$	1,240
Ultrasound		821		908		885
PCS		383		341		356
PDx		617		520		693
Other(1)		11		(8)		(2)
		2,956		2,861		3,172
Restructuring costs		(54)		(146)		(155)
Acquisition and disposition-related benefits (charges)		15		34		(14)
Gain (loss) on business and asset dispositions		—		1		2
Spin-Off and separation costs		(270)		(14)		—
Amortization of acquisition-related intangible assets		(127)		(121)		(90)
Investment revaluation gain (loss)		1		(31)		3
Interest and other financial charges – net		(542)		(77)		(40)
Non-operating benefit income (costs)		382		5		(3)
Income from continuing operations before income taxes		$	2,361	$	2,512	$	2,875

Schedule of Revenues by Geographic Region

Revenues are classified according to the country in which products and services are sold.


Total Revenues by Country
	For the years ended December 31
	2023		2022		2021
United States	$	8,228	$	7,819	$	7,060
China	2,560		2,325		2,510
All other countries	8,764		8,197		8,015
Total revenues	$	19,552	$	18,341	$	17,585

Schedule of Long-Lived Assets by Geographic Areas

Long-lived assets represent Property, plant, and equipment – net, and are classified according to the country where the asset is located.


Long-Lived Assets – Net by Country
	As of
	December 31, 2023		December 31, 2022
United States	$	913	$	860
China	391		393
Norway	286		249
All other countries	910		812
Total long-lived assets – net	$	2,500	$	2,314

RECEIVABLES

12 Months Ended

Dec. 31, 2023

Receivables [Abstract]

RECEIVABLES


Current Receivables
	As of
	December 31, 2023		December 31, 2022
Current customer receivables(1)	$	3,339	$	3,112
Non-income based tax receivables	166		174
Other sundry receivables	118		100
Sundry receivables	284		274
Allowance for credit losses	(98)		(91)
Total current receivables – net	$	3,525	$	3,295

(1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $144 million and $157 million as of December 31, 2023 and 2022, respectively.

Activity in the allowance for credit losses related to current receivables for the years ended December 31, 2023, 2022, and 2021 consisted of the following:


Balance at December 31, 2020	$	93
Additions charged to costs and expenses	12
Write-offs	(10)
Foreign currency exchange and other	12
Balance at December 31, 2021	107
Additions charged to costs and expenses	2
Write-offs	(13)
Foreign currency exchange and other	(5)
Balance at December 31, 2022	91
Additions charged to costs and expenses	16
Write-offs	(11)
Foreign currency exchange and other	2
Balance at December 31, 2023	$	98


Long-Term Receivables
	As of
	December 31, 2023		December 31, 2022
Long-term customer receivables	$	55	$	80
Sundry receivables	73		68
Non-income based tax receivables	26		28

Allowance for credit losses(1)	(30)		(31)
Total long-term receivables – net(2)	$	124	$	145

(1) Write-offs of long-term receivables were not material for the years ended December 31, 2023 and 2022.

(2) Long-term receivables are recognized within All other assets in the Consolidated and Combined Statements of Financial Position.

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

On February 17, 2023, the Company acquired 100% of the stock of Caption Health, Inc. (“Caption Health”) for $127 million of upfront payment, $10 million of future holdback payment, and potential earn-out payments valued at $13 million based primarily on various milestones and sales targets. This transaction was accounted for as a business combination. The preliminary purchase price allocation resulted in goodwill of $94 million, intangible assets of $60 million, and deferred tax liabilities of $3 million. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the Ultrasound segment. Caption Health is an artificial intelligence (“AI”) company whose technology expands access to AI-guided ultrasound screening for novice users.

See Note 13, “Financial Instruments and Fair Value Measurements” for further information about the fair value measurement of contingent consideration.


Goodwill
	Imaging		Ultrasound		PCS		PDx		Total
Balance at December 31, 2021	$	4,433	$	3,876	$	2,049	$	2,534	$	12,892
Acquisitions	—		—		—		—		—
Foreign currency exchange and other(1)	(24)		(41)		(13)		(1)		(79)
Balance at December 31, 2022	4,409		3,835		2,036		2,533		12,813
Acquisitions(2)	16		94		—		—		110
Foreign currency exchange and other	6		4		2		1		13
Balance at December 31, 2023	$	4,431	$	3,933	$	2,038	$	2,534	$	12,936

(1) Other includes purchase accounting adjustments for prior year acquisitions.

(2) Includes the acquisition of IMACTIS SAS in the second quarter of 2023.

The Company performs an impairment test of goodwill annually in the fourth quarter. In 2023, the Company performed qualitative testing for all reporting units that carried goodwill. Based on the results of the qualitative testing, the Company concluded that it was more likely than not that the fair value of each reporting unit exceeded its carrying value and no quantitative testing was required. Quantitative testing was performed for all reporting units in 2022 and 2021. The quantitative testing conducted in 2022 and 2021 concluded that no goodwill impairments existed.


Intangible Assets
	As of December 31, 2023						As of December 31, 2022
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Customer-related	$	60	$	(16)	$	44	$	60	$	(10)	$	50
Patents and technology	2,541		(1,867)		674		2,544		(1,815)		729
Capitalized software	1,963		(1,509)		454		2,309		(1,638)		671
Trademarks and other	33		(27)		6		35		(27)		8
Indefinite-lived assets(1)	75		—		75		62		—		62
Total	$	4,672	$	(3,419)	$	1,253	$	5,010	$	(3,490)	$	1,520

(1) Indefinite-lived intangible assets relate to acquired IPR&D prior to project completion and are not amortized.

The Company performs an impairment test of IPR&D in the third quarter. In 2023, the Company performed qualitative testing for all IPR&D assets. Based on the results of the qualitative testing, the Company concluded that it was more likely than not that the fair value of each IPR&D asset exceeded its carrying value and no quantitative testing was required, with one exception. A quantitative test was performed for one IPR&D asset. Quantitative testing was performed for all IPR&D assets in 2022 and 2021. There were no material impairments of indefinite-lived intangible assets recognized in the years ended December 31, 2023, 2022, or 2021.

During the year ended December 31, 2023, we recorded additions to acquired intangible assets subject to amortization of $62 million, primarily related to patents and technology, with a weighted-average useful life of nine years.

Amortization expense was $362 million, $405 million, and $400 million for the years ended December 31, 2023, 2022, and 2021, respectively. There were no material impairments of definite-lived intangible assets recognized in the years ended December 31, 2023, 2022, or 2021.

Estimated annual pre-tax amortization expense for intangible assets as of December 31, 2023 over the next five calendar years is as follows.


Estimated Intangible Pre-tax Amortization
	2024		2025		2026		2027		2028
Estimated annual pre-tax amortization	$	303	$	259	$	207	$	122	$	71

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

See Note 13, “Financial Instruments and Fair Value Measurements” for further information about the fair value measurement of contingent consideration.


Goodwill
	Imaging		Ultrasound		PCS		PDx		Total
Balance at December 31, 2021	$	4,433	$	3,876	$	2,049	$	2,534	$	12,892
Acquisitions	—		—		—		—		—
Foreign currency exchange and other(1)	(24)		(41)		(13)		(1)		(79)
Balance at December 31, 2022	4,409		3,835		2,036		2,533		12,813
Acquisitions(2)	16		94		—		—		110
Foreign currency exchange and other	6		4		2		1		13
Balance at December 31, 2023	$	4,431	$	3,933	$	2,038	$	2,534	$	12,936

(1) Other includes purchase accounting adjustments for prior year acquisitions.

(2) Includes the acquisition of IMACTIS SAS in the second quarter of 2023.


Intangible Assets
	As of December 31, 2023						As of December 31, 2022
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Customer-related	$	60	$	(16)	$	44	$	60	$	(10)	$	50
Patents and technology	2,541		(1,867)		674		2,544		(1,815)		729
Capitalized software	1,963		(1,509)		454		2,309		(1,638)		671
Trademarks and other	33		(27)		6		35		(27)		8
Indefinite-lived assets(1)	75		—		75		62		—		62
Total	$	4,672	$	(3,419)	$	1,253	$	5,010	$	(3,490)	$	1,520

(1) Indefinite-lived intangible assets relate to acquired IPR&D prior to project completion and are not amortized.

Estimated annual pre-tax amortization expense for intangible assets as of December 31, 2023 over the next five calendar years is as follows.


Estimated Intangible Pre-tax Amortization
	2024		2025		2026		2027		2028
Estimated annual pre-tax amortization	$	303	$	259	$	207	$	122	$	71

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On January 8, 2024, we announced an agreement to acquire MIM Software, a global provider of medical imaging analysis and AI solutions for the practice of radiation oncology, molecular radiotherapy, diagnostic imaging, and urology at imaging centers, hospitals, specialty clinics, and research organizations worldwide. The transaction is subject to customary closing conditions, including regulatory approvals. On January 22, 2024, we repaid an additional $150 million of the outstanding Term Loan Facility. On January 22, 2024, we executed an additional $700 million of interest-rate swap contracts to hedge the benchmark interest rate risk of specific designated cash flows of our senior unsecured notes. These derivatives are designated as fair value hedges.

POSTRETIREMENT BENEFIT PLANS - Plan Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2023
Change in plan assets
Funded status – surplus (deficit)				$ (4,045)
Pension Plans
Change in plan assets
Funded status – surplus (deficit)				(2,835)
Pension Plans \| Principal Pension Plans
Change in projected benefit obligations
Balance at January 1	$ 0
Transfers from GE at Spin-Off	17,997
Service cost	32
Interest cost	952
Participant contributions	4
Plan amendments	53
Actuarial loss (gain) – net	493
Benefits paid	(1,341)
Curtailments	(30)
Exchange rate adjustments	0
Balance at December 31	18,160	$ 0
Change in plan assets
Balance at January 1	0
Transfers from GE at Spin-Off	14,838
Actual gain (loss) on plan assets	1,057
Employer contributions	142
Participant contributions	4
Benefits paid	(1,341)
Acquisitions/Divestitures/Mergers	0
Exchange rate adjustments	0
Balance at December 31	14,700	0
Funded status – surplus (deficit)	(3,460)
Pension Plans \| Other Pension Plans
Change in projected benefit obligations
Balance at January 1	640
Transfers from GE at Spin-Off	3,707
Service cost	23	19	$ 24
Interest cost	209	17	15
Participant contributions	1
Plan amendments	2
Actuarial loss (gain) – net	221
Benefits paid	(359)
Curtailments	0
Exchange rate adjustments	144
Balance at December 31	4,588	640
Change in plan assets
Balance at January 1	382
Transfers from GE at Spin-Off	4,046
Actual gain (loss) on plan assets	189
Employer contributions	84
Participant contributions	1
Benefits paid	(359)
Acquisitions/Divestitures/Mergers	1
Exchange rate adjustments	174
Balance at December 31	4,518	382
Funded status – surplus (deficit)	(70)
Pension Plans \| Other Pension Plans, under $20 Million Threshold
Change in projected benefit obligations
Balance at January 1	703	940
Transfers from GE at Spin-Off		0
Service cost		19
Interest cost		17
Participant contributions		1
Plan amendments		0
Actuarial loss (gain) – net		(193)
Benefits paid		(38)
Curtailments		0
Exchange rate adjustments		(43)
Balance at December 31		703	940
Change in plan assets
Balance at January 1	425	553
Transfers from GE at Spin-Off		0
Actual gain (loss) on plan assets		(101)
Employer contributions		18
Participant contributions		1
Benefits paid		(38)
Acquisitions/Divestitures/Mergers		0
Exchange rate adjustments		(8)
Balance at December 31		425	$ 553
Funded status – surplus (deficit)		(278)
OPEB Plans
Change in projected benefit obligations
Balance at January 1	0
Transfers from GE at Spin-Off	1,149
Service cost	6
Interest cost	59
Participant contributions	18
Plan amendments	0
Actuarial loss (gain) – net	50
Benefits paid	(149)
Curtailments	0
Exchange rate adjustments	0
Balance at December 31	1,133	0
Change in plan assets
Balance at January 1	0
Transfers from GE at Spin-Off	0
Actual gain (loss) on plan assets	0
Employer contributions	131
Participant contributions	18
Benefits paid	(149)
Acquisitions/Divestitures/Mergers	0
Exchange rate adjustments	0
Balance at December 31	0	$ 0
Funded status – surplus (deficit)	$ (1,133)			$ (1,210)

SHARE-BASED COMPENSATION

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION

We grant stock options, restricted stock units (“RSU”), and performance share units (“PSU”) to employees under the 2023 Long-Term Incentive Plan (“LTIP”). The Talent, Culture, and Compensation Committee of the Board of Directors approves grants under the LTIP. Under the LTIP, we are authorized to issue up to approximately 41 million shares. We record compensation expense for awards expected to vest over the vesting period. We estimate forfeitures based on experience and adjust expense to reflect actual forfeitures. When options are exercised, RSUs vest, and PSUs are earned, we issue shares from authorized unissued common stock.

Stock options provide employees the opportunity to purchase GE HealthCare shares in the future at the market price of our stock on the date the award is granted (the strike price). The options become exercisable over the vesting period, typically becoming fully vested in three to three and a half years, and expire ten years from the grant date if not exercised. We value stock options using a Black-Scholes option pricing model.

RSUs provide an employee the right to shares of GE HealthCare stock when the restrictions lapse over the vesting period of three to three and a half years. Upon vesting, each RSU is converted into one share of GE HealthCare common stock. We value RSUs using the market price on the grant date.

PSUs provide an employee with the right to receive shares of GE HealthCare stock based upon achievement of certain performance metrics. PSUs are subject to an employee service period of three to three and a half years. PSUs may include a relative total shareholder return (“TSR”) modifier to determine the number of shares earned at the end of the performance period. We engage third-party valuation specialists to assist with the fair value estimate of the PSUs that include the TSR modifier using a Monte Carlo simulation to model the probability of possible outcomes.

The following tables provide the weighted average fair value of options, RSUs, and PSUs granted to employees during the year ended December 31, 2023, and the related weighted average stock option valuation assumptions used in the Black-Scholes model.


Weighted Average Grant Date Fair Value
(In dollars)	December 31, 2023
Stock options	$	25
RSUs	73
PSUs	85


Key Assumptions in the Black-Scholes Valuation for Stock Options
	December 31, 2023
Risk-free rate	3.6	%
Dividend yield	0.01	%
Expected volatility	26.2	%
Expected term (in years)	6.2

For new awards granted in 2023, the expected volatility was derived from a peer group’s blended historical and implied volatility as GE HealthCare does not have sufficient historical volatility based on the expected term of the underlying options. The expected term of the stock options was determined using the simplified method. The risk-free interest rate was determined using the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options. The dividend yield assumption is based on the expected annualized dividend payment at the date of grant.


Stock Option Activity
	Shares (in thousands)	Weighted average exercise price (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)
Outstanding as of January 4, 2023(1)	3,738	$	90
Granted	2,155	72
Exercised/Vested	(561)	60
Forfeited	(159)	71
Expired	(210)	127
Outstanding as of December 31, 2023	4,963	$	84	6.1	$	35
Exercisable as of December 31, 2023	2,810	$	94	3.8	$	23
Expected to vest	1,755	$	72	9.0	$	10

(1) Our common stock began “regular way” trading on The Nasdaq Stock Market LLC (“Nasdaq”) on January 4, 2023. The shares outstanding as of January 4, 2023 pertain to GE equity-based awards issued by GE in prior periods to employees of the Company that were converted to GE HealthCare equity-based awards as part of the Spin-Off.


RSU and PSU Activity
	RSUs						PSUs
	Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average vesting period (in years)	Intrinsic value (in millions)		Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average vesting period (in years)	Intrinsic value (in millions)
Outstanding as of January 4, 2023(1)	3,551	$	58				1,365	$	68
Granted	1,904	73					539	85
Exercised/Vested	(1,317)	56					—	—
Forfeited	(409)	60					(483)	72
Expired	—	—					(175)	66
Outstanding as of December 31, 2023	3,729	$	67	1.5	$	290	1,246	$	85	1.4	$	96
Expected to vest	3,333	$	60	1.5	$	258	N/A	N/A		N/A	N/A

(1) Our common stock began “regular way” trading on Nasdaq on January 4, 2023. The shares outstanding as of January 4, 2023 pertain to GE equity-based awards issued by GE in prior periods to employees of the Company that were converted to GE HealthCare equity-based awards as part of the Spin-Off.

Share-based compensation expense is recognized within Cost of products, Cost of services, SG&A, or R&D, as appropriate, in the Consolidated Statement of Income.


Share-based Compensation Expense	For the year ended
	December 31, 2023



Share-based compensation expense (pre-tax)	$	114
Income tax benefits	(23)
Share-based compensation expense (after-tax)	$	91


Other Share-based Compensation Data

Unrecognized compensation expense as of December 31, 2023(1)	$	149
Cash received from stock options exercised in the year ended December 31, 2023	34
Intrinsic value of stock options exercised and RSU/PSUs vested in the year ended December 31, 2023	106

(1) Amortized over a weighted average period of 1.9 years.

RELATED PARTIES - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
All other assets, noncurrent	$ 1,881	$ 1,024
All other liabilities, noncurrent	1,877	1,603
Majority shareholder \| Separation costs related to pension, benefit and contribution plans
Related Party Transaction [Line Items]
Transaction amount		207	$ 237
Majority shareholder \| Share-based compensation expense
Related Party Transaction [Line Items]
Transaction amount		$ 67	$ 76
Related party
Related Party Transaction [Line Items]
All other assets, noncurrent	81
All other liabilities, noncurrent	33
Related party \| Transition Services Agreement
Related Party Transaction [Line Items]
Transaction amount	$ 372
Agreement term	24 months
Related party \| Tax Matters Agreement
Related Party Transaction [Line Items]
Period following distribution date	2 years

POSTRETIREMENT BENEFIT PLANS - Weighted Average Asset Allocation (Details) - Pension Plans	Dec. 31, 2023
Global equity securities \| Principal Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Target allocation	18.00%
Actual allocation	18.00%
Global equity securities \| Other Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Target allocation	11.00%
Actual allocation	10.00%
Debt securities (including cash and cash equivalents) \| Principal Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Target allocation	54.00%
Actual allocation	55.00%
Debt securities (including cash and cash equivalents) \| Other Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Target allocation	58.00%
Actual allocation	66.00%
Real estate \| Principal Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Target allocation	7.00%
Actual allocation	6.00%
Real estate \| Other Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Target allocation	17.00%
Actual allocation	11.00%
Private equities and other investments \| Principal Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Target allocation	21.00%
Actual allocation	21.00%
Private equities and other investments \| Other Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Target allocation	14.00%
Actual allocation	13.00%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Equity investments without readily determinable fair value	$ 156	$ 117
Foreign currency transactions gain (loss)	$ 16	$ (88)	$ 130
Supplier Finance Program [Line Items]
Supplier finance program, payment terms, maximum threshold	180 days
Minimum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	30 days
Maximum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	150 days

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Tables)

12 Months Ended

Dec. 31, 2023

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in AOCI by component, net of income taxes, were as follows.


Accumulated Other Comprehensive Income (Loss)
	Currency translation adjustments(1)		Benefit plans		Cash flow hedges		Total AOCI
December 31, 2020	$	(643)	$	(180)	$	(16)	$	(839)
Other comprehensive income (loss) before reclasses – net of taxes of $(9), $(57), and $(12)	(326)		74		40		(212)
Reclasses from AOCI – net of taxes(2) of $0, $37, and $(3)	—		6		8		14
Other comprehensive income (loss)	(326)		80		48		(198)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
December 31, 2021	(969)		(100)		32		(1,037)
Other comprehensive income (loss) before reclasses – net of taxes of $(5), $(39), and $(10)	(878)		58		27		(793)
Reclasses from AOCI – net of taxes(2) of $0, $0, and $17	—		—		(50)		(50)
Other comprehensive income (loss)	(878)		58		(23)		(843)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(2)		—		—		(2)
December 31, 2022	(1,845)		(42)		9		(1,878)
Other comprehensive income (loss) before reclasses – net of taxes(3) of $22, $186, and $1	74		(601)		(5)		(532)
Reclasses from AOCI – net of taxes(2) of $0, $97, and $6	—		(296)		(22)		(318)
Other comprehensive income (loss)	74		(897)		(27)		(850)
Spin-Off related adjustments – net of taxes(4) of $0 $(509), and $0	28		1,972		—		2,000
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(37)		—		—		(37)
December 31, 2023	$	(1,706)	$	1,033	$	(18)	$	(691)

(1) The amount of Currency translation adjustments (“CTA”) recognized in Other comprehensive income (loss) (“OCI”) during the years ended December 31, 2023 and 2022 included net gains (losses) relating to net investment hedges, as further discussed in Note 13, “Financial Instruments and Fair Value Measurements.”

(2) Reclassifications from AOCI into earnings for Benefit plans are recognized within Non-operating benefit (income) loss, while Cash flow hedges are recognized within Cost of products or Cost of services in our Consolidated and Combined Statements of Income.

(3) Includes pre-tax impact to Benefit plans of $(305) million for the pension plan amendment and related remeasurement of plan assets and benefit obligations. Refer to Note 10, “Postretirement Benefit Plans” for further information.

(4) Includes impact of $1,972 million to Benefit plans for unrecognized gain transferred from the GE pension and other postretirement plans and $28 million to CTA associated with other Spin-Off related adjustments. Refer to Note 10, “Postretirement Benefit Plans” for further information on the unrecognized gain transferred from the GE pension and other postretirement plans in connection with the Spin-Off.

FINANCING RECEIVABLES (Tables)

12 Months Ended

Dec. 31, 2023

Receivables [Abstract]

Schedule of Receivables


Current Receivables
	As of
	December 31, 2023		December 31, 2022
Current customer receivables(1)	$	3,339	$	3,112
Non-income based tax receivables	166		174
Other sundry receivables	118		100
Sundry receivables	284		274
Allowance for credit losses	(98)		(91)
Total current receivables – net	$	3,525	$	3,295


Long-Term Receivables
	As of
	December 31, 2023		December 31, 2022
Long-term customer receivables	$	55	$	80
Sundry receivables	73		68
Non-income based tax receivables	26		28

Allowance for credit losses(1)	(30)		(31)
Total long-term receivables – net(2)	$	124	$	145

(1) Write-offs of long-term receivables were not material for the years ended December 31, 2023 and 2022.

(2) Long-term receivables are recognized within All other assets in the Consolidated and Combined Statements of Financial Position.


Financing Receivables
	As of
	December 31, 2023		December 31, 2022
Loans, net of deferred income	$	29	$	29
Investment in financing leases, net of deferred income	71		72
Allowance for credit losses	(3)		(4)
Current financing receivables – net(1)	97		97
Loans, net of deferred income	37		44
Investment in financing leases, net of deferred income	146		158
Allowance for credit losses	(5)		(6)
Non-current financing receivables – net(1)	$	178	$	196

(1) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other assets, respectively, in the Consolidated and Combined Statements of Financial Position.

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		$ 9,362	$ 16,676	$ 14,751
Other comprehensive income (loss) before reclass – net of taxes		(532)	(793)	(212)
Reclass from AOCI – net of taxes		(318)	(50)	14
Other comprehensive income (loss)		(850)	(843)	(198)
Less: Other comprehensive income (loss) attributable to noncontrolling interests		(37)	(2)	0
Equity, ending balance		7,145	9,362	16,676
Pension Plans \| GE HealthCare Pension Plan
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
AOCI, decrease due to remeasurement	$ 305
Accumulated other comprehensive income (loss) – net
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		(1,878)	(1,037)	(839)
Spin-Off related adjustments – net of taxes		2,000
Equity, ending balance		(691)	(1,878)	(1,037)
Currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		(1,845)	(969)	(643)
Other comprehensive income (loss) before reclass – net of taxes		74	(878)	(326)
Reclass from AOCI – net of taxes		0	0	0
Other comprehensive income (loss)		74	(878)	(326)
Less: Other comprehensive income (loss) attributable to noncontrolling interests		(37)	(2)	0
Spin-Off related adjustments – net of taxes		28
Equity, ending balance		(1,706)	(1,845)	(969)
Other comprehensive income (loss) before reclass, tax		22	(5)	(9)
Reclass from AOCI, tax		0	0	0
Spin-Off related adjustments, tax		0
Benefit plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		(42)	(100)	(180)
Other comprehensive income (loss) before reclass – net of taxes		(601)	58	74
Reclass from AOCI – net of taxes		(296)	0	6
Other comprehensive income (loss)		(897)	58	80
Less: Other comprehensive income (loss) attributable to noncontrolling interests		0	0	0
Spin-Off related adjustments – net of taxes		1,972
Equity, ending balance		1,033	(42)	(100)
Other comprehensive income (loss) before reclass, tax		186	(39)	(57)
Reclass from AOCI, tax		97	0	37
Spin-Off related adjustments, tax		(509)
Cash flow hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance		9	32	(16)
Other comprehensive income (loss) before reclass – net of taxes		(5)	27	40
Reclass from AOCI – net of taxes		(22)	(50)	8
Other comprehensive income (loss)		(27)	(23)	48
Less: Other comprehensive income (loss) attributable to noncontrolling interests		0	0	0
Spin-Off related adjustments – net of taxes		0
Equity, ending balance		(18)	9	32
Other comprehensive income (loss) before reclass, tax		1	(10)	(12)
Reclass from AOCI, tax		6	$ 17	$ (3)
Spin-Off related adjustments, tax		$ 0

ORGANIZATION AND BASIS OF PRESENTATION (Details) - USD ($) $ / shares in Units, $ in Millions			12 Months Ended
	Jan. 03, 2023	Dec. 31, 2022	Dec. 31, 2023
Subsidiary, Sale of Stock [Line Items]
Sale of stock, percent of stock distributed	80.10%
Sale of stock, number of shares issued	454,000,000	100
Sale of stock, price per share (in dollars per share)		$ 1.00
Net transfers from GE, including Spin-Off-related adjustments	$ 2,849		$ 2,849
Separation-related adjustments, deferred compensation liability	$ 548
GE \| GE HealthCare Technologies Inc
Subsidiary, Sale of Stock [Line Items]
Ownership percentage			13.50%

EARNINGS PER SHARE

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

EARNINGS PER SHARE

On January 3, 2023, there were approximately 454 million shares of GE HealthCare common stock outstanding, including the interest in our outstanding shares of common stock retained by GE following the Distribution. The computation of basic and diluted earnings per common share for all periods through December 31, 2022 was calculated using this same number of common shares outstanding since no GE HealthCare equity awards were outstanding as of the Distribution Date and is net of Net (income) loss attributable to noncontrolling interests which is fully associated with continuing operations. Subsequent to the Spin-Off, the dilutive effect of outstanding stock options, RSUs, and PSUs is reflected in the denominator for diluted earnings per share using the treasury stock method.


Earnings Per Share
	For the years ended December 31
(In millions, except per share amounts)		2023		2022		2021
Numerator:
Net income from continuing operations		$	1,618	$	1,949	$	2,275
Net (income) loss attributable to noncontrolling interests		(46)		(51)		(46)
Net income from continuing operations attributable to GE HealthCare		1,572		1,898		2,229
Deemed preferred stock dividend of redeemable noncontrolling interest		(183)		—		—
Net income from continuing operations attributable to GE HealthCare common stockholders		1,389		1,898		2,229
Income (loss) from discontinued operations, net of taxes		(4)		18		18
Net income attributable to GE HealthCare common stockholders		$	1,385	$	1,916	$	2,247
Denominator:
Basic weighted-average shares outstanding		455		454		454
Dilutive effect of common stock equivalents		3		—		—
Diluted weighted-average shares outstanding		458		454		454
Basic Earnings Per Share:
Continuing operations		$	3.06	$	4.18	$	4.91
Discontinued operations		(0.01)		0.04		0.04
Attributable to GE HealthCare common stockholders		3.05		4.22		4.95
Diluted Earnings Per Share:
Continuing operations		$	3.04	$	4.18	$	4.91
Discontinued operations		(0.01)		0.04		0.04
Attributable to GE HealthCare common stockholders		3.03		4.22		4.95
Antidilutive securities(1)		4		—		—

(1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

POSTRETIREMENT BENEFIT PLANS - Amounts Recorded in Statements of Financial Position and AOCI (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Amounts Recorded in Consolidated and Combined Statements of Financial Position
Compensation and benefits	$ (5,782)	$ (549)
OPEB Plans
Amounts Recorded in Consolidated and Combined Statements of Financial Position
All other assets	0
All other current liabilities	(130)
Compensation and benefits	(1,003)
Net amount recorded	(1,133)
Pre-Tax Amounts Recorded in AOCI
Net loss (gain)	(482)
Prior service cost (credit)	(533)
Total recorded in AOCI	(1,015)
Principal Pension Plans \| Pension Plans
Amounts Recorded in Consolidated and Combined Statements of Financial Position
All other assets	0
All other current liabilities	(143)
Compensation and benefits	(3,317)
Net amount recorded	(3,460)
Pre-Tax Amounts Recorded in AOCI
Net loss (gain)	(1,213)
Prior service cost (credit)	(43)
Total recorded in AOCI	(1,256)
Other Pension Plans \| Pension Plans
Amounts Recorded in Consolidated and Combined Statements of Financial Position
All other assets	712	65
All other current liabilities	(47)	(16)
Compensation and benefits	(735)	(327)
Net amount recorded	(70)	(278)
Pre-Tax Amounts Recorded in AOCI
Net loss (gain)	1,075	60
Prior service cost (credit)	(18)	(5)
Total recorded in AOCI	$ 1,057	$ 55

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Cash and Cash Equivalents


Cash, Cash Equivalents, and Restricted Cash	As of
	December 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,494	$	1,440
Short-term restricted cash	10		5
Total Cash, cash equivalents, and restricted cash as presented on the Consolidated and Combined Statements of Financial Position	2,504		1,445
Long-term restricted cash(1)	2		6
Total Cash, cash equivalents, and restricted cash as presented on the Consolidated and Combined Statements of Cash Flows	$	2,506	$	1,451

(1) Long-term restricted cash is recognized within All other assets in the Consolidated and Combined Statements of Financial Position.

Schedule of Restricted Cash and Cash Equivalents


Cash, Cash Equivalents, and Restricted Cash	As of
	December 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,494	$	1,440
Short-term restricted cash	10		5
Total Cash, cash equivalents, and restricted cash as presented on the Consolidated and Combined Statements of Financial Position	2,504		1,445
Long-term restricted cash(1)	2		6
Total Cash, cash equivalents, and restricted cash as presented on the Consolidated and Combined Statements of Cash Flows	$	2,506	$	1,451

(1) Long-term restricted cash is recognized within All other assets in the Consolidated and Combined Statements of Financial Position.

Schedule of Inventory


Inventories
	As of
	December 31, 2023		December 31, 2022
Raw materials	$	961	$	1,053
Work in process	91		91
Finished goods	908		1,011
Inventories(1)	$	1,960	$	2,155

(1) Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Consolidated and Combined Statements of Financial Position. See the supplemental table “All Other Current and Non-Current Assets” for further information.

Summary of Property, Plant and Equipment


Property, Plant, and Equipment – Net
	Depreciable lives (in years)	Original Cost				Accumulated Depreciation				Net Carrying Value
As of December 31		2023		2022		2023		2022		2023		2022
Land and improvements(1)	8	$	70	$	70	$	(1)	$	(1)	$	69	$	69
Buildings, structures and related equipment	8-40	1,956		1,889		(1,167)		(1,109)		789		780
Machinery and equipment(2)	4-20	2,617		2,541		(1,802)		(1,791)		815		750
Leasehold costs and manufacturing plants under construction	1-40	565		489		(94)		(87)		471		402
Property, plant, and equipment – net, exclusive of ROU operating lease assets		$	5,208	$	4,989	$	(3,064)	$	(2,988)	$	2,144	$	2,001
ROU operating lease assets(3)										356		313
Property, plant, and equipment – net										$	2,500	$	2,314

(1) Depreciable lives exclude land.

(2) Equipment leased to customers is classified as Machinery and equipment and is reported at cost less accumulated depreciation, and was $38 million and $39 million as of December 31, 2023 and 2022, respectively.

(3) See Note 7, “Leases” for further information.

Schedule of Other Current Assets


All Other Current and Non-Current Assets
	As of
	December 31, 2023		December 31, 2022
Prepaid expenses and deferred costs	$	147	$	163
Financing receivables – net	97		97
Derivative instruments	84		63
Other(1)	61		94
All other current assets	$	389	$	417
Prepaid pension asset	716		70
Equity method and other investments	357		322
Financing receivables – net	178		196
Long-term receivables – net	124		145
Inventories	147		104
Contract and other deferred assets	168		119
Other(2)	191		68
All other non-current assets(3)	$	1,881	$	1,024

(1) Current Other primarily consists of tax receivables.

(2) Non-current Other primarily consists of indemnities due from GE and derivative instruments.

(3) All other non-current assets increased in the year ended December 31, 2023, primarily due to assets transferred from GE as a result of the Spin-Off. Refer to Note 1, “Organization and Basis of Presentation” for further information.

Schedule of Other Assets, Noncurrent


All Other Current and Non-Current Assets
	As of
	December 31, 2023		December 31, 2022
Prepaid expenses and deferred costs	$	147	$	163
Financing receivables – net	97		97
Derivative instruments	84		63
Other(1)	61		94
All other current assets	$	389	$	417
Prepaid pension asset	716		70
Equity method and other investments	357		322
Financing receivables – net	178		196
Long-term receivables – net	124		145
Inventories	147		104
Contract and other deferred assets	168		119
Other(2)	191		68
All other non-current assets(3)	$	1,881	$	1,024

(1) Current Other primarily consists of tax receivables.

(2) Non-current Other primarily consists of indemnities due from GE and derivative instruments.

Schedule of Equity Method Investments


Equity Method Investments
		Equity method investment balance				Equity method income (loss)
As of December 31	Ownership Percentage	2023		2022		2023		2022		2021
Nihon Medi-Physics Co., Ltd	50%	$	150	$	162	$	10	$	16	$	22
Other		20		20		1		(3)		5
Total		$	170	$	182	$	11	$	13	$	27

Schedule of Other Current Liabilities


All Other Current and Non-Current Liabilities
	As of
	December 31, 2023		December 31, 2022
Employee compensation and benefit liabilities(1)	$	1,518	$	853
Sales allowances and related liabilities	228		243
Uncertain and other income taxes and related liabilities	260		237
Product warranties	192		193
Accrued freight and utilities	132		150
Operating lease liabilities	110		104
Derivative instruments(2)	128		86
Interest payable on borrowings	87		52
Environmental and asset retirement obligations	21		34
Other(3)	335		238
All other current liabilities(4)	$	3,011	$	2,190
Contract liabilities	705		630
Operating lease liabilities	273		243
Environmental and asset retirement obligations	265		251
Uncertain and other income taxes and related liabilities	208		182
Derivative instruments	136		119
Finance lease obligations	38		39
Sales allowances and related liabilities	27		26
Other(5)	225		113
All other non-current liabilities(4)	$	1,877	$	1,603

(1) Employee compensation and benefit liabilities consists of incentive compensation and commissions, pension and other postretirement benefit obligations, payroll accruals, deferred compensation, and other employee related liabilities.

(2) Derivative instruments include the related accrued interest. Refer to Note 13, “Financial Instruments and Fair Value Measurements” for further information.

(3) Current Other primarily consists of miscellaneous accrued costs, dividends payable to shareholders, and contingent consideration liabilities.

(4) All other current and non-current liabilities increased in the year ended December 31, 2023, primarily due to liabilities transferred from GE as a result of the Spin-Off. Refer to Note 1, “Organization and Basis of Presentation” for further information.

(5) Non-current Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and indemnities due to GE.

Schedule of Other Noncurrent Liabilities


All Other Current and Non-Current Liabilities
	As of
	December 31, 2023		December 31, 2022
Employee compensation and benefit liabilities(1)	$	1,518	$	853
Sales allowances and related liabilities	228		243
Uncertain and other income taxes and related liabilities	260		237
Product warranties	192		193
Accrued freight and utilities	132		150
Operating lease liabilities	110		104
Derivative instruments(2)	128		86
Interest payable on borrowings	87		52
Environmental and asset retirement obligations	21		34
Other(3)	335		238
All other current liabilities(4)	$	3,011	$	2,190
Contract liabilities	705		630
Operating lease liabilities	273		243
Environmental and asset retirement obligations	265		251
Uncertain and other income taxes and related liabilities	208		182
Derivative instruments	136		119
Finance lease obligations	38		39
Sales allowances and related liabilities	27		26
Other(5)	225		113
All other non-current liabilities(4)	$	1,877	$	1,603

(2) Derivative instruments include the related accrued interest. Refer to Note 13, “Financial Instruments and Fair Value Measurements” for further information.

(3) Current Other primarily consists of miscellaneous accrued costs, dividends payable to shareholders, and contingent consideration liabilities.

(5) Non-current Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and indemnities due to GE.

Schedule of Redeemable Noncontrolling Interest

The activity attributable to redeemable noncontrolling interests for the years ended December 31, 2023, 2022, and 2021 is presented below.


Redeemable Noncontrolling Interests
	For the years ended December 31
	2023		2022		2021
Balance at beginning of period	$	230	$	220	$	223
Net income attributable to redeemable noncontrolling interests	41		47		39
Redemption value adjustments(1)	183		—		—
Distributions to and exercise of redeemable noncontrolling interests and other(2)	(289)		(37)		(42)
Balance at end of period	$	165	$	230	$	220

(1) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. These redeemable noncontrolling interests were remeasured to their current redemption value resulting in a redemption value adjustment of $183 million. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to retained earnings.

(2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $211 million was paid in the second quarter of 2023.

Schedule of Other Income (Expense)


Other Income (Expense) – Net
	For the years ended December 31
		2023		2022		2021
Net interest and investment income (expense)		$	26	$	(9)	$	34
Equity method income (loss)		11		13		27
Change in fair value of assumed obligations		(32)		—		—
Other items, net(1)		81		58		62
Total other income (expense) – net		$	86	$	62	$	123

(1) Other items, net primarily consists of change in tax indemnities with GE, lease income, gains and losses related to derivatives, and licensing and royalty income for the year ended December 31, 2023, and licensing and royalty income and gains and losses related to derivatives for the years ended December 31, 2022 and 2021.

POSTRETIREMENT BENEFIT PLANS - Schedule of Defined Benefit Plans (Details) - USD ($) $ in Millions	Dec. 31, 2023	Jan. 01, 2023	Dec. 31, 2022
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations	$ 23,841	$ 22,906	$ 687
Unrecognized gain recorded in AOCI		2,481
Net Benefit Liability
Projected benefit obligations		22,953
Fair value of assets		18,908
Net liability		4,045
Pension Plans
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations		21,696
Unrecognized gain recorded in AOCI		1,258
Net Benefit Liability
Projected benefit obligations		21,743
Fair value of assets		18,908
Net liability		2,835
OPEB Plans
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations		1,210
Unrecognized gain recorded in AOCI		1,223
Net Benefit Liability
Projected benefit obligations	1,133	1,210	0
Fair value of assets	0	0	$ 0
Net liability	$ 1,133	$ 1,210

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References + Details

SHARE-BASED COMPENSATION - Summary of Weighted Average Grant Date Fair Value (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value of stock options (in dollars per share)	$ 25
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)	73	$ 73
PSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)	$ 85	$ 85

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

DISCONTINUED OPERATIONS	12 Months Ended
DISCONTINUED OPERATIONS	Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	DISCONTINUED OPERATIONS On March 31, 2020, we completed the sale of our BioPharma business to Danaher Corporation for $20,718 million. Activity within discontinued operations for the years ended December 31, 2023, 2022, and 2021 primarily relates to gain on disposal and Benefit (provision) for income taxes.

FINANCING RECEIVABLES - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Financing Receivable, Past Due [Line Items]
Proceeds from sale of finance receivables	$ 27	$ 8	$ 104
Financing receivable, nonaccrual, percent past due	6.00%	6.00%
Over 30 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	5.00%	7.00%
Over 90 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	5.00%	6.00%

POSTRETIREMENT BENEFIT PLANS - Schedule of Expected Benefit Payments (Details) $ in Millions	Dec. 31, 2023 USD ($)
Pension Plans \| Principal Pension Plans
Defined Benefit Plan Disclosure [Line Items]
2024	$ 1,277
2025	1,289
2026	1,300
2027	1,307
2028	1,310
2029-2033	6,449
Pension Plans \| Other Pension Plans
Defined Benefit Plan Disclosure [Line Items]
2024	226
2025	239
2026	239
2027	243
2028	254
2029-2033	1,334
OPEB Plans
Defined Benefit Plan Disclosure [Line Items]
2024	130
2025	124
2026	119
2027	114
2028	110
2029-2033	$ 454

POSTRETIREMENT BENEFIT PLANS - Schedule of Pre-tax Cost of Postretirement Benefit Plans and Changes in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Pension Plans \| Principal Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Cost of postretirement benefit plans	$ (290)
Changes in other comprehensive loss (income):
Transfers from GE at Spin-Off	(1,989)
Plan amendments	53
Net loss (gain) – current year	606
Reclassifications out of AOCI:
Curtailment / settlement gain (loss)	(47)
Amortization of net loss (gain)	125
Amortization of prior service credit	(4)
Total changes in other comprehensive loss (income)	(1,256)
Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)	(1,546)
Pension Plans \| Other Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Cost of postretirement benefit plans	44	$ 9	$ 25
Changes in other comprehensive loss (income):
Transfers from GE at Spin-Off	740	0	0
Plan amendments	0	0	0
Net loss (gain) – current year	287	(74)	(86)
Reclassifications out of AOCI:
Curtailment / settlement gain (loss)	(61)	0	0
Amortization of net loss (gain)	(10)	(5)	(16)
Amortization of prior service credit	3	5	4
Total changes in other comprehensive loss (income)	959	(74)	(98)
Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)	1,003	$ (65)	(75)
Pension Plans \| Other Pension Plans \| Previously reported
Defined Benefit Plan Disclosure [Line Items]
Cost of postretirement benefit plans			$ 23
OPEB Plans
Defined Benefit Plan Disclosure [Line Items]
Cost of postretirement benefit plans	(86)
Changes in other comprehensive loss (income):
Transfers from GE at Spin-Off	(1,216)
Plan amendments	0
Net loss (gain) – current year	50
Reclassifications out of AOCI:
Curtailment / settlement gain (loss)	0
Amortization of net loss (gain)	64
Amortization of prior service credit	87
Total changes in other comprehensive loss (income)	(1,015)
Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)	$ (1,101)

INCOME TAXES - Schedule of Income before Income Tax (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
U.S. income	$ 816	$ 1,090	$ 1,587
Non-U.S. income	1,545	1,422	1,288
Income from continuing operations before income taxes	$ 2,361	$ 2,512	$ 2,875

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-SubTopic 20
-Topic 940
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481913/940-20-25-1

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Dec. 31, 2023
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION. The consolidated and combined financial statements have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) and present the historical results of operations, comprehensive income (loss), and cash flows for the years ended December 31, 2023, 2022, and 2021, and the financial position as of December 31, 2023 and 2022. All intercompany balances and transactions within the Company have been eliminated in the consolidated and combined financial statements. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position and operating results. The following tables are presented in millions of U.S. dollars (“USD”) unless otherwise stated. Prior to the Spin-Off, the combined financial statements were derived from the consolidated financial statements and accounting records of GE including the historical cost basis of assets and liabilities comprising the Company, as well as the historical revenues, direct costs, and allocations of indirect costs attributable to the operations of the Company, using the historical accounting policies applied by GE. The combined financial statements do not purport to reflect what the results of operations, comprehensive income (loss), financial position, or cash flows would have been had the Company operated as a separate, stand-alone entity prior to the Spin-Off. The financial statements include certain transactions with GE, which are disclosed as related party transactions.
RECLASSIFICATION	Following the Spin-Off, certain prior year amounts in the financial statements and notes thereto have been reclassified to conform to the current year presentation, which provides additional detail to readers of our financial statements. Amounts in the Consolidated and Combined Statements of Cash Flows that were previously included within the All other operating activities line have been reclassified to separate lines including Net periodic postretirement benefit plan (income) expense, Postretirement plan contributions, and Share-based compensation.
ESTIMATES AND ASSUMPTIONS	ESTIMATES AND ASSUMPTIONS. The preparation of the consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the consolidated and combined financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows. Estimates are used for, but are not limited to, determining the following: revenue from contracts with customers, recoverability of long-lived assets and inventory, valuation of goodwill and intangible assets, useful lives used in depreciation and amortization, asset retirement obligations, income taxes and related valuation allowances, accruals for contingencies including legal and product warranties, actuarial assumptions used to determine costs of pension and other postretirement benefits, valuation of pension assets, valuation and recoverability of receivables, valuation of derivatives, and valuation of assets acquired, liabilities assumed, and contingent consideration as a result of acquisitions. There have been no material impacts to our accounting estimates as of December 31, 2023 and 2022, or the results for the years ended December 31, 2023, 2022, and 2021, from the COVID-19 pandemic. The federal COVID-19 Public Health Emergency declaration in the U.S. ended in May 2023, and COVID-19 restrictions have been lifted in many locations globally.
REVENUE RECOGNITION	REVENUE RECOGNITION. Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as related parts and labor, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services. The Company recognizes a contract with a customer when there is a legally enforceable agreement between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on the consideration specified in the contract with each customer net of any sales incentives, discounts, returns, chargebacks, group purchasing organization fees, rebates, or credits, as well as taxes collected from customers that are remitted to government authorities. Our estimates for these deductions, which are accounted for as variable consideration, are based on historical experience and consider current and forecasted market trends. We record these estimated amounts as a reduction to revenue when we recognize the related product or service sales. Payment terms are generally within 12 months. Payment terms within 12 months are not treated as significant financing components. Contracts for the sale of products and services often include multiple distinct performance obligations, usually involving an upfront deliverable of equipment and future performance obligations such as installation, training, or the future delivery of products or services. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative stand-alone selling price. Stand-alone selling price is obtained from sources such as the separate selling price for that or a similar item if reasonably available. If such evidence is not reasonably available, we use our best estimate of selling price, which is established consistent with the pricing strategy of the Company and considers product configuration, geography, customer type, and other market-specific factors. Revenue is recognized in the period in which the customer obtains control of the underlying products or services, allowing them the ability to direct the use of, and obtain substantially all of, the remaining benefits of such product or service. This may occur at a point in time or over time. Shipping and handling costs to deliver products to customers are expensed as incurred and recognized within Cost of products or Cost of services in our Consolidated and Combined Statements of Income. For standard, assurance-type warranties that are provided with products, we estimate the cost that may be incurred during the warranty period and record a liability at the time the revenue is recognized. The provision recorded reflects the estimated costs of replacement and free-of-charge services that will be incurred related to the products sold. Service-type warranties or extended warranties sold with products are considered separate performance obligations. As such, a portion of the overall transaction price is allocated to these performance obligations and recognized in revenue over time, as the performance obligations are satisfied. The Company capitalizes certain direct incremental costs incurred to obtain a contract, primarily commissions. Costs to obtain a contract are classified within Contract and other deferred assets or All other assets in the Consolidated and Combined Statements of Financial Position and are recognized based on the timing of when the Company expects to earn related revenues. Management assesses these costs for impairment based on periodic assessments of recoverability. Performance Obligations Satisfied at a Point in Time We primarily recognize revenue from sales of products at the point in time that the customer obtains control, which is generally no earlier than when the customer has physical possession. Where arrangements include customer acceptance provisions based on seller- or customer-specified criteria, we recognize revenue when we have concluded that the customer has control of the products, which is typically at the point of acceptance. Our billing terms for these point-in-time product contracts generally coincide with delivery to the customer and customer acceptance; however, periodically, we receive customer advances and deposits from customers. These are recognized as contract liabilities in the Consolidated and Combined Statements of Financial Position. Any differences between the timing of our revenue recognition and customer billings (based on contractual terms) result in changes to our contract asset or contract liability positions. Performance Obligations Satisfied Over Time We recognize revenue from the sale of certain service contracts, including preventative maintenance, corrective services, and extended warranties over time on a ratable basis consistent with the nature, timing, and extent of our services, which primarily relate to routine maintenance and as-needed product repairs. Our billing terms for these contracts vary and can occur in advance of or following the period of service; however, we generally invoice periodically as services are provided. The differences between the timing of our revenue recognized and customer billings (based on contractual terms) result in changes to our contract asset or contract liability positions.
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	CASH, CASH EQUIVALENTS, AND RESTRICTED CASH. Cash deposits, short-term investments, and high-liquidity mutual funds with original maturities of three months or less are included in Cash, cash equivalents, and restricted cash. Restricted cash primarily relates to funds restricted in connection with escrow accounts and other contractual and legal restrictions. For the period prior to the Spin-Off, the cash presented in the Combined Statement of Financial Position represents cash not subject to the GE centralized cash management process. Cash held in commingled accounts with GE, or its affiliates, is presented within Net parent investment in the Combined Statement of Financial Position.
INVESTMENT SECURITIES	INVESTMENT SECURITIES. Publicly traded equity securities for which we do not have the ability to exercise significant influence are recorded at fair value with changes in fair value recognized in Other (income) expense – net in the Consolidated and Combined Statements of Income. Privately held equity securities for which we do not have the ability to exercise significant influence are accounted for using the measurement alternative approach and are recorded at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, with changes in the measurement recognized through Other (income) expense – net in the Consolidated and Combined Statements of Income. Equity investments without readily determinable fair value as of December 31, 2023 and 2022 were $156 million and $117 million, respectively. Investment securities are recognized within All other assets in the Consolidated and Combined Statements of Financial Position.
EQUITY METHOD INVESTMENTS	EQUITY METHOD INVESTMENTS. Equity method investments are investments in entities in which we do not have a controlling financial interest, but over which we have significant influence. Equity method investments are assessed for other-than-temporary impairment when events occur or circumstances change that indicate it is more likely than not the fair value of the asset is below its carrying value. Equity method investments are recognized within All other assets in the Consolidated and Combined Statements of Financial Position. Our share of the results of equity method investments is recognized within Other (income) expense – net in the Consolidated and Combined Statements of Income.
RECEIVABLES	RECEIVABLES. Amounts due from customers arising from the sales of products and services are recorded at the outstanding amount, less allowances for credit losses, chargebacks, and other credits. We regularly monitor the recoverability of our receivables.
FINANCING RECEIVABLES	FINANCING RECEIVABLES. Our financing receivables portfolio consists of a variety of loans and leases, including both larger-balance, non-homogeneous loans and leases, and smaller-balance homogeneous loans and leases. Loans Loans represent term loans that are collateralized by equipment and other assets. Loans are classified as either held for sale or held for investment (“HFI”) based on management’s intent and ability to hold the loans for the foreseeable future. Loans which the Company does not have the ability and intent to hold for investment purposes and those which the Company intends to hold for sale in the foreseeable future are accounted for as loans held for sale. Loans held for sale are recorded at the lower of historical cost or current fair value with any fair value write-down (or change to the write-down) recorded as a valuation allowance through current period earnings in the period in which the change occurs. Loans classified as HFI are recorded at amortized cost. Investment in Finance Leases Finance leases include mostly sales-type leases of equipment and represent net unpaid rentals and estimated unguaranteed residual values of leased equipment, less related deferred income and less the allowance for credit losses. See Note 7, “Leases” for further information. See “Allowance for credit losses” below for the Company’s policy regarding allowances on financing receivables. Credit Quality Indicators We manage our financing receivables portfolio using delinquency and nonaccrual data as key performance indicators. We assess the overall quality of the portfolio based on a potential risk of loss measure. The metric incorporates both the borrower’s credit quality along with any related collateral protection. Financing receivables are considered past due if default on a contractual principal or interest payment exists for a period of 30 days or more. We stop accruing interest on financing receivables at the earlier of when collection of an account becomes doubtful or the account becomes 90 days past due. Although we stop accruing interest in advance of payments, we recognize income within Other (income) expense – net in the Consolidated and Combined Statements of Income when we determine that the account is returned to accrual status, provided that the amount does not exceed that which would have been earned at the historical effective interest rate.
ALLOWANCE FOR CREDIT LOSSES	ALLOWANCE FOR CREDIT LOSSES. When we record customer receivables, contract assets, and financing receivables, we maintain an allowance for credit losses for the current expected credit losses. Each period, the allowance for credit losses is adjusted through earnings to reflect expected credit losses over the remaining lives of the assets. The credit losses are recognized within Selling, general, and administrative (“SG&A”) in the Consolidated and Combined Statements of Income. For financing receivables, expected credit losses are calculated based on the gross carrying amount of the financial asset, multiplied by a factor reflecting the probability of default and the loss in the event of default. We routinely evaluate our entire portfolio for potential specific credit or collection issues that might indicate an impairment. We estimate expected credit losses based on relevant information from past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. When measuring expected credit losses, we pool assets with similar credit risk characteristics. Changes in the relevant information may significantly affect the estimates of expected credit losses.
INVENTORIES	INVENTORIES. Inventories are stated at lower of cost or net realizable values. Cost of inventories is determined on a first-in, first-out basis. Inventories are generally classified as current, however, based on age or historical consumption certain inventories are considered non-current and are recognized, net of related reserves, within All other assets in the Consolidated and Combined Statements of Financial Position. As necessary, we record provisions and write-downs for excess, slow moving, and obsolete inventory. To determine these amounts, we regularly review inventory quantities on hand and compare them to historical utilization and estimates of future product demand, market conditions and technological developments.
PROPERTY, PLANT, AND EQUIPMENT	PROPERTY, PLANT, AND EQUIPMENT. The cost of property, plant, and equipment is depreciated on a straight-line basis over its estimated useful life. Equipment leased to others under operating leases is depreciated on a straight-line basis over the term of the lease. Repair and maintenance costs are expensed as incurred.
LEASES, Lessee Arrangements	Lessee Arrangements At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. ROU assets are recognized within Property, plant, and equipment – net and lease liabilities are recognized within All other current liabilities and All other liabilities in the Consolidated and Combined Statements of Financial Position. Options to extend a lease are included as part of the ROU lease asset and liability at commencement when it is reasonably certain the Company will exercise the option. We have elected to combine lease and non-lease components in determining our lease liability for all leased assets except our vehicle leases. Non-lease components are generally related to services that the lessor performs for the Company associated with the leased asset. As the Company’s leases typically do not provide an implicit rate, the present value of our lease liability is determined using our incremental collateralized borrowing rate at lease commencement for leases that commenced post-Spin-Off and GE’s incremental collateralized borrowing rate at lease commencement for leases that commenced pre-Spin-Off. For leases with an initial term of 12 months or less, an ROU asset and lease liability are not recognized, and lease expense is recognized on a straight-line basis over the lease term. Certain of our leases include provisions for variable lease payments which are based on, but not limited to, maintenance, insurance, taxes, index escalations, and usage-based amounts. The Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. We review ROU assets for impairment annually or when events occur or circumstances change that indicate that the asset may be impaired.
LEASES, Lessor Arrangements	Lessor Arrangements Equipment leased to others under operating leases is recognized within Property, plant, and equipment – net in the Consolidated and Combined Statements of Financial Position. Leases classified as sales-type leases or direct financing leases are recognized within All other current assets and All other assets, respectively, in the Consolidated and Combined Statements of Financial Position. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term or purchase the underlying asset, vary by customer. Finance lease receivables are tested for impairment as described in the “Financing Receivables” section above.
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS. Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. We test goodwill for impairment at the reporting unit level annually in the fourth quarter of each year as of October 1st, or more frequently when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. When testing goodwill for impairment, the Company may first assess qualitative factors. If an initial qualitative assessment identifies that it is more likely than not that the fair value of a reporting unit is less than its carrying value, additional quantitative testing is performed. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. If the quantitative testing indicates that goodwill is impaired, an impairment charge is recognized based on the difference between the reporting unit’s carrying value and its fair value. When performing a quantitative test, the market approach is typically used for estimating the fair values for our reporting units. Under the market approach, we estimate the fair value based on market multiples of earnings derived from comparable publicly traded companies with operating and investment characteristics similar to the reporting unit. Depending on the specific reporting unit circumstances, we may also consider performing a valuation based on an income approach. It is reasonably possible that the judgments and estimates used could change in future periods. In-process research and development (“IPR&D”) acquired as part of a business acquisition is capitalized at fair value when acquired and is considered an indefinite-lived intangible asset. We test indefinite-lived intangible assets for impairment annually in the third quarter of each year or when events occur or circumstances change that indicate it is more likely than not the fair value of the asset is below its carrying value. When testing IPR&D for impairment, the Company may first assess qualitative factors. If an initial qualitative assessment identifies that it is more likely than not that the fair value of the IPR&D is less than its carrying value, additional quantitative testing is performed. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. If the quantitative testing indicates that the IPR&D is impaired, an impairment charge is recognized based on the difference between the IPR&D’s carrying value and its fair value. When the IPR&D project is complete, the asset is considered a finite-lived intangible asset and subject to an impairment test at that date. Thereafter, the resulting asset is amortized over its estimated useful life and is subject to impairment assessment in the same manner as all amortizing intangible assets. For other intangible assets that are not deemed indefinite-lived, the cost of the intangible asset is amortized on a straight-line basis over the asset’s estimated useful life. Amortizable intangible assets are reviewed for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. In such circumstances, they are tested for impairment based on undiscounted cash flows and, if impaired, written down to estimated fair value based on either discounted cash flows or appraised values. Internal-Use Software Internal-use software is software that is developed, purchased, or modified to meet internal needs and for which no substantive plan exists to sell, lease, or otherwise market the software externally. All costs associated with project tasks classified in the preliminary project development or post-implementation/operation stage are expensed as incurred. Capitalization of application development stage costs begins after both of the following occur: (1) the preliminary project development stage is completed and (2) management authorizes and commits to funding the software project and it is probable that the project will be completed and the software will be used for the purpose for which it was intended. Capitalization ceases when the project is substantially complete. Capitalized amounts are recognized within Other intangible assets – net in the Consolidated and Combined Statements of Financial Position and are amortized on a straight-line basis over the asset’s estimated useful life. External Use Software External use software relates to software that is (1) intended to be sold, licensed, or marketed to our customers or (2) embedded and integral to our tangible products for which research and development (“R&D”) has been completed. Costs that are related to the conceptual formulation and design of software are expensed as incurred. Costs that are incurred after technological feasibility has been established until general release of the product are capitalized as an intangible asset and recognized within Other intangible assets – net in the Consolidated and Combined Statements of Financial Position. Capitalized costs for software to be sold, leased, or otherwise marketed are amortized on an individual product basis using straight-line amortization over the estimated useful life of the product. The Company performs regular reviews to assess whether unamortized capitalized external use software program costs remain recoverable through future revenue.
DERIVATIVES AND HEDGING	DERIVATIVES AND HEDGING. We use derivative contracts to reduce the volatility of earnings and cash flows associated with risks related to foreign currency exchange rates, interest rates, equity prices, and commodity prices. Our policy is to use derivatives solely for managing risks and not for speculative purposes. We employ the following hedge types: (1) cash flow hedges of foreign currency risk associated with third-party and intercompany foreign currency-denominated forecasted transactions and firm commitments, (2) net investment hedges of foreign currency risk associated with investments in foreign operations, (3) fair value hedges of interest rate risk associated with long-term borrowings, and (4) economic hedges not designated as qualifying hedging relationships of foreign currency risk associated with monetary assets and liabilities, including intercompany balances, equity price risk, and commodity price risk. For net investment hedges, changes in the fair value of the components of the hedging derivatives excluded from the assessment of hedge effectiveness are deferred and amortized to earnings in the Consolidated and Combined Statements of Income using a systematic and rational method over the life of the derivative transaction. Contracts that do not in their entirety meet the definition of a derivative instrument and are not measured at fair value may contain embedded features affecting some or all of the cash flows or value of other exchanges that would otherwise be considered derivatives when assessed separately from the host contract. Such embedded features are separated from the hybrid contract and accounted for as a derivative measured at fair value if their economic characteristics and risks are not clearly and closely related to those of the host contract.
INCOME TAXES	INCOME TAXES. For the years ended December 31, 2022 and 2021, the Company’s income tax provision was prepared using the separate return method. The calculation of income taxes on a separate return basis requires a considerable amount of judgment and use of both estimates and allocations. As a result, actual transactions included in the consolidated financial statements of GE may not be included in these combined financial statements. Similarly, the tax treatment of certain items reflected in the combined financial statements may not be reflected in the consolidated financial statements and tax returns of GE. Therefore, items such as net operating losses, credit carryforwards, and valuation allowances may exist in the stand-alone combined financial statements that may or may not exist in GE’s consolidated financial statements. For post-Spin-Off periods, as a stand-alone entity, GE HealthCare will file tax returns on its own behalf, and its deferred taxes and actual income tax rate differ from those in the historical periods. For the years prior to the Spin-Off, all income taxes due to or due from GE that had not been settled or recovered by the end of the period are recognized within Net parent investment in the Combined Statement of Financial Position. Any differences between actual amounts paid or received by the Company and taxes accrued under the separate return method are deemed to be settled and are recognized within Net parent investment in the Combined Statement of Financial Position. Current obligations for tax in jurisdictions where the Company did not file a consolidated tax return with GE in the pre-Spin-Off period, including certain foreign and certain U.S. state tax jurisdictions, are recorded as accrued liabilities and recognized within All other liabilities in the Combined Statement of Financial Position. The effects of tax adjustments and settlements with taxing authorities are presented in the consolidated and combined financial statements in the period to which they relate. Uncertain tax positions that meet the more likely than not recognition threshold are measured to determine the amount of tax benefit to recognize in the consolidated and combined financial statements. An uncertain tax position is measured at the largest amount of benefit that the Company believes has a greater than 50% likelihood of realization upon settlement. Tax benefits not meeting the measurement or realization criteria represent unrecognized tax benefits. Penalties related to income tax matters are recognized within Benefit (provision) for income taxes in the Consolidated and Combined Statements of Income. Our policy is to adjust these reserves when facts and circumstances change, such as the actual settlement or effective settlement of positions with the relevant taxing authorities. Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their respective tax bases, as well as from net operating loss and tax credit carryforwards. The deferred income tax balances are stated at enacted tax rates expected to be in effect when those taxes are paid or recovered. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years. We evaluate the recoverability of these future tax deductions and credits by evaluating all available positive and negative evidence, specifically assessing the adequacy of future expected taxable income from all sources, including reversal of existing taxable temporary differences, forecasted operating earnings, and available tax planning strategies. To the extent we consider it more likely than not that a deferred tax asset will not be recovered, a valuation allowance is established to reduce the carrying value of the deferred asset to its more likely than not realizable value. Deferred taxes are provided for our investment in non-U.S. affiliates and associated companies based upon our evaluation of the undistributed earnings of such entities.
POSTRETIREMENT BENEFIT PLANS	POSTRETIREMENT BENEFIT PLANS. Prior to the Spin-Off, GE sponsored plans were accounted for as multiemployer plans. Therefore, the related assets and liabilities are not reflected in the Combined Statement of Financial Position for the year ended December 31, 2022. The Combined Statements of Income reflect a proportionate allocation of net periodic benefit costs for the multiemployer plans associated with the Company for the years ended December 31, 2022 and 2021. In connection with the Spin-Off, on January 1, 2023, GE HealthCare assumed a portion of former GE pension and postretirement obligations and assets. The pension and postretirement obligations assumed relate to benefits owed to current GE HealthCare employees, former GE HealthCare employees, and certain GE legacy plan participants. The pension plans are now sponsored by GE HealthCare. For the postretirement plans, GE HealthCare is now a participant in a multiple-employer plan with GE. Management accounts for the pension and postretirement plans as defined benefit plans. We measure our plan assets at fair value and categorize plan assets for disclosure purposes in accordance with the fair value hierarchy. Certain assets for which the fair value is measured using the net asset value (“NAV”) per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The components of net periodic benefit costs, other than the service cost component, are recognized within Non-operating benefit (income) costs in the Consolidated and Combined Statements of Income for plans sponsored by the Company. We engage third-party actuaries to assist in the determination of pension obligations and related plan costs. We develop significant long-term assumptions including discount rates and the expected rate of return on assets in connection with our pension accounting. We recognize differences between the expected long-term return on plan assets, the actual return, and net actuarial gains and losses for the pension plan liabilities annually in the fourth quarter of each fiscal year and whenever a plan is determined to qualify for a remeasurement within the Consolidated and Combined Statements of Comprehensive Income (Loss). We amortize gains and losses, as well as the effects of changes in actuarial assumptions and plan provisions, that exceed 10% of the greater of plan assets or benefit obligations. The period over which gains and losses are amortized is generally over the average remaining service of employees.
LOSS CONTINGENCIES	LOSS CONTINGENCIES. Loss contingencies are uncertain and unresolved matters that arise in the ordinary course of business and result from events that have the potential to result in a future loss. Such contingencies include, but are not limited to, product warranties, claims, litigation, environmental obligations, regulatory investigations and proceedings, product quality, and losses resulting from other events and developments. When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the loss. When there appears to be a range of possible losses with equal likelihood, liabilities are based on the low end of such range. Disclosure is provided for material loss contingencies when a loss is probable and an estimate can be made, when a loss is probable but a reasonable estimate cannot be made, and when it is reasonably possible that a loss will be incurred or the amount of a loss will exceed the recorded provision. We regularly review contingencies to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. Legal costs incurred in connection with loss contingencies are expensed as incurred.
SUPPLY CHAIN FINANCE PROGRAMS	SUPPLY CHAIN FINANCE PROGRAMS. The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables as borrowings. In connection with the supply chain finance programs, payment terms normally range from 30 to 150 days, not exceeding 180 days, depending on the underlying supplier agreements.
RECURRING AND NON-RECURRING FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS. The following sections describe the valuation methodologies we use to measure financial and non-financial instruments at fair value including certain assets within our postretirement benefit plans. Observable inputs for fair value measurements reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. These inputs establish the following fair value hierarchy: •Level 1 — Quoted prices for identical instruments in active markets. •Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable. •Level 3 — Significant inputs to the valuation model are unobservable. RECURRING FAIR VALUE MEASUREMENTS. For financial assets and liabilities measured at fair value on a recurring basis, primarily investment securities, derivatives, and contingent consideration, fair value is the price we would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. In the absence of active markets for the identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date. Investment Securities Publicly traded equity securities are valued using Level 1 quoted price inputs. Derivatives The majority of our derivatives are valued using model-derived offers received from financial institutions for similar over-the-counter instruments without an active market or internal models. The models maximize observable inputs including interest rates and both forward and spot prices for currencies and commodities. As of December 31, 2023 and 2022, foreign currency contracts, interest rate contracts, commodity exchange contracts, embedded derivatives, and the equity-linked total return swap were valued using Level 2 inputs. Contingent Consideration When an acquisition involves a contingent consideration arrangement, we record on the date of acquisition a liability for the fair value of the estimated additional consideration we may be obligated to pay in the future. The fair value is based upon estimates of future financial projections under various potential scenarios using a probability-weighted expected payment model discounted to present value. The estimates used to determine the fair value are subject to significant judgement and as such are considered Level 3 inputs. We subsequently remeasure such liabilities at the end of each reporting period and record changes in the fair value within SG&A in the Consolidated and Combined Statements of Income. Investments in private equity, real estate and collective funds held within our postretirement benefit plans Most investments are generally valued using the NAV per share as a practical expedient for fair value provided certain criteria are met. The NAVs are determined based on the fair values of the underlying investments in the funds. Investments that are measured at fair value using the NAV practical expedient are not required to be classified in the fair value hierarchy. Investments classified within Level 3 primarily relate to real estate and private equities which are valued using unobservable inputs, primarily by discounting expected future cash flows, using comparative market multiples, third-party pricing sources, or a combination of these approaches as appropriate. See Note 10, “Postretirement Benefit Plans” for further information. Debt securities held within our postretirement benefit plans When available, we use quoted market prices to determine the fair value of debt securities which are Level 1 inputs. For our remaining debt securities, we obtain pricing information from an independent pricing vendor. The inputs and assumptions to the pricing vendor’s models are derived from market observable sources including benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers and other market-related data. These investments are classified within Level 2. See Note 10, “Postretirement Benefit Plans” for further information. There were no transfers between Levels 1, 2, and 3 of the fair value hierarchy during the years ended December 31, 2023 and 2022. See Note 13, “Financial Instruments and Fair Value Measurements” for further information. NON-RECURRING FAIR VALUE MEASUREMENTS. Certain assets and liabilities are measured at fair value on a non-recurring basis. These items may include financing receivables and long-lived assets reduced to fair value upon classification as held for sale and impaired equity method investments and long-lived assets, which, when written down to fair value upon an impairment, are not subsequently adjusted to fair value unless further impairment occurs. The following sections describe the valuation methodologies the Company uses to measure these assets not measured on a recurring fair value basis. Equity Method Investments Equity method investments are initially recorded at cost and are adjusted in each period for the Company’s share of the investee’s income or loss and dividends paid. In instances of impairment, equity method investments are written down to fair value using market observable data such as quoted prices when available. When market observable data is unavailable, investments are valued using either a discounted cash flow model, comparative market multiples, third-party pricing sources, or a combination of these approaches, as appropriate. These investments are generally valued using Level 3 inputs. Equity Investments Without Readily Determinable Fair Value Equity investments without readily determinable fair value, subject to a policy choice on a transaction-by-transaction basis, are accounted for under the measurement alternative at cost less impairment and adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. In the instance of impairment, if any, equity investments are adjusted to fair value using market observable data if available. If market observable data is not available, fair values are estimated using discounted cash flow models, comparative market multiples, or a combination of these approaches using Level 3 inputs. Financing Receivables We generally use market data, including pricing on recently closed market transactions, to value financing receivables that are held for sale. Such financing receivables are valued using Level 2 inputs. When the data is unobservable, we use valuation methodologies based on current market interest rate data adjusted for inherent credit risk. Such financing receivables are valued using Level 3 inputs. Long-Lived Assets Fair values of long-lived assets are primarily developed internally and are corroborated by available external appraisal information, as applicable. These assets are generally valued using Level 3 inputs.
FOREIGN CURRENCY	FOREIGN CURRENCY. We have determined that the functional currency for many of our international operations is the local currency, and for other international operations the functional currency is the USD. The basis of this determination is the currency in which each of the international operations primarily generates and expends cash. When the functional currency is not the USD, asset and liability accounts are translated at period-end exchange rates. The Company translates functional currency income and expense amounts to their USD equivalents using average exchange rates for the period. These translation gains and losses are recognized within Accumulated other comprehensive income (loss) – net (“AOCI”) in the Consolidated and Combined Statements of Financial Position. Gains and losses from foreign currency transactions, such as those resulting from the settlement of monetary items in the non-functional currency and those resulting from remeasurements of monetary items, are included in Cost of products, Cost of services, SG&A, and R&D in the Consolidated and Combined Statements of Income, depending on the underlying nature of the item.
BUSINESS COMBINATIONS	BUSINESS COMBINATIONS. Our consolidated and combined financial statements include the operations of acquired businesses from the date of acquisition. The Company accounts for acquired businesses using the acquisition method of accounting in accordance with U.S. GAAP, which requires that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date. When we acquire the remaining equity ownership of a company in which we hold an equity interest, we remeasure our equity interest to fair value. Any excess of the purchase price over the assigned values of the net assets acquired is recorded as Goodwill. Transaction costs are expensed as incurred. For those arrangements that involve potential future contingent consideration, on the date of acquisition we record a liability equal to the fair value of the estimated additional consideration we may be obligated to pay in the future.
DISCONTINUED OPERATIONS	DISCONTINUED OPERATIONS. Certain of our operations have been presented as discontinued. We present businesses whose disposal represents a strategic shift that has, or will have, a major effect on our operations and financial results as discontinued operations when the components meet the criteria for held for sale, are sold, or spun-off. Presentation as discontinued operations is consistent for all periods presented.
RESTRUCTURING COSTS	RESTRUCTURING COSTS. We record liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee termination costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.
RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT. The Company conducts R&D activities to create new products, develop new applications for existing products, and enhance existing products. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. R&D costs are expensed as incurred. In certain instances, R&D activities may be funded by third parties, including government entities. These R&D funding arrangements may include upfront payments, R&D cost sharing payments, and future milestone payments that may be based upon the occurrence of future R&D or commercialization events. Payments received as part of the R&D funding arrangements are generally presented as an offset to R&D expense.
COLLABORATIVE ARRANGEMENTS	COLLABORATIVE ARRANGEMENTS. We enter into collaborative arrangements primarily related to development of new products. A collaborative arrangement is a contractual arrangement that involves two or more parties who are active participants in the activity, and are exposed to significant risks and rewards dependent on the commercial success of the activity. The assessment for a collaborative arrangement is performed throughout the life of the arrangement based on changes in the responsibilities of all parties. Amounts that are owed by collaboration partners related to R&D activities are generally presented as an offset to R&D expense.
ACCOUNTING CHANGES	ACCOUNTING CHANGES. Accounting Standards Codification (“ASC”) Topic 740, Income Taxes, provides that interest and penalties related to unrecognized income tax benefits may either be classified as income tax expense or interest expense in the consolidated statements of operations. In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions. The interest was previously presented within Interest and other financial charges – net and has changed to being presented within Benefit (provision) for income taxes. The Company believes this presentation is preferable because the cost is related to income tax matters and this presentation enhances comparability with our peers. The effects of the change in accounting have been prospectively applied to periods beginning in the first quarter of 2023 and were not material to any previously reported periods prior to March 31, 2023. Recent Accounting Pronouncements Reflected in These Consolidated and Combined Financial Statements In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50). The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted this guidance on January 1, 2023. See Note 18, “Supplemental Financial Information” for further information. In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The ASU requires companies to apply the definition of a performance obligation under ASC 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities relating to contracts with customers acquired in a business combination. Prior to the adoption of this ASU, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. The ASU results in the acquirer recording acquired contract assets and contract liabilities from contracts with customers on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance on January 1, 2023 using a prospective method, and the adoption did not have a material impact on the consolidated financial statements. Other Recent Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07 (“ASU 2023-07”), Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 requires annual and interim disclosures that are expected to improve reportable segment disclosures, primarily through enhanced disclosures about significant segment expenses. The provisions of ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-07. In December 2023, the FASB issued ASU No. 2023-09 (“ASU 2023-09”), Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The provisions of ASU 2023-09 are effective for annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact of adopting ASU 2023-09.

SUPPLEMENTAL FINANCIAL INFORMATION

12 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SUPPLEMENTAL FINANCIAL INFORMATION


Cash, Cash Equivalents, and Restricted Cash	As of
	December 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,494	$	1,440
Short-term restricted cash	10		5
Total Cash, cash equivalents, and restricted cash as presented on the Consolidated and Combined Statements of Financial Position	2,504		1,445
Long-term restricted cash(1)	2		6
Total Cash, cash equivalents, and restricted cash as presented on the Consolidated and Combined Statements of Cash Flows	$	2,506	$	1,451

(1) Long-term restricted cash is recognized within All other assets in the Consolidated and Combined Statements of Financial Position.


Inventories
	As of
	December 31, 2023		December 31, 2022
Raw materials	$	961	$	1,053
Work in process	91		91
Finished goods	908		1,011
Inventories(1)	$	1,960	$	2,155


Property, Plant, and Equipment – Net
	Depreciable lives (in years)	Original Cost				Accumulated Depreciation				Net Carrying Value
As of December 31		2023		2022		2023		2022		2023		2022
Land and improvements(1)	8	$	70	$	70	$	(1)	$	(1)	$	69	$	69
Buildings, structures and related equipment	8-40	1,956		1,889		(1,167)		(1,109)		789		780
Machinery and equipment(2)	4-20	2,617		2,541		(1,802)		(1,791)		815		750
Leasehold costs and manufacturing plants under construction	1-40	565		489		(94)		(87)		471		402
Property, plant, and equipment – net, exclusive of ROU operating lease assets		$	5,208	$	4,989	$	(3,064)	$	(2,988)	$	2,144	$	2,001
ROU operating lease assets(3)										356		313
Property, plant, and equipment – net										$	2,500	$	2,314

(1) Depreciable lives exclude land.

(3) See Note 7, “Leases” for further information.

Depreciation related to Property, plant, and equipment – net, exclusive of ROU operating lease assets, was $248 million, $228 million, and $225 million for the years ended December 31, 2023, 2022, and 2021, respectively.


All Other Current and Non-Current Assets
	As of
	December 31, 2023		December 31, 2022
Prepaid expenses and deferred costs	$	147	$	163
Financing receivables – net	97		97
Derivative instruments	84		63
Other(1)	61		94
All other current assets	$	389	$	417
Prepaid pension asset	716		70
Equity method and other investments	357		322
Financing receivables – net	178		196
Long-term receivables – net	124		145
Inventories	147		104
Contract and other deferred assets	168		119
Other(2)	191		68
All other non-current assets(3)	$	1,881	$	1,024

(1) Current Other primarily consists of tax receivables.

(2) Non-current Other primarily consists of indemnities due from GE and derivative instruments.


Equity Method Investments
		Equity method investment balance				Equity method income (loss)
As of December 31	Ownership Percentage	2023		2022		2023		2022		2021
Nihon Medi-Physics Co., Ltd	50%	$	150	$	162	$	10	$	16	$	22
Other		20		20		1		(3)		5
Total		$	170	$	182	$	11	$	13	$	27


All Other Current and Non-Current Liabilities
	As of
	December 31, 2023		December 31, 2022
Employee compensation and benefit liabilities(1)	$	1,518	$	853
Sales allowances and related liabilities	228		243
Uncertain and other income taxes and related liabilities	260		237
Product warranties	192		193
Accrued freight and utilities	132		150
Operating lease liabilities	110		104
Derivative instruments(2)	128		86
Interest payable on borrowings	87		52
Environmental and asset retirement obligations	21		34
Other(3)	335		238
All other current liabilities(4)	$	3,011	$	2,190
Contract liabilities	705		630
Operating lease liabilities	273		243
Environmental and asset retirement obligations	265		251
Uncertain and other income taxes and related liabilities	208		182
Derivative instruments	136		119
Finance lease obligations	38		39
Sales allowances and related liabilities	27		26
Other(5)	225		113
All other non-current liabilities(4)	$	1,877	$	1,603

(2) Derivative instruments include the related accrued interest. Refer to Note 13, “Financial Instruments and Fair Value Measurements” for further information.

(3) Current Other primarily consists of miscellaneous accrued costs, dividends payable to shareholders, and contingent consideration liabilities.

(5) Non-current Other primarily consists of miscellaneous accrued costs, contingent consideration liabilities, and indemnities due to GE.

SUPPLY CHAIN FINANCE PROGRAMS.

Included within Accounts payable in the Consolidated and Combined Statements of Financial Position as of December 31, 2023 and 2022 were $365 million and $392 million, respectively, of confirmed supplier invoices that are outstanding and subject to third-party programs. See Note 2, “Summary of Significant Accounting Policies” for further information regarding our supply chain finance programs.

COLLABORATIVE ARRANGEMENTS.

In October 2023, we entered into a Collaboration and License Agreement (“Agreement”) with Novo Nordisk (“Novo”) to pursue a collaboration on the development, regulatory approval and commercialization of an ultrasound therapy. Under the terms of the Agreement, in return for providing development activities associated with the development of the underlying ultrasound device to deliver Novo’s clinical therapies, we received an upfront nonrefundable payment with the potential for additional nonrefundable payments over the next four years. We will recognize the nonrefundable payments as an offset to R&D expense as we perform activities contemplated under the Agreement. These nonrefundable payments are not material. We may also receive future payments based on the achievement of certain development milestones and regulatory approvals associated with the ultrasound therapy.

REDEEMABLE NONCONTROLLING INTERESTS.

The Company has noncontrolling interests with redemption features. These redemption features, such as put options, could require the Company to purchase the noncontrolling interests upon the occurrence of certain events. All noncontrolling interests with redemption features that are not solely within our control are recognized within the Consolidated and Combined Statements of Financial Position between liabilities and equity. Redeemable noncontrolling interests are initially recorded at the issuance date fair value. Those that are currently redeemable or probable of becoming redeemable are subsequently adjusted to the greater of current redemption value or initial carrying value.

The activity attributable to redeemable noncontrolling interests for the years ended December 31, 2023, 2022, and 2021 is presented below.


Redeemable Noncontrolling Interests
	For the years ended December 31
	2023		2022		2021
Balance at beginning of period	$	230	$	220	$	223
Net income attributable to redeemable noncontrolling interests	41		47		39
Redemption value adjustments(1)	183		—		—
Distributions to and exercise of redeemable noncontrolling interests and other(2)	(289)		(37)		(42)
Balance at end of period	$	165	$	230	$	220


Other Income (Expense) – Net
	For the years ended December 31
		2023		2022		2021
Net interest and investment income (expense)		$	26	$	(9)	$	34
Equity method income (loss)		11		13		27
Change in fair value of assumed obligations		(32)		—		—
Other items, net(1)		81		58		62
Total other income (expense) – net		$	86	$	62	$	123

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

12 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Abstract]

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

DERIVATIVES AND HEDGING.

Our primary objective in executing and holding derivative contracts is to reduce the volatility of earnings and cash flows associated with risks related to foreign currency exchange rates, interest rates, equity prices, and commodity prices. These derivative contracts reduce, but do not entirely eliminate, the aforementioned risks. Our policy is to use derivative contracts solely for managing risks and not for speculative purposes.

The fair values of derivative contracts are recognized within All other current assets, All other assets, All other current liabilities, and All other liabilities in the Consolidated and Combined Statements of Financial Position based upon the contractual timing of settlements for these contracts. We designate certain derivative contracts as hedging instruments in cash flow, fair value, or net investment hedges. We evaluate the effectiveness of our derivative contracts designated as hedging instruments on a quarterly basis.

Cash Flow Hedges

We use foreign currency forward contracts to hedge the volatility of cash flows related to forecasted transactions and firm commitments, including intercompany transactions, denominated in foreign currencies other than a subsidiary’s functional currency. The maximum length of time over which we hedge forecasted transactions is two years. As of December 31, 2023, these contracts have a maximum remaining maturity of 12 months.

For derivative instruments designated as cash flow hedges, changes in the fair value of designated hedging instruments are initially recorded as a component of AOCI and subsequently reclassified to earnings in the period in which the hedged transaction occurs and to the same financial statement line item impacted by the hedged transaction. We expect to reclassify $21 million of pre-tax net deferred losses associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the impact on earnings of the related hedged transactions.

The cash flows associated with derivatives designated as cash flow hedges are recorded in Cash from (used for) operating activities in the Consolidated and Combined Statements of Cash Flows.

Net Investment Hedges

We use cross-currency interest rate swaps and foreign currency forward contracts in combination with foreign currency option contracts to hedge the foreign currency risk associated with our net investment in foreign operations. The maximum length of time over which we are hedging our net investment in foreign operations is approximately five years. As of December 31, 2023, these contracts have a maximum remaining maturity of 52 months and were designated as hedges of our net investment in foreign operations with Euro, Japanese Yen, and Chinese Renminbi functional currencies.

We use the spot method to assess hedge effectiveness for our net investment hedges. Changes in the fair value of the designated hedging instruments attributable to fluctuations in foreign currency to USD spot exchange rates are initially recorded and held as a component of the CTA portion of AOCI until the hedged foreign operation is either sold or substantially liquidated. Changes in fair value of the portion of net investment hedging derivatives excluded from the assessment of effectiveness are recorded in CTA and then recognized within Interest and other financial charges – net in the Consolidated and Combined Statements of Income using a systematic and rational method over the life of the hedge. Excluded components on the cross-currency swaps designated as net investment hedges, in the form of accrued interest, are recorded within Interest and other financial charges – net in the Consolidated and Combined Statements of Income.

The cash flows associated with derivatives designated as net investment hedges are recorded in Cash from (used for) investing activities in the Consolidated and Combined Statements of Cash Flows. Cash flows from the periodic interest settlements on the cross-currency swaps are recorded in Cash from (used for) operating activities in the Consolidated and Combined Statements of Cash Flows.

Fair Value Hedges

We use interest rate swaps to hedge the interest rate risk on our fixed rate borrowings. These derivatives are designated as fair value hedges. In the fourth quarter of 2023, we executed interest-rate swap contracts to hedge the benchmark interest rate risk of specific designated cash flows of a senior unsecured note.

We record the changes in fair value on the swap contracts in Interest and other financial charges – net in our Consolidated and Combined Statements of Income, the same line item where the offsetting change in the fair value of the designated cash flows of the senior unsecured note is recorded as a basis adjustment.

Cash flows for the periodic interest settlements on the interest rate swaps are recorded in Cash from (used for) operating activities in the Consolidated and Combined Statements of Cash Flows.

Derivatives Not Designated as Hedging Instruments

We also execute derivative instruments, such as foreign currency forward contracts, equity-linked total return swaps, and commodity forward contracts that are not designated as qualifying hedges. These derivatives serve as economic hedges of the foreign currency rate risk, equity price risk and commodity price risk. We identify foreign currency-related features in our purchase or sales contracts where the currency is not the local or functional currency of a substantive party to the contract and record them as embedded derivatives.

The changes in fair value of derivatives not designated in qualifying hedge transactions are recorded in Cost of products, Cost of services, SG&A, and Other (income) expense – net in the Consolidated and Combined Statements of Income based on the nature of the underlying hedged transaction. Changes in fair value of embedded derivatives are recognized in Other (income) expense – net in the Consolidated and Combined Statements of Income.

The cash flows associated with derivatives not designated as hedges are recorded in Cash from (used for) operating activities and Cash from (used for) investing activities in the Consolidated and Combined Statements of Cash Flows based on the nature of the underlying hedged transaction.

The following table presents the gross fair values of our outstanding derivative instruments.


Fair Value of Derivatives
	December 31, 2023						December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,356	$	8	$	30	$	1,240	$	32	$	53
Derivatives accounted for as cash flow hedges	1,356		8		30		1,240		32		53
Cross-currency swaps(1)	2,209		—		204		2,132		—		111
Foreign currency exchange contracts and options	991		9		11		—		—		—
Derivatives accounted for as net investment hedges	3,200		9		215		2,132		—		111
Interest rate swaps(1)	1,000		35		10		—		—		—
Derivatives accounted for as fair value hedges	1,000		35		10		—		—		—
Foreign currency exchange contracts	3,597		19		12		4,456		9		20
Other derivatives(2)	438		57		2		660		25		25



Derivatives not designated as hedging instruments	4,035		76		14		5,116		34		45
Total derivatives	$	9,591	$	128	$	269	$	8,488	$	66	$	209

(1) Accrued interest was immaterial for the periods presented and is excluded from fair value. These amounts are recognized within All other current assets and All other current liabilities in the Consolidated and Combined Statements of Financial Position.

(2) Other derivatives are comprised of embedded derivatives, derivatives related to equity contracts, and commodity derivatives.

The following table presents amounts recorded in Long-term borrowings on the Consolidated Statement of Financial Position related to cumulative basis adjustment for fair value hedges.


	December 31, 2023
	Carrying amount		Cumulative basis adjustment included in the carrying amount
Long-term borrowings designated in fair value hedges	$	1,023	$	25

Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis on our Consolidated and Combined Statements of Financial Position and in the table above.

As of December 31, 2023, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $41 million.

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges.


Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges
	For the years ended December 31
		2023		2022		2021
Cash flow hedges		$	(6)	$	37	$	40
Net investment hedges(1)		(97)		(111)		—

(1) Amounts recognized in OCI for excluded components for the periods presented were immaterial.

The tables below present the effects of our derivative financial instruments and hedging activity in the Consolidated and Combined Statements of Income.


Derivative Financial Instruments and Hedging Activity
	For the year ended December 31, 2023
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(3)

Foreign currency exchange contracts	$	23	$	6	$	—	$	—	$	—
Effects of cash flow hedges	23		6		—		—		—
Cross-currency swaps	—		—		—		34		—
Foreign currency exchange contracts and options	—		—		—		3		—
Effects of net investment hedges(1)	—		—		—		37		—
Foreign currency exchange contracts	—		—		—		—		—
Interest rate swaps	—		—		—		24		—
Debt basis adjustment on Long-term borrowings	—		—		—		(25)		—
Other derivatives(2)	—		—		—		—		—
Effects of fair value hedges	—		—		—		(1)		—
Foreign currency exchange contracts	3		2		—		—		5



Other derivatives(2)	—		—		10		—		47
Effects of derivatives not designated as hedging instruments	$	3	$	2	$	10	$	—	$	52

	For the year ended December 31, 2022
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(3)

Foreign currency exchange contracts	$	54	$	—	$	—	$	—	$	—
Effects of cash flow hedges	54		—		—		—		—
Cross-currency swaps	—		—		—		—		—
Foreign currency exchange contracts and options	—		—		—		—		—
Effects of net investment hedges(1)	—		—		—		—		—
Foreign currency exchange contracts	—		—		—		—		—
Interest rate swaps	—		—		—		—		—
Debt basis adjustment on Long-term borrowings	—		—		—		—		—
Other derivatives(2)	—		—		—		—		—
Effects of fair value hedges	—		—		—		—		—
Foreign currency exchange contracts	(96)		—		—		—		11
Other derivatives(2)	—		—		—		—		11
Effects of derivatives not designated as hedging instruments	$	(96)	$	—	$	—	$	—	$	22

	For the year ended December 31, 2021
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(3)

Foreign currency exchange contracts	$	(8)	$	—	$	—	$	—	$	—
Effects of cash flow hedges	(8)		—		—		—		—
Cross-currency swaps	—		—		—		—		—
Foreign currency exchange contracts and options	—		—		—		—		—
Effects of net investment hedges	—		—		—		—		—
Foreign currency exchange contracts	(12)		—		—		—		—
Interest rate swaps	—		—		—		—		—
Debt basis adjustment on Long-term borrowings	—		—		—		—		—
Other derivatives(2)	—		—		—		—		24
Effects of fair value hedges	(12)		—		—		—		24
Foreign currency exchange contracts	—		—		—		—		10



Other derivatives(2)	—		—		—		—		—
Effects of derivatives not designated as hedging instruments	$	—	$	—	$	—	$	—	$	10

(1) Amounts are excluded from effectiveness testing for 2023 and 2022.

(2) Other derivatives are comprised of embedded derivatives, derivatives related to equity contracts, and commodity derivatives.

(3) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Consolidated and Combined Statements of Income.

Counterparty Credit Risk

The Company would be exposed to credit-related losses in the event of non-performance by counterparties on executed derivative instruments. The credit exposure of derivative contracts is represented by the fair value of contracts as of the reporting date. The fair value of the Company’s derivatives can change significantly from period to period based on, among other factors, market movements, and changes in our positions.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, by limiting the amount of credit exposure to individual counterparties, and by actively monitoring counterparty credit ratings and the amount of individual credit exposure.

We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. None of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

FAIR VALUE MEASUREMENTS.

The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis.


Fair Value of Assets and Liabilities Measured on a Recurring Basis
	As of December 31, 2023								As of December 31, 2022
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Investment securities	$	31	$	—	$	—	$	31	$	21	$	—	$	—	$	21
Derivatives	—		128		—		128		—		66		—		66
Liabilities:
Deferred compensation	264		5		—		269		62		2		—		64
Derivatives	—		269		—		269		—		203		6		209
Contingent consideration	—		—		44		44		—		—		42		42

Contingent Consideration

The contingent consideration liabilities as of December 31, 2023 and 2022 were recorded in connection with business acquisitions. During the years ended December 31, 2023 and 2022, we recorded benefits of $17 million and $65 million, respectively, from fair value adjustments related to the remeasurement of contingent consideration liabilities. These benefits are recognized within SG&A in the Consolidated and Combined Statements of Income. Changes in the Level 3 fair value measurement of contingent consideration were not material during the year ended December 31, 2021.

Non-recurring Fair Value Measurements

Changes in fair value measurements of assets and liabilities measured at fair value on a non-recurring basis, such as equity method investments, equity investments without readily determinable fair value, financing receivables, and long-lived assets, were not material for the years ended December 31, 2023, 2022, and 2021.

Fair Value of Other Financial Instruments

The estimated fair value of borrowings as of December 31, 2023 and 2022 was $9,959 million and $8,521 million compared to a carrying value (which includes a reduction for amortized debt issuance costs and discounts) of $9,442 million and $8,249 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 9, “Borrowings” for further information.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Fair Values (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Gross Notional	$ 9,591	$ 8,488
Fair Value – Assets	128	66
Fair Value – Liabilities	269	209
Designated as hedging instrument \| Cash flow hedges
Derivative [Line Items]
Gross Notional	1,356	1,240
Fair Value – Assets	8	32
Fair Value – Liabilities	30	53
Designated as hedging instrument \| Cash flow hedges \| Foreign currency exchange contracts
Derivative [Line Items]
Gross Notional	1,356	1,240
Fair Value – Assets	8	32
Fair Value – Liabilities	30	53
Designated as hedging instrument \| Net investment hedges
Derivative [Line Items]
Gross Notional	3,200	2,132
Fair Value – Assets	9	0
Fair Value – Liabilities	215	111
Designated as hedging instrument \| Net investment hedges \| Cross-currency swaps
Derivative [Line Items]
Gross Notional	2,209	2,132
Fair Value – Assets	0	0
Fair Value – Liabilities	204	111
Designated as hedging instrument \| Net investment hedges \| Foreign currency exchange contracts and options
Derivative [Line Items]
Gross Notional	991	0
Fair Value – Assets	9	0
Fair Value – Liabilities	11	0
Designated as hedging instrument \| Fair value hedges
Derivative [Line Items]
Gross Notional	1,000	0
Fair Value – Assets	35	0
Fair Value – Liabilities	10	0
Designated as hedging instrument \| Fair value hedges \| Interest rate swaps
Derivative [Line Items]
Gross Notional	1,000	0
Fair Value – Assets	35	0
Fair Value – Liabilities	10	0
Not designated as hedging instrument
Derivative [Line Items]
Gross Notional	4,035	5,116
Fair Value – Assets	76	34
Fair Value – Liabilities	14	45
Not designated as hedging instrument \| Foreign currency exchange contracts
Derivative [Line Items]
Gross Notional	3,597	4,456
Fair Value – Assets	19	9
Fair Value – Liabilities	12	20
Not designated as hedging instrument \| Other derivatives
Derivative [Line Items]
Gross Notional	438	660
Fair Value – Assets	57	25
Fair Value – Liabilities	$ 2	$ 25

POSTRETIREMENT BENEFIT PLANS - Plan Obligations in Excess of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2023	Jan. 01, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
Accumulated benefit obligations	$ 23,841	$ 22,906	$ 687
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	20,774		390
Fair value of plan assets	15,433		63
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	20,808		406
Fair value of plan assets	$ 15,433		$ 63

INCOME TAXES - Narrative (Details) - USD ($)		12 Months Ended
INCOME TAXES - Narrative (Details) - USD ($)	Jan. 03, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Contingency [Line Items]
Additions for tax positions of prior years		$ 156,000,000	$ 137,000,000	$ 14,000,000
Reductions for tax positions of prior years		203,000,000	41,000,000	78,000,000
Interest expense on uncertain tax positions		12,000,000	12,000,000	9,000,000
Penalties expense on uncertain tax positions		6,000,000	0	$ 0
Capitalized R&D, related to 2023 R&D expenses		267,000,000
Capitalized R&D, related to 2022 R&D expenses		197,000,000	293,000,000
Total deferred income tax asset		4,996,000,000	1,963,000,000
Increase in valuation allowance related to spin-off activities		269,000,000
Deferred tax asset, net operating loss carryforward, increase due to spin-off	$ 1,075,000,000
Operating loss carryforwards		6,526,000,000
Deferred tax asset, net operating loss carryforward, gross		1,241,000,000
Unrecognized tax benefits, net operating loss		149,000,000
Unrecognized tax benefits, US foreign tax credits		444,000,000
Deferred tax liabilities, undistributed foreign earnings		21,000,000
Unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries		7,729,000,000
GE
Income Tax Contingency [Line Items]
Additions for tax positions of prior years		134,000,000	132,000,000
Reductions for tax positions of prior years		$ 183,000,000
Total deferred income tax asset			$ 80,000,000
Deferred tax asset increase, transfer from GE	3,099,000,000
Deferred tax asset increase, transfer from GE, pension and postretirement benefits	$ 964,000,000

POSTRETIREMENT BENEFIT PLANS - Components of Expense (Income) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Non-operating		$ (382)	$ (5)	$ 3
Pension Plans \| Principal Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost		32
Interest cost		952
Expected return on plan assets		(1,170)
Amortization of net loss (gain)		(125)
Amortization of prior service cost (credit)		4
Curtailment loss (gain)		17
Settlement loss (gain)		0
Non-operating		(322)
Net periodic expense (income)		(290)
Pension Plans \| Other Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost		23	19	24
Interest cost		209	17	15
Expected return on plan assets		(256)	(27)	(27)
Amortization of net loss (gain)		10	5	17
Amortization of prior service cost (credit)		(3)	(5)	(4)
Curtailment loss (gain)		0	0	0
Settlement loss (gain)	$ 61	61	0	0
Non-operating		21	(10)	1
Net periodic expense (income)		44	$ 9	$ 25
OPEB Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost		6
Interest cost		59
Expected return on plan assets		0
Amortization of net loss (gain)		(64)
Amortization of prior service cost (credit)		(87)
Curtailment loss (gain)		0
Settlement loss (gain)		0
Non-operating		(92)
Net periodic expense (income)		$ (86)

RESTRUCTURING AND OTHER ACTIVITIES - NET

12 Months Ended

Dec. 31, 2023

Restructuring and Related Activities [Abstract]

RESTRUCTURING AND OTHER ACTIVITIES - NET

RESTRUCTURING AND OTHER ACTIVITIES – NET

Restructuring activities are essential to optimize the business operating model for GE HealthCare as a stand-alone company and mostly involve workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring and other charges (gains) primarily include facility exit costs, employee-related termination benefits associated with workforce reductions, asset write-downs, and cease-use costs. For segment reporting, restructuring and other activities are not allocated.

For restructuring initiatives committed to by management through December 31, 2023, we recorded net expenses of $54 million, $146 million, and $155 million for the years ended December 31, 2023, 2022, and 2021. These restructuring initiatives are expected to result in additional expenses of approximately $20 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and facility exit costs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or SG&A, as appropriate, in the Consolidated and Combined Statements of Income.


Restructuring and Other Activities
	For the years ended December 31
		2023		2022		2021
Employee termination costs		$	38	$	74	$	127
Facility and other exit costs		3		46		20
Asset write-downs		13		26		8
Total restructuring and other activities – net		$	54	$	146	$	155

In connection with the Spin-Off, GE transferred employee termination obligations for services already rendered of $31 million to GE HealthCare of which $4 million was remaining as of December 31, 2023. Liabilities related to restructuring are recognized within All other current liabilities and All other liabilities in the Consolidated and Combined Statements of Financial Position and totaled $68 million and $75 million as of December 31, 2023 and 2022, respectively.

Consolidated and Combined Statements of Financial Position (Parentheticals) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 98	$ 91
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	455,342,290	100
Common stock, outstanding (in shares)	455,342,290	100

LEASES - Net Investment in Financing Leases (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Total minimum lease payments receivable	$ 236	$ 248
Less: deferred income	(30)	(30)
Discounted lease receivable	206	218
Estimated unguaranteed residual value of leased assets, net of deferred income	11	12
Investment in financing leases, net of deferred income	$ 217	$ 230

Consolidated and Combined Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue	$ 19,552	$ 18,341	$ 17,585
Gross profit	7,922	7,179	7,174
Selling, general, and administrative	4,282	3,631	3,563
Research and development	1,205	1,026	816
Total operating expenses	5,487	4,657	4,379
Operating income	2,435	2,522	2,795
Interest and other financial charges – net	542	77	40
Non-operating benefit (income) costs	(382)	(5)	3
Other (income) expense – net	(86)	(62)	(123)
Income from continuing operations before income taxes	2,361	2,512	2,875
Benefit (provision) for income taxes	(743)	(563)	(600)
Net income from continuing operations	1,618	1,949	2,275
Income (loss) from discontinued operations, net of taxes	(4)	18	18
Net income	1,614	1,967	2,293
Net (income) loss attributable to noncontrolling interests	(46)	(51)	(46)
Net income attributable to GE HealthCare	1,568	1,916	2,247
Deemed preferred stock dividend of redeemable noncontrolling interest	(183)	0	0
Net income attributable to GE HealthCare common stockholders	$ 1,385	$ 1,916	$ 2,247
Earnings per share from continuing operations attributable to GE HealthCare common stockholders:
Basic (in dollars per share)	$ 3.06	$ 4.18	$ 4.91
Diluted (in dollars per share)	3.04	4.18	4.91
Earnings per share attributable to GE HealthCare common stockholders:
Basic (in dollars per share)	3.05	4.22	4.95
Diluted (in dollars per share)	$ 3.03	$ 4.22	$ 4.95
Weighted-average number of shares outstanding:
Basic (in shares)	455	454	454
Diluted (in shares)	458	454	454
Products
Revenue	$ 13,127	$ 12,044	$ 11,165
Cost of revenue	8,465	7,975	7,196
Services
Revenue	6,425	6,297	6,420
Cost of revenue	$ 3,165	$ 3,187	$ 3,215

POSTRETIREMENT BENEFIT PLANS

12 Months Ended

Dec. 31, 2023

Retirement Benefits [Abstract]

POSTRETIREMENT BENEFIT PLANS

PENSION BENEFITS AND RETIREE HEALTH AND LIFE BENEFITS SPONSORED BY GE PRIOR TO SPIN-OFF.

Certain GE HealthCare employees were covered under various pension and retiree health and life plans sponsored by GE prior to the Spin-Off. These plans were accounted for as multiemployer plans prior to the Spin-Off. Certain of these benefit plans are closed to new participants. For the years ended December 31, 2022 and 2021, relevant costs for these plans were allocated to the Company by GE and recognized within the Combined Statements of Income. These costs included service costs for active employees in the U.S. GE Pension Plan, certain international pension plans, the U.S. GE Supplementary Pension Plan, and certain U.S. retiree benefit plans. We did not record any assets or liabilities associated with our participation in these plans in our Combined Statement of Financial Position as of December 31, 2022.

Expenses associated with our employees’ participation in the U.S. GE Pension Plan and certain U.S. retiree benefit plans, which represent the majority of related expense, were $73 million and $96 million for the years ended December 31, 2022 and 2021, respectively. Expenses associated with our employees’ participation in certain international pension plans were $11 million and $22 million for the years ended December 31, 2022 and 2021, respectively.

In addition, certain GE HealthCare employees were covered under various pension plans historically sponsored by GE HealthCare. The assets and liabilities associated with these plans are included in our Combined Statement of Financial Position as of December 31, 2022.

PENSION BENEFITS AND RETIREE HEALTH AND LIFE BENEFITS POST SPIN-OFF.

In connection with the Spin-Off, on January 1, 2023, GE HealthCare assumed a portion of former GE pension and postretirement obligations and assets. The pension and postretirement obligations assumed relate to benefits owed to current GE HealthCare employees, former GE HealthCare employees, and certain GE legacy plan participants. For the postretirement plans, GE HealthCare is now a participant in a multiple-employer plan with GE.

The total assets and liabilities for all plans assumed by GE HealthCare on January 1, 2023, are shown in the tables below.


Accumulated Benefit Obligations and Unrecognized Gain
	As of January 1, 2023
	Defined benefit plans(1)		Other postretirement plans(2)		Total
Accumulated benefit obligations	$	21,696	$	1,210	$	22,906

Unrecognized gain recorded in AOCI	1,258		1,223		2,481


Net Benefit Liability
	As of January 1, 2023
	Defined benefit plans(1)		Other postretirement plans(2)		Total
Projected benefit obligations	$	21,743	$	1,210	$	22,953
Fair value of assets	18,908		—		18,908
Net liability	$	2,835	$	1,210	$	4,045

DESCRIPTION OF OUR PLANS.

For the years ended December 31, 2022 and 2021, we disclose postretirement plans with assets or obligations that exceed $20 million in the following tables. As a result of the liabilities and assets transferred to GE HealthCare on January 1, 2023, we disclose in the following tables postretirement plans with assets or obligations that exceed $50 million for the year ended December 31, 2023. We use a December 31st measurement date for these plans.

Our Principal Pension Plans include the GE HealthCare Pension Plan which covers U.S. participants and our GE HealthCare Supplemental Pension Plan which provides supplementary benefits to higher-level, longer-service U.S. employees. The Principal Pension Plans are comprised of the obligations transferred to GE HealthCare from GE in connection with the Spin-Off. These plans have been closed to new participants since 2012. All remaining service accruals for the GE HealthCare Pension Plan will freeze effective December 31, 2024. Benefits for participants of the GE HealthCare Supplemental Pension Plan who became executives before 2011 were frozen effective January 1, 2021, and thereafter these employees accrue a benefit which is paid out in ten annual installments upon retirement. The GE HealthCare Pension Plan has a projected benefit obligation of $16,138 million, plan assets of $14,700 million, and is 91% funded per U.S. GAAP as of December 31, 2023. The GE HealthCare Supplemental Pension plan has a projected benefit obligation of $2,022 million as of December 31, 2023, and the benefits are paid to eligible participants directly by the Company as described further in the ‘Funding’ section of this Note.

Our Other Pension Plans include all other plans, which cover certain U.S. participants and non-U.S. participants. These plans include obligations that existed prior to the Spin-Off and obligations transferred to GE HealthCare from GE in connection with the Spin-Off. In certain countries, benefit accruals have ceased and/or have been closed to new hires as of various dates.

The OPEB Plans include health and life insurance benefits to U.S. participants. GE HealthCare assumed the obligations associated with these plans in connection with the Spin-Off. Participants share in the cost of the healthcare and life insurance benefits. Certain benefits for salaried and hourly participants were closed to new retirees in 2015 and 2019.

Funding

The funding policy for the GE HealthCare Pension Plan and our Other Pension Plans is to contribute amounts sufficient to meet minimum funding requirements as set forth in employee benefit and tax laws plus any additional amounts as we may determine to be appropriate. The GE HealthCare Supplemental Pension Plan and OPEB Plans are unfunded and we pay benefits from our cash on hand. In 2023, the Company made cash payments totaling $142 million for its GE HealthCare Supplemental Pension Plan, $84 million to its Other Pension Plans and $131 million to its OPEB Plans. In 2024, the Company expects to make total cash contributions of approximately $336 million to our pension and OPEB plans. The Company does not have a required minimum funding contribution for its U.S.-based GE HealthCare Pension Plan in 2024. Future contributions will depend on market conditions, interest rates, and other factors.


Plan Funded Status
	As of
	December 31, 2023						December 31, 2022
	Principal Pension Plans		Other Pension Plans		OPEB Plans			Other Pension Plans
Change in projected benefit obligations
Balance at January 1	$	—	$	640	$	—		$	940
Transfers from GE at Spin-Off	17,997		3,707		1,149			—
Service cost	32		23		6			19
Interest cost	952		209		59			17
Participant contributions	4		1		18			1
Plan amendments	53		2		—			—
Actuarial loss (gain) – net	493		221		50			(193)
Benefits paid	(1,341)		(359)		(149)			(38)
Curtailments	(30)		—		—			—

Exchange rate adjustments	—		144		—			(43)
Balance at December 31	$	18,160	$	4,588	$	1,133		$	703
Change in plan assets
Balance at January 1	$	—	$	382	$	—		$	553
Transfers from GE at Spin-Off	14,838		4,046		—			—
Actual gain (loss) on plan assets	1,057		189		—			(101)
Employer contributions	142		84		131			18
Participant contributions	4		1		18			1
Benefits paid	(1,341)		(359)		(149)			(38)
Acquisitions/Divestitures/Mergers	—		1		—			—
Exchange rate adjustments	—		174		—			(8)
Balance at December 31	$	14,700	$	4,518	$	—		$	425
Funded status – surplus (deficit)	$	(3,460)	$	(70)	$	(1,133)		$	(278)


Amounts Recorded in Consolidated and Combined Statements of Financial Position
	As of
	December 31, 2023						December 31, 2022
	Principal Pension Plans		Other Pension Plans		OPEB Plans		Other Pension Plans
All other assets	$	—	$	712	$	—	$	65
All other current liabilities	(143)		(47)		(130)		(16)
Compensation and benefits	(3,317)		(735)		(1,003)		(327)
Net amount recorded	$	(3,460)	$	(70)	$	(1,133)	$	(278)


Pre-Tax Amounts Recorded in AOCI
	As of
	December 31, 2023						December 31, 2022
	Principal Pension Plans		Other Pension Plans		OPEB Plans			Other Pension Plans
Net loss (gain)	$	(1,213)	$	1,075	$	(482)		$	60
Prior service cost (credit)	(43)		(18)		(533)			(5)
Total recorded in AOCI	$	(1,256)	$	1,057	$	(1,015)		$	55

The accumulated benefit obligation represents the actuarial present value of benefits based on employee service and compensation as of the measurement date and does not include an assumption about future compensation levels. The table below summarizes the total accumulated benefit obligation, the accumulated benefit obligation in excess of plan assets, and the projected benefit obligation and fair value of plan assets for the defined benefit pension plans with projected benefit obligation in excess of plan assets.


Plan Obligations in Excess of Plan Assets
	As of
	December 31, 2023		December 31, 2022
Accumulated benefit obligation	$	23,841	$	687
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	$	20,774	$	390
Fair value of plan assets	15,433		63
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	$	20,808	$	406
Fair value of plan assets	15,433		63


Components of Expense (Income)
	For the years ended December 31
	Principal Pension Plans		Other Pension Plans					OPEB Plans

	2023			2023		2022		2021		2023
Service cost – Operating	$	32		$	23	$	19	$	24	$	6
Interest cost	952			209		17		15		59
Expected return on plan assets	(1,170)			(256)		(27)		(27)		—
Amortization of net loss (gain)	(125)			10		5		17		(64)
Amortization of prior service cost (credit)	4			(3)		(5)		(4)		(87)
Curtailment loss (gain)	17			—		—		—		—
Settlement loss (gain)	—			61		—		—		—
Non-operating	$	(322)		$	21	$	(10)	$	1	$	(92)
Net periodic expense (income)	$	(290)		$	44	$	9	$	25	$	(86)

In the third quarter of 2023, management approved an amendment to the U.S.-based GE HealthCare Pension Plan whereby the benefits for all remaining active employees will be frozen effective December 31, 2024, and additional benefit enhancements were provided. As a result, we recognized a non-cash pre-tax curtailment loss of approximately $17 million as non-operating benefit costs and an increase to our pension liability of $23 million. As a result of the plan changes, we remeasured the plan assets and the projected benefit obligation. These changes collectively decreased AOCI by $305 million in the Consolidated Statement of Financial Position.

In the fourth quarter of 2023, management approved and paid a one-time lump sum payment for certain terminated employees in two plans who were vested in their benefits. These lump sum settlements reduce our future cash requirements and premiums. As a result of the partial settlement of the pension liability, we recognized a non-cash pre-tax settlement charge. The settlement charge of $61 million represents a pro rata portion of unrecognized net loss recorded in AOCI and is recorded in Non-operating benefit (income) costs in the Consolidated Statement of Income.


Pre-tax Cost of Postretirement Benefit Plans and Changes in Other Comprehensive Income
	For the years ended December 31
	2023						2022			2021
	Principal Pension Plans		Other Pension Plans		OPEB Plans			Other Pension Plans			Other Pension Plans
Cost of postretirement benefit plans	$	(290)	$	44	$	(86)		$	9		$	23
Changes in other comprehensive loss (income):
Transfers from GE at Spin-Off	(1,989)		740		(1,216)			—			—
Plan amendments	53		—		—			—			—
Net loss (gain) – current year	606		287		50			(74)			(86)
Reclassifications out of AOCI:
Curtailment / settlement gain (loss)	(47)		(61)		—			—			—

Amortization of net loss (gain)	125		(10)		64			(5)			(16)
Amortization of prior service credit	(4)		3		87			5			4
Total changes in other comprehensive loss (income)	$	(1,256)	$	959	$	(1,015)		$	(74)		$	(98)
Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)	$	(1,546)	$	1,003	$	(1,101)		$	(65)		$	(75)


Assumptions
	For the years ended December 31
	2023						2022			2021
	Principal Pension Plans		Other Pension Plans		OPEB Plans			Other Pension Plans			Other Pension Plans
Weighted-average benefit obligations assumptions
Discount rate	5.2	%	4.5	%	5.1	%		4.3	%		1.9	%
Compensation increases	3.9	%	3.1	%	3.6	%		3.0	%		2.8	%
Weighted-average benefit cost assumptions
Discount rate	5.5	%	4.9	%	5.4	%		1.9	%		1.4	%
Expected rate of return on plan assets	7.0	%	5.6	%	—	%		6.3	%		5.4	%

For the December 31, 2023 postretirement health care obligations remeasurement, the Company assumed a 6.5% initial weighted average rate of increase in the per capita cost of the various covered health care benefits, which applies primarily to non-Medicare eligible participants. The trend rate was assumed to decrease gradually to an ultimate rate of 5.0% in 2029 and remain at that level thereafter.

Assumptions Used in Calculations

Accounting requirements necessitate the use of assumptions to reflect the uncertainties and the length of time over which the pension obligations will be paid. The actual amount of future benefit payments will depend upon when participants retire, the amount of their benefit at retirement, and how long they live. To reflect the obligation in today’s U.S. dollars, we discount the future payments using a rate that matches the time frame over which the payments are expected to be made. We also assume a long-term rate of return that will be earned on investments used to fund these payments.

GE HealthCare engages third-party actuaries to assist in the determination of the pension and other postretirement plan assumptions. We evaluate these assumptions annually. We periodically evaluate other assumptions, such as retirement age, mortality, and turnover, and update them as necessary to reflect our actual experience and expectations for the future.

We determine the discount rate using the weighted average yields on high-quality fixed-income securities that have maturities consistent with the expected timing of benefit payments. Lower discount rates increase the size of the benefit obligations and generally increase pension expense in the following year; higher discount rates reduce the size of the benefit obligation and generally reduce subsequent-year pension expense.

The expected return on plan assets is the estimated long-term rate of return that will be earned on the investments used to fund the pension obligations. To determine this rate, we consider the current and target composition of plan investments, our historical returns earned, and our expectations about the future.

The compensation assumption is used to estimate the annual rate at which compensation of active plan participants will grow. If the rate of growth assumed increases, the size of the pension obligations will increase, as will the amount recorded in AOCI in our Consolidated and Combined Statements of Financial Position and amortized to earnings in subsequent periods.

With respect to the pension balances included on our Consolidated Statement of Financial Position as of December 31, 2023, we estimate that we will amortize $(116) million of net actuarial gain and $(81) million of prior service credit from AOCI into Non-operating benefit (income) cost in the Consolidated Statement of Income during 2024.


Expected Future Benefit Payments of Our Benefit Plans
	Principal Pension Plans		Other Pension Plans		OPEB Plans
2024	$	1,277	$	226	$	130
2025	1,289		239		124
2026	1,300		239		119
2027	1,307		243		114
2028	1,310		254		110
2029-2033	6,449		1,334		454

PENSION PLAN ASSETS.

The GE HealthCare Employee Benefits Investment Committee (the “Investment Committee”) oversees and monitors the investment of the assets of our U.S. funded pension plans. The Investment Committee retains independent investment managers and advisors and uses documented policies and procedures relating to investment goals, targeted asset allocations, risk management practices, allowable and prohibited investment holdings, diversification, use of derivatives, the relationship between plan assets and benefit obligations, the funded status of the plans, and other relevant factors and considerations.

The assets of our U.S. funded pension plans are invested in a portfolio that includes U.S. and international equity securities; U.S. government, agency and corporate debt securities; asset-backed debt securities; private equity; real estate and other alternative investments; as well as cash and cash equivalents and derivatives contracts. This combination of assets and derivatives is utilized to implement the investment strategies as well as for hedging asset and liability risks. The Investment Committee sets target allocation percentages at an asset class level, including permitted ranges above or below the target allocation percentages.

The plan assets for international plans are managed and allocated by the entities in each country.


Composition of Plan Assets as of December 31, 2023
	Principal Pension Plans										Other Pension Plans
			Basis of fair value measurement										Basis of fair value measurement
	Balance as of December 31, 2023		Level 1		Level 2		Level 3		Measured at NAV(1)		Balance as of December 31, 2023		Level 1		Level 2		Level 3		Measured at NAV(1)
Global equity securities	$	2,609	$	954	$	—	$	—	$	1,655	$	467	$	51	$	1	$	—	$	415
Debt securities (including cash and cash equivalents)	8,121		866		6,309		—		946		2,977		239		2,203		—		535
Real estate	912		—		—		382		530		508		—		—		20		488
Private equities and other investments	3,058		—		9		213		2,836		566		—		1		11		554
Fair value of plan assets	$	14,700	$	1,820	$	6,318	$	595	$	5,967	$	4,518	$	290	$	2,205	$	31	$	1,992

(1) Certain assets that are measured at fair value using the NAV per share (or its equivalent), as a practical expedient, have not been classified in the fair value hierarchy.


Composition of Plan Assets as of December 31, 2022
	Other Pension Plans
			Basis of fair value measurement
	Balance as of December 31, 2022		Level 1		Level 2		Level 3		Measured at NAV(1)
Global equity securities	$	67	$	33	$	—	$	—	$	34
Debt securities (including cash and cash equivalents)	205		24		150		—		31
Real estate	25		—		—		12		13
Private equities and other investments	128		3		7		49		69
Fair value of plan assets	$	425	$	60	$	157	$	61	$	147

(1) Certain assets that are measured at fair value using the NAV per share (or its equivalent), as a practical expedient, have not been classified in the fair value hierarchy.

As of December 31, 2023 and 2022, the fair value of plan assets that used significant unobservable inputs (Level 3) was $626 million and $61 million, respectively. These assets primarily relate to real estate and private equity investments. The changes to the balances of Level 3 plan assets during 2023 were primarily a result of the transferred liabilities and assets to GE HealthCare on January 1, 2023. The changes to the balances of Level 3 plan assets during 2022 were not significant.


Weighted Average Asset Allocation of Pension Plans
	2023 Target				2023 Actual
	Principal Pension Plans		Other Pension Plans			Principal Pension Plans		Other Pension Plans
Global equity securities	18	%	11	%		18	%	10	%
Debt securities (including cash and cash equivalents)	54	%	58	%		55	%	66	%
Real estate	7	%	17	%		6	%	11	%
Private equities and other instruments	21	%	14	%		21	%	13	%

DEFINED CONTRIBUTION PLAN.

As a result of the Spin-Off, GE HealthCare established a defined contribution plan for its eligible U.S. employees that was largely consistent with the plan they participated in while GE HealthCare operated as a business of GE. Expenses associated with our employees’ participation in GE HealthCare’s defined contribution plan in 2023 and GE’s defined contribution plan in 2022 and 2021 represent the employer matching contributions for GE HealthCare employees and were $122 million, $123 million and $119 million for the years ended December 31, 2023, 2022, and 2021, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480266/715-60-50-3

+ Details

RESTRUCTURING AND OTHER ACTIVITIES - NET - Schedule of Restructuring and Related Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Restructuring and Related Activities [Abstract]
Employee termination costs	$ 38	$ 74	$ 127
Facility and other exit costs	3	46	20
Asset write-downs	13	26	8
Total restructuring and other activities – net	$ 54	$ 146	$ 155

SUPPLEMENTAL FINANCIAL INFORMATION - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Supplier Finance Program [Line Items]
Depreciation of property, plant, and equipment		$ 248	$ 228	$ 225
Supplier finance program, payment terms, maximum threshold		180 days
Supplier finance program obligation		$ 365	$ 392
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]		Accounts payable	Accounts payable
Additional non refundable payments period	4 years
Minimum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms		30 days
Maximum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms		150 days

INCOME TAXES - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income before taxes	$ 2,361	$ 2,512	$ 2,875
Tax expected at 21%	496	528	604
Foreign operations	63	43	(54)
Withholding taxes	28	4	11
U.S. tax on foreign operations	(35)	(36)	(23)
Uncertain tax positions	11	6	11
R&D benefits	(33)	(33)	(32)
State taxes, net of federal benefit	24	39	45
Valuation allowance	19	8	33
Spin-Off and separation costs	184	0	0
Other	(14)	4	5
Total	$ 743	$ 563	$ 600
Actual income tax rate	31.50%	22.40%	20.90%

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Guarantor obligations, maximum exposure	$ 114
Environmental remediation liabilities	19	$ 11
Asset retirement obligations	$ 267	$ 274

FINANCING RECEIVABLES

12 Months Ended

Dec. 31, 2023

Receivables [Abstract]

FINANCING RECEIVABLES


Financing Receivables
	As of
	December 31, 2023		December 31, 2022
Loans, net of deferred income	$	29	$	29
Investment in financing leases, net of deferred income	71		72
Allowance for credit losses	(3)		(4)
Current financing receivables – net(1)	97		97
Loans, net of deferred income	37		44
Investment in financing leases, net of deferred income	146		158
Allowance for credit losses	(5)		(6)
Non-current financing receivables – net(1)	$	178	$	196

Total financing receivables sold were $27 million, $8 million, and $104 million for the years ended December 31, 2023, 2022, and 2021, respectively.

As of December 31, 2023, 5%, 5%, and 6% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2022, 7%, 6%, and 6% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral.

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2023
Audit Information [Abstract]
Auditor Location	Chicago, Illinois
Auditor Firm ID	34
Auditor Name	Deloitte & Touche LLP

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)		12 Months Ended
	Feb. 17, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Consideration transferred, upfront payment		$ 147,000,000	$ 0	$ 1,481,000,000
Goodwill		12,936,000,000	12,813,000,000	12,892,000,000
Goodwill impairment			0	0
Impairment of intangible assets, indefinite-lived		0	0	0
Additions to acquired finite-lived intangible assets		$ 62,000,000
Acquired finite-lived intangible assets, weighted average useful life		9 years
Amortization of intangible assets		$ 362,000,000	405,000,000	400,000,000
Impairment of intangible assets, definite-lived		$ 0	$ 0	$ 0
Caption Health
Business Acquisition [Line Items]
Percent of interest acquired	100.00%
Consideration transferred, upfront payment	$ 127,000,000
Consideration transferred, holdback payment	10,000,000
Contingent consideration	13,000,000
Goodwill	94,000,000
Intangible assets	60,000,000
Deferred tax liabilities	$ 3,000,000

RELATED PARTIES (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Related Party Transactions


Corporate Allocations from GE	For the years ended
	December 31, 2022		December 31, 2021
Costs for centralized services(1)	$	42	$	56
Costs associated with employee medical insurance(2)	122		132
Costs for corporate and shared services(3)	457		455

(1) Costs for centralized services such as public relations, treasury and cash management, and other services were recognized within SG&A in the Combined Statements of Income.

(2) Costs associated with employee medical insurance were recognized within Cost of products, Cost of services, SG&A, and R&D in the Combined Statements of Income based on the employee population.

(3) Costs for corporate and shared services such as information technology, finance and other services were primarily recognized in SG&A and R&D in the Combined Statements of Income.

SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 19,552	$ 18,341	$ 17,585
EBIT	2,956	2,861	3,172
Restructuring costs	(54)	(146)	(155)
Acquisition and disposition-related benefits (charges)	15	34	(14)
Gain (loss) on business and asset dispositions	0	1	2
Spin-Off and separation costs	(270)	(14)	0
Amortization of acquisition-related intangible assets	(127)	(121)	(90)
Investment revaluation gain (loss)	1	(31)	3
Interest and other financial charges – net	(542)	(77)	(40)
Non-operating benefit income (costs)	382	5	(3)
Income from continuing operations before income taxes	2,361	2,512	2,875
Operating segments \| Imaging
Segment Reporting Information [Line Items]
Revenue	10,581	9,985	9,433
EBIT	1,124	1,100	1,240
Operating segments \| Imaging \| Radiology
Segment Reporting Information [Line Items]
Revenue	8,944	8,395	8,019
Operating segments \| Imaging \| Interventional Guidance
Segment Reporting Information [Line Items]
Revenue	1,637	1,590	1,414
Operating segments \| Ultrasound
Segment Reporting Information [Line Items]
Revenue	3,457	3,422	3,172
EBIT	821	908	885
Operating segments \| PCS
Segment Reporting Information [Line Items]
Revenue	3,142	2,916	2,915
EBIT	383	341	356
Operating segments \| PCS \| Monitoring Solutions
Segment Reporting Information [Line Items]
Revenue	2,283	2,092	2,119
Operating segments \| PCS \| Life Support Solutions
Segment Reporting Information [Line Items]
Revenue	859	824	796
Operating segments \| PDx
Segment Reporting Information [Line Items]
Revenue	2,306	1,958	2,018
EBIT	617	520	693
Other
Segment Reporting Information [Line Items]
Revenue	66	60	47
EBIT	$ 11	$ (8)	$ (2)

SHARE-BASED COMPENSATION - Schedule of Stock Options Valuation Assumptions (Details) - Stock options	12 Months Ended
	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free rate	3.60%
Dividend yield	0.01%
Expected volatility	26.20%
Expected term (in years)	6 years 2 months 12 days

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

BORROWINGS - Schedule of Maturities of Long-Term Debt (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Maturities of Long-Term Debt [Abstract]
2024	$ 1,008
2025	1,541
2026	1,152
2027	1,751
2028	0
Thereafter	4,000
Total	$ 9,452	$ 8,296

RESTRUCTURING AND OTHER ACTIVITIES - NET (Tables)

12 Months Ended

Dec. 31, 2023

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs


Restructuring and Other Activities
	For the years ended December 31
		2023		2022		2021
Employee termination costs		$	38	$	74	$	127
Facility and other exit costs		3		46		20
Asset write-downs		13		26		8
Total restructuring and other activities – net		$	54	$	146	$	155

REVENUE RECOGNITION

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

CONTRACT ASSETS.

Contract assets primarily reflect revenue recognized on contracts with customers in excess of billings based on contractual terms. Contract assets are classified as current or non-current based on the amount of time expected to lapse until the Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs.


Contract and Other Deferred Assets
	As of
	December 31, 2023		December 31, 2022
Contract assets	$	600	$	584
Other deferred assets	400		405
Contract and other deferred assets	1,000		989
Non-current contract assets(1)	72		37
Non-current other deferred assets(1)	96		82
Total contract and other deferred assets	$	1,168	$	1,108

(1)Non-current contract and other deferred assets are recognized within All other assets in the Consolidated and Combined Statements of Financial Position.

Capitalized costs to obtain a contract were $213 million and $204 million as of December 31, 2023 and December 31, 2022, respectively. Generally, these costs are recognized within two years of being capitalized. When recognized, the costs to obtain a contract are recorded within SG&A in the Consolidated and Combined Statements of Income.

CONTRACT LIABILITIES.

Contract liabilities primarily include customer advances and deposits received when orders are placed and billed in advance of completion of performance obligations. Contract liabilities are classified as current or non-current based on the periods over which remaining performance obligations are expected to be satisfied with our customers.

As of December 31, 2023 and December 31, 2022, contract liabilities were approximately $2,623 million and $2,526 million, respectively, of which the non-current portion of $705 million and $630 million, respectively, was recognized in All other liabilities in the Consolidated and Combined Statements of Financial Position. Contract liabilities increased $97 million in 2023 primarily due to an increase in extended warranty contracts. Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately $1,554 million and $1,562 million for the years ended December 31, 2023 and 2022, respectively.

REMAINING PERFORMANCE OBLIGATIONS.

Remaining performance obligations represent the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the ability to cancel or terminate without incurring a substantive penalty. As of December 31, 2023, the aggregate amount of the contracted revenues allocated to our unsatisfied (or partially unsatisfied) performance obligations was $14,655 million. We expect to recognize revenue as we satisfy our remaining performance obligations as follows: a) product-related remaining performance obligations of $4,930 million of which 98% is expected to be recognized within two years, and the remaining thereafter; and b) services-related remaining performance obligations of $9,725 million of which 65% and 93% are expected to be recognized within two years and five years, respectively, and the remaining thereafter.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

Consolidated and Combined Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows - operating activities
Net income	$ 1,614	$ 1,967	$ 2,293
Income (loss) from discontinued operations, net of taxes	(4)	18	18
Net income from continuing operations	1,618	1,949	2,275
Adjustments to reconcile Net income from continuing operations to Cash from (used for) operating activities
Depreciation of property, plant, and equipment	248	228	225
Amortization of intangible assets	362	405	400
Gain on fair value remeasurement of contingent consideration	(17)	(65)	0
Net periodic postretirement benefit plan (income) expense	(332)	9	25
Postretirement plan contributions	(357)	(18)	(20)
Share-based compensation	114	67	76
Provision for income taxes	743	563	600
Cash paid during the year for income taxes	(474)	(851)	(615)
Changes in operating assets and liabilities, excluding the effects of acquisitions and dispositions:
Receivables	(185)	(231)	(1,336)
Due from related parties	4	13	157
Inventories	111	(402)	(435)
Contract and other deferred assets	10	(222)	23
Accounts payable	(13)	481	263
Due to related parties	(84)	(33)	(21)
Contract liabilities	26	138	(21)
All other operating activities	327	103	11
Cash from (used for) operating activities – continuing operations	2,101	2,134	1,607
Cash flows – investing activities
Additions to property, plant and equipment and internal-use software	(387)	(310)	(248)
Dispositions of property, plant, and equipment	1	4	15
Purchases of businesses, net of cash acquired	(147)	0	(1,481)
All other investing activities	(25)	(92)	(47)
Cash from (used for) investing activities – continuing operations	(558)	(398)	(1,761)
Cash flows – financing activities
Net increase (decrease) in borrowings (maturities of 90 days or less)	(12)	9	(7)
Newly issued debt, net of debt issuance costs (maturities longer than 90 days)	2,006	8,198	5
Repayments and other reductions (maturities longer than 90 days)	(855)	(3)	(10)
Dividends paid to stockholders	(41)	0	0
Redemption of noncontrolling interests	(211)	0	0
Net transfers (to) from GE	(1,317)	(8,934)	(238)
All other financing activities	(48)	(92)	(13)
Cash from (used for) financing activities – continuing operations	(478)	(822)	(263)
Cash from (used for) operating activities – discontinued operations	0	(21)	0
Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash	(10)	(3)	(34)
Increase (decrease) in cash, cash equivalents, and restricted cash	1,055	890	(451)
Cash, cash equivalents, and restricted cash at beginning of year	1,451	561	1,012
Cash, cash equivalents, and restricted cash as of December 31	2,506	1,451	561
Supplemental disclosure of cash flows information
Cash paid during the year for interest	(570)	0	(21)
Non-cash investing activities
Acquired but unpaid property, plant, and equipment	$ 140	$ 136	$ 93

BORROWINGS - Schedule of Long-Term Borrowings (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal debt issued	$ 9,452	$ 8,296
Less: Unamortized debt issuance costs and discounts	35	47
Add: Cumulative basis adjustment for fair value hedges	25	0
Total borrowings	9,442	8,249
Less: Short-term borrowings (net of debt issuance costs)	1,006	15
Long-term borrowings	$ 8,436	8,234
Senior notes \| 5.550% senior notes due November 15, 2024
Debt Instrument [Line Items]
Stated interest rate	5.55%
Principal debt issued	$ 1,000	1,000
Senior notes \| 5.600% senior notes due November 15, 2025
Debt Instrument [Line Items]
Stated interest rate	5.60%
Principal debt issued	$ 1,500	1,500
Senior notes \| 5.650% senior notes due November 15, 2027
Debt Instrument [Line Items]
Stated interest rate	5.65%
Principal debt issued	$ 1,750	1,750
Senior notes \| 5.857% senior notes due March 15, 2030
Debt Instrument [Line Items]
Stated interest rate	5.857%
Principal debt issued	$ 1,250	1,250
Senior notes \| 5.905% senior notes due November 22, 2032
Debt Instrument [Line Items]
Stated interest rate	5.905%
Principal debt issued	$ 1,750	1,750
Senior notes \| 6.377% senior notes due November 22, 2052
Debt Instrument [Line Items]
Stated interest rate	6.377%
Principal debt issued	$ 1,000	1,000
Line of credit \| Floating rate Term Loan Facility due January 2, 2026
Debt Instrument [Line Items]
Principal debt issued	1,150	0
Other
Debt Instrument [Line Items]
Principal debt issued	$ 52	$ 46

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET

12 Months Ended

Dec. 31, 2023

Equity [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET

Changes in AOCI by component, net of income taxes, were as follows.


Accumulated Other Comprehensive Income (Loss)
	Currency translation adjustments(1)		Benefit plans		Cash flow hedges		Total AOCI
December 31, 2020	$	(643)	$	(180)	$	(16)	$	(839)
Other comprehensive income (loss) before reclasses – net of taxes of $(9), $(57), and $(12)	(326)		74		40		(212)
Reclasses from AOCI – net of taxes(2) of $0, $37, and $(3)	—		6		8		14
Other comprehensive income (loss)	(326)		80		48		(198)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
December 31, 2021	(969)		(100)		32		(1,037)
Other comprehensive income (loss) before reclasses – net of taxes of $(5), $(39), and $(10)	(878)		58		27		(793)
Reclasses from AOCI – net of taxes(2) of $0, $0, and $17	—		—		(50)		(50)
Other comprehensive income (loss)	(878)		58		(23)		(843)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(2)		—		—		(2)
December 31, 2022	(1,845)		(42)		9		(1,878)
Other comprehensive income (loss) before reclasses – net of taxes(3) of $22, $186, and $1	74		(601)		(5)		(532)
Reclasses from AOCI – net of taxes(2) of $0, $97, and $6	—		(296)		(22)		(318)
Other comprehensive income (loss)	74		(897)		(27)		(850)
Spin-Off related adjustments – net of taxes(4) of $0 $(509), and $0	28		1,972		—		2,000
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(37)		—		—		(37)
December 31, 2023	$	(1,706)	$	1,033	$	(18)	$	(691)

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Abstract]

Schedule of Derivative Assets at Fair Value

The following table presents the gross fair values of our outstanding derivative instruments.


Fair Value of Derivatives
	December 31, 2023						December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,356	$	8	$	30	$	1,240	$	32	$	53
Derivatives accounted for as cash flow hedges	1,356		8		30		1,240		32		53
Cross-currency swaps(1)	2,209		—		204		2,132		—		111
Foreign currency exchange contracts and options	991		9		11		—		—		—
Derivatives accounted for as net investment hedges	3,200		9		215		2,132		—		111
Interest rate swaps(1)	1,000		35		10		—		—		—
Derivatives accounted for as fair value hedges	1,000		35		10		—		—		—
Foreign currency exchange contracts	3,597		19		12		4,456		9		20
Other derivatives(2)	438		57		2		660		25		25



Derivatives not designated as hedging instruments	4,035		76		14		5,116		34		45
Total derivatives	$	9,591	$	128	$	269	$	8,488	$	66	$	209

(2) Other derivatives are comprised of embedded derivatives, derivatives related to equity contracts, and commodity derivatives.

Schedule of Derivative Liabilities at Fair Value

The following table presents the gross fair values of our outstanding derivative instruments.


Fair Value of Derivatives
	December 31, 2023						December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,356	$	8	$	30	$	1,240	$	32	$	53
Derivatives accounted for as cash flow hedges	1,356		8		30		1,240		32		53
Cross-currency swaps(1)	2,209		—		204		2,132		—		111
Foreign currency exchange contracts and options	991		9		11		—		—		—
Derivatives accounted for as net investment hedges	3,200		9		215		2,132		—		111
Interest rate swaps(1)	1,000		35		10		—		—		—
Derivatives accounted for as fair value hedges	1,000		35		10		—		—		—
Foreign currency exchange contracts	3,597		19		12		4,456		9		20
Other derivatives(2)	438		57		2		660		25		25



Derivatives not designated as hedging instruments	4,035		76		14		5,116		34		45
Total derivatives	$	9,591	$	128	$	269	$	8,488	$	66	$	209

(2) Other derivatives are comprised of embedded derivatives, derivatives related to equity contracts, and commodity derivatives.

Effect of Derivatives Instruments on Statement of Financial Position and Statement of Income

The following table presents amounts recorded in Long-term borrowings on the Consolidated Statement of Financial Position related to cumulative basis adjustment for fair value hedges.


	December 31, 2023
	Carrying amount		Cumulative basis adjustment included in the carrying amount
Long-term borrowings designated in fair value hedges	$	1,023	$	25

The tables below present the effects of our derivative financial instruments and hedging activity in the Consolidated and Combined Statements of Income.


Derivative Financial Instruments and Hedging Activity
	For the year ended December 31, 2023
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(3)

Foreign currency exchange contracts	$	23	$	6	$	—	$	—	$	—
Effects of cash flow hedges	23		6		—		—		—
Cross-currency swaps	—		—		—		34		—
Foreign currency exchange contracts and options	—		—		—		3		—
Effects of net investment hedges(1)	—		—		—		37		—
Foreign currency exchange contracts	—		—		—		—		—
Interest rate swaps	—		—		—		24		—
Debt basis adjustment on Long-term borrowings	—		—		—		(25)		—
Other derivatives(2)	—		—		—		—		—
Effects of fair value hedges	—		—		—		(1)		—
Foreign currency exchange contracts	3		2		—		—		5



Other derivatives(2)	—		—		10		—		47
Effects of derivatives not designated as hedging instruments	$	3	$	2	$	10	$	—	$	52

	For the year ended December 31, 2022
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(3)

Foreign currency exchange contracts	$	54	$	—	$	—	$	—	$	—
Effects of cash flow hedges	54		—		—		—		—
Cross-currency swaps	—		—		—		—		—
Foreign currency exchange contracts and options	—		—		—		—		—
Effects of net investment hedges(1)	—		—		—		—		—
Foreign currency exchange contracts	—		—		—		—		—
Interest rate swaps	—		—		—		—		—
Debt basis adjustment on Long-term borrowings	—		—		—		—		—
Other derivatives(2)	—		—		—		—		—
Effects of fair value hedges	—		—		—		—		—
Foreign currency exchange contracts	(96)		—		—		—		11
Other derivatives(2)	—		—		—		—		11
Effects of derivatives not designated as hedging instruments	$	(96)	$	—	$	—	$	—	$	22

	For the year ended December 31, 2021
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(3)

Foreign currency exchange contracts	$	(8)	$	—	$	—	$	—	$	—
Effects of cash flow hedges	(8)		—		—		—		—
Cross-currency swaps	—		—		—		—		—
Foreign currency exchange contracts and options	—		—		—		—		—
Effects of net investment hedges	—		—		—		—		—
Foreign currency exchange contracts	(12)		—		—		—		—
Interest rate swaps	—		—		—		—		—
Debt basis adjustment on Long-term borrowings	—		—		—		—		—
Other derivatives(2)	—		—		—		—		24
Effects of fair value hedges	(12)		—		—		—		24
Foreign currency exchange contracts	—		—		—		—		10



Other derivatives(2)	—		—		—		—		—
Effects of derivatives not designated as hedging instruments	$	—	$	—	$	—	$	—	$	10

(1) Amounts are excluded from effectiveness testing for 2023 and 2022.

(2) Other derivatives are comprised of embedded derivatives, derivatives related to equity contracts, and commodity derivatives.

(3) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Consolidated and Combined Statements of Income.

Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges.


Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges
	For the years ended December 31
		2023		2022		2021
Cash flow hedges		$	(6)	$	37	$	40
Net investment hedges(1)		(97)		(111)		—

(1) Amounts recognized in OCI for excluded components for the periods presented were immaterial.

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis.


Fair Value of Assets and Liabilities Measured on a Recurring Basis
	As of December 31, 2023								As of December 31, 2022
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Investment securities	$	31	$	—	$	—	$	31	$	21	$	—	$	—	$	21
Derivatives	—		128		—		128		—		66		—		66
Liabilities:
Deferred compensation	264		5		—		269		62		2		—		64
Derivatives	—		269		—		269		—		203		6		209
Contingent consideration	—		—		44		44		—		—		42		42

SHARE-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2023

Share-Based Payment Arrangement [Abstract]

Summary of Weighted Average Grant Date Fair Value and Share-Based Compensation Activity


Weighted Average Grant Date Fair Value
(In dollars)	December 31, 2023
Stock options	$	25
RSUs	73
PSUs	85


Stock Option Activity
	Shares (in thousands)	Weighted average exercise price (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)
Outstanding as of January 4, 2023(1)	3,738	$	90
Granted	2,155	72
Exercised/Vested	(561)	60
Forfeited	(159)	71
Expired	(210)	127
Outstanding as of December 31, 2023	4,963	$	84	6.1	$	35
Exercisable as of December 31, 2023	2,810	$	94	3.8	$	23
Expected to vest	1,755	$	72	9.0	$	10

Schedule of Stock Options Valuation Assumptions


Key Assumptions in the Black-Scholes Valuation for Stock Options
	December 31, 2023
Risk-free rate	3.6	%
Dividend yield	0.01	%
Expected volatility	26.2	%
Expected term (in years)	6.2

Schedule of RSU and PSU Activity


RSU and PSU Activity
	RSUs						PSUs
	Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average vesting period (in years)	Intrinsic value (in millions)		Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average vesting period (in years)	Intrinsic value (in millions)
Outstanding as of January 4, 2023(1)	3,551	$	58				1,365	$	68
Granted	1,904	73					539	85
Exercised/Vested	(1,317)	56					—	—
Forfeited	(409)	60					(483)	72
Expired	—	—					(175)	66
Outstanding as of December 31, 2023	3,729	$	67	1.5	$	290	1,246	$	85	1.4	$	96
Expected to vest	3,333	$	60	1.5	$	258	N/A	N/A		N/A	N/A

Summary of Share-Based Compensation Expense and Other Share-Based Compensation Data


Share-based Compensation Expense	For the year ended
	December 31, 2023



Share-based compensation expense (pre-tax)	$	114
Income tax benefits	(23)
Share-based compensation expense (after-tax)	$	91


Other Share-based Compensation Data

Unrecognized compensation expense as of December 31, 2023(1)	$	149
Cash received from stock options exercised in the year ended December 31, 2023	34
Intrinsic value of stock options exercised and RSU/PSUs vested in the year ended December 31, 2023	106

(1) Amortized over a weighted average period of 1.9 years.

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Roll Forward]
Beginning balance	$ 12,813	$ 12,892
Acquisitions	110	0
Foreign currency exchange and other	13	(79)
Ending balance	12,936	12,813
Imaging
Goodwill [Roll Forward]
Beginning balance	4,409	4,433
Acquisitions	16	0
Foreign currency exchange and other	6	(24)
Ending balance	4,431	4,409
Ultrasound
Goodwill [Roll Forward]
Beginning balance	3,835	3,876
Acquisitions	94	0
Foreign currency exchange and other	4	(41)
Ending balance	3,933	3,835
PCS
Goodwill [Roll Forward]
Beginning balance	2,036	2,049
Acquisitions	0	0
Foreign currency exchange and other	2	(13)
Ending balance	2,038	2,036
PDx
Goodwill [Roll Forward]
Beginning balance	2,533	2,534
Acquisitions	0	0
Foreign currency exchange and other	1	(1)
Ending balance	$ 2,534	$ 2,533

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

INCOME TAXES - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Total assets	$ 4,474	$ 1,550
Total liabilities	(68)	(370)
Net deferred income tax asset (liability)	4,406	1,180
Deferred tax assets:
Employee benefits	1,418	222
Contract liabilities	171	193
Inventories	95	84
Operating loss carryforwards	648	176
Other accrued expenses	68	70
Receivables	45	42
Lease liabilities	75	57
Tax credit carryforwards	59	128
Contract assets	79	99
U.S. interest restriction carryforwards	61	0
Goodwill and other intangible assets	1,461	0
Property, plant, and equipment	261	338
Capitalized R&D	547	554
Other	8	0
Total deferred income tax asset	4,996	1,963
Valuation allowances	(540)	(272)	$ (279)	$ (250)
Total deferred income tax asset after valuation allowance	4,456	1,691
Deferred tax liabilities:
Goodwill and other intangible assets	0	(458)
ROU assets	(50)	(47)
Other	0	(6)
Total deferred income tax liability	(50)	(511)
Net deferred income tax asset (liability)	$ 4,406	$ 1,180

Consolidated and Combined Statements of Changes in Equity - USD ($) $ in Millions	Total	Common stock	Additional paid-in capital	Retained earnings	Net parent investment	Accumulated other comprehensive income (loss) – net	Equity attributable to noncontrolling interests
Equity, beginning balance (in shares) at Dec. 31, 2020		0
Equity, beginning balance at Dec. 31, 2020	$ 14,751	$ 0	$ 0	$ 0	$ 15,566	$ (839)	$ 24
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to GE HealthCare	2,247				2,247
Other comprehensive income (loss) attributable to GE HealthCare	(198)					(198)
Transfers (to) from GE	(121)				(121)
Changes in equity attributable to noncontrolling interests	(3)						(3)
Equity, ending balance (in shares) at Dec. 31, 2021		0
Equity, ending balance at Dec. 31, 2021	16,676	$ 0	0	0	17,692	(1,037)	21
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to GE HealthCare	1,916				1,916
Other comprehensive income (loss) attributable to GE HealthCare	(841)					(841)
Transfers (to) from GE	(8,373)				(8,373)
Changes in equity attributable to noncontrolling interests	$ (16)						(16)
Equity, ending balance (in shares) at Dec. 31, 2022	100	0
Equity, ending balance at Dec. 31, 2022	$ 9,362	$ 0	0	0	11,235	(1,878)	5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net transfers from GE, including Spin-Off-related adjustments	(2,849)				(4,851)	2,000	2
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment (in shares)		454,000,000
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	0	$ 5	6,379		(6,384)
Issuance of common stock in connection with employee stock plans, net of shares withheld for employee taxes (in shares)		1,000,000
Net income attributable to GE HealthCare	1,568			1,568
Dividends declared	(55)			(55)
Other comprehensive income (loss) attributable to GE HealthCare	(813)					(813)
Changes in equity attributable to noncontrolling interests	5						5
Share-based compensation	114		114
Changes in equity due to redemption value adjustments on redeemable noncontrolling interests	$ (187)			(187)
Equity, ending balance (in shares) at Dec. 31, 2023	455,342,290	455,000,000
Equity, ending balance at Dec. 31, 2023	$ 7,145	$ 5	$ 6,493	$ 1,326	$ 0	$ (691)	$ 12

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Cash flow hedges	$ (6)	$ 37	$ 40
Net investment hedges	$ (97)	$ (111)	$ 0

Pay vs Performance Disclosure - USD ($) $ in Millions	12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Pay vs Performance Disclosure
Net income attributable to GE HealthCare	$ 1,568	$ 1,916	$ 2,247

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

SHARE-BASED COMPENSATION - Summary of RSU and PSU Activity (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
RSUs
Shares
Outstanding at beginning of period (in shares) \| shares		3,551
Granted (in shares) \| shares		1,904
Vested (in shares) \| shares		(1,317)
Forfeited (in shares) \| shares		(409)
Expired (in shares) \| shares		0
Outstanding at end of period (in shares) \| shares	3,729	3,729
Expected to vest (in shares) \| shares	3,333	3,333
Weighted average grant date fair value
Outstanding at beginning of period (in dollars per share) \| $ / shares		$ 58
Granted (in dollars per share) \| $ / shares	$ 73	73
Vested (in dollars per share) \| $ / shares		56
Forfeited (in dollars per share) \| $ / shares		60
Expired (in dollars per share) \| $ / shares		0
Outstanding at end of period (in dollars per share) \| $ / shares	67	67
Expected to vest (in dollars per share) \| $ / shares	$ 60	$ 60
RSU and PSU, weighted average contractual term (in years)
Weighted average remaining contractual term, outstanding		1 year 6 months
Weighted average remaining contractual term, expected to vest		1 year 6 months
RSU and PSU, intrinsic value
Intrinsic value, outstanding \| $	$ 290	$ 290
Intrinsic value, expected to vest \| $	$ 258	$ 258
PSUs
Shares
Outstanding at beginning of period (in shares) \| shares		1,365
Granted (in shares) \| shares		539
Vested (in shares) \| shares		0
Forfeited (in shares) \| shares		(483)
Expired (in shares) \| shares		(175)
Outstanding at end of period (in shares) \| shares	1,246	1,246
Weighted average grant date fair value
Outstanding at beginning of period (in dollars per share) \| $ / shares		$ 68
Granted (in dollars per share) \| $ / shares	$ 85	85
Vested (in dollars per share) \| $ / shares		0
Forfeited (in dollars per share) \| $ / shares		72
Expired (in dollars per share) \| $ / shares		66
Outstanding at end of period (in dollars per share) \| $ / shares	$ 85	$ 85
RSU and PSU, weighted average contractual term (in years)
Weighted average remaining contractual term, outstanding		1 year 4 months 24 days
RSU and PSU, intrinsic value
Intrinsic value, outstanding \| $	$ 96	$ 96

RECEIVABLES - Long-Term Receivables (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Long-term customer receivables	$ 55	$ 80
Sundry receivables	73	68
Non-income based tax receivables	26	28
Allowance for credit losses	(30)	(31)
Total long-term receivables – net	$ 124	$ 145

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Recurring - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Assets:
Investment securities	$ 31	$ 21
Derivatives	128	66
Liabilities:
Deferred compensation	269	64
Derivatives	269	209
Contingent consideration	44	42
Level 1
Assets:
Investment securities	31	21
Derivatives	0	0
Liabilities:
Deferred compensation	264	62
Derivatives	0	0
Contingent consideration	0	0
Level 2
Assets:
Investment securities	0	0
Derivatives	128	66
Liabilities:
Deferred compensation	5	2
Derivatives	269	203
Contingent consideration	0	0
Level 3
Assets:
Investment securities	0	0
Derivatives	0	0
Liabilities:
Deferred compensation	0	0
Derivatives	0	6
Contingent consideration	$ 44	$ 42

SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Long-Lived Assets by Geographic Areas (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets – net	$ 2,500	$ 2,314
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets – net	913	860
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets – net	391	393
Norway
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets – net	286	249
All other countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets – net	$ 910	$ 812

INCOME TAXES

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Abstract]

INCOME TAXES

The Company is subject to income taxes in the U.S. (both federal and state) and in numerous foreign jurisdictions. Changes in the tax laws or regulations in these jurisdictions, or in positions by the relevant authorities regarding their application, administration, or interpretation, may affect our tax liability, return on investments, and business operations.

The Tax Cuts and Jobs Act imposes tax on U.S. shareholders for global intangible low-taxed income (“GILTI”) earned by certain non-U.S. subsidiaries. The Company has elected to account for GILTI as a period cost.


Income Before Income Taxes
	For the years ended December 31
	2023		2022		2021
U.S. income	$	816	$	1,090	$	1,587
Non-U.S. income	1,545		1,422		1,288
Total	$	2,361	$	2,512	$	2,875


Provision for Income Taxes
	For the years ended December 31
	2023		2022		2021
Current
U.S. Federal	$	171	$	396	$	141
Non – U.S.	345		324		422
U.S. State	42		97		55
Deferred
U.S. Federal	—		(213)		82
Non – U.S.	103		7		(101)
U.S. State	82		(48)		1
Total	$	743	$	563	$	600


Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate
	For the years ended December 31
	2023		2022		2021
Income before taxes	$	2,361	$	2,512	$	2,875
Tax expected at 21%	496		528		604
Foreign operations	63		43		(54)
Withholding taxes	28		4		11
U.S. tax on foreign operations	(35)		(36)		(23)
Uncertain tax positions	11		6		11
R&D benefits	(33)		(33)		(32)
State taxes, net of federal benefit	24		39		45
Valuation allowance	19		8		33
Spin-Off and separation costs	184		—		—
Other	(14)		4		5
Provision for income taxes	$	743	$	563	$	600
Actual income tax rate	31.5%		22.4%		20.9%

UNRECOGNIZED TAX BENEFITS.

The Company is subject to periodic tax audits by tax authorities in the U.S. (both federal and state) and the numerous countries in which we operate. In 2021, the Company settled with tax authorities in certain foreign jurisdictions. While the Company currently is being audited in a number of jurisdictions for tax years 2004-2022, including China, Germany, Norway, the United Kingdom, and the United States, we believe that there are no jurisdictions in which the ultimate outcome of unresolved issues or claims is likely to be material to the results of operations, financial position, or cash flows. We believe that we have made adequate provisions for all unrecognized tax benefits.

UNRECOGNIZED TAX BENEFITS RECONCILIATION.

The balance of unrecognized tax benefits, the amount of related interest and penalties, and what we believe to be the range of reasonably possible changes in the next 12 months are as follows.


	2023		2022		2021
Balance at beginning of period	$	465	$	365	$	684
Additions for tax positions of the current year	—		9		9
Additions for tax positions of prior years	156		137		14
Reductions for tax positions of prior years	(203)		(41)		(78)
Settlements with tax authorities	(6)		(1)		(262)
Expiration of the statute of limitations	(3)		(4)		(2)
Balance at end of period	$	409	$	465	$	365

During the year ended December 31, 2023, $134 million of unrecognized tax benefits were contributed to the Company by GE as a part of the opening balance sheet adjustments, and are included in the Additions for tax positions of the prior years line in the table above. Also during the year ended December 31, 2023, a matter was closed with local tax authorities which resulted in the reversal of a net operating loss deferred tax asset and the related $183 million unrecognized tax benefit, which is included in the Reductions for tax positions of prior years line above. During the year ended December 31, 2022, $132 million of unrecognized tax benefits were contributed to the Company by GE, which are included in the Combined Statement of Financial Position as of December 31, 2022, and are included in the Additions for tax positions of prior years line in the table above.


Unrecognized Tax Benefits
	For the years ended December 31
	2023		2022		2021
Unrecognized tax benefits	$	409	$	465	$	365
Accrued interest on unrecognized tax benefits	72		56		53
Reasonably possible reduction to the balance of unrecognized tax benefits in succeeding 12 months	29		45		36
Portion that, if recognized, would reduce tax expense and effective tax rate	157		153		111

In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions from within Interest and other financial charges – net to within Benefit (provision) for income taxes. See Note 2, “Summary of Significant Accounting Policies” for further information. For the year ended December 31, 2023, $12 million of interest expense on uncertain tax positions was recorded in Benefit (provision) for income taxes and for the years ended December 31, 2022, and 2021, $12 million and $9 million of interest expense on uncertain tax positions were recorded in Interest and other financial charges – net, respectively, in the Consolidated and Combined Statements of Income. For the year ended December 31, 2023, $6 million of income tax penalties was recorded in (Benefit) provision for income taxes in the Consolidated Statement of Income. No accrual for penalties was made in the years ended December 31, 2022 or 2021.

DEFERRED INCOME TAXES.

We regularly evaluate the recoverability of our deferred tax assets and establish a valuation allowance, if necessary, to reduce the deferred tax assets to an amount that is more likely than not to be realized (a likelihood of more than 50%). Significant judgment is required in determining whether a valuation allowance is necessary and the amount of such valuation allowance. In assessing the recoverability of our deferred tax assets at December 31, 2023, we considered all available evidence, including the nature of financial statement losses, reversing taxable temporary differences, estimated future operating profits, and tax planning actions and strategies.


Deferred Income Taxes
	As of
	December 31, 2023		December 31, 2022
Total assets	$	4,474	$	1,550
Total liabilities	(68)		(370)
Net deferred income tax asset (liability)	$	4,406	$	1,180


Components of the Net Deferred Income Tax Asset (Liability)
	As of
	December 31, 2023		December 31, 2022
Deferred tax assets:
Employee benefits	$	1,418	$	222
Contract liabilities	171		193
Inventories	95		84
Operating loss carryforwards	648		176
Other accrued expenses	68		70
Receivables	45		42
Lease liabilities	75		57
Tax credit carryforwards	59		128
Contract assets	79		99
U.S. interest restriction carryforwards	61		—
Goodwill and other intangible assets	1,461		—
Property, plant, and equipment	261		338
Capitalized R&D	547		554
Other	8		—
Total deferred income tax asset	4,996		1,963
Valuation allowances	(540)		(272)
Total deferred income tax asset after valuation allowance	4,456		1,691
Deferred tax liabilities:
Goodwill and other intangible assets	—		(458)
ROU assets	(50)		(47)
Other	—		(6)
Total deferred income tax liability	(50)		(511)
Net deferred income tax asset (liability)	$	4,406	$	1,180

Effective January 1, 2022, U.S. taxpayers are required to capitalize certain R&D expenses and amortize them over five or fifteen years pursuant to the Internal Revenue Code of 1986, as amended. This provision increased our taxable income for the years ended December 31, 2023 and 2022, and resulted in additional cash payments for U.S. federal and state income taxes. A deferred tax asset on 2023 R&D expenses was recorded related to this provision with a balance of $267 million as of December 31, 2023. A deferred tax asset on 2022 R&D expenses was recorded related to this provision with a balance of $197 million and $293 million as of December 31, 2023 and 2022, respectively. In the event the capitalization of research costs is adjusted through retroactive legislation effective for 2022, the Company expects to record a reduction to the 2022 deferred tax asset resulting in a charge to tax expense under the Tax Matters Agreement with GE.

In connection with the Spin-Off, certain deferred income taxes were contributed to the Company by GE. During 2022, a net deferred income tax asset of $80 million was contributed to the Company by GE and are recognized within Deferred income taxes in the Combined Statement of Financial Position as of December 31, 2022.

Also, in connection with the Spin-Off, our net deferred income tax assets increased by $3,099 million primarily due to transfers from GE, including $964 million related to pension and postretirement benefits, with the remainder primarily attributable to tax attributes that were not part of the Company’s stand-alone operations, and changes to valuation on a GE HealthCare basis.


Valuation Allowances

Balance at December 31, 2020	$	250
Provision for income taxes	39
Foreign currency exchange and other	(10)
Balance at December 31, 2021	$	279
Provision for income taxes	(5)
Foreign currency exchange and other	(2)
Balance at December 31, 2022	$	272
Provision for income taxes	(12)
Foreign currency exchange and other	280
Balance at December 31, 2023	$	540

As a result of the Spin-Off, there was an increase in the valuation allowance of $269 million, which is included in the Foreign currency exchange and other line of the table above.

NET OPERATING LOSSES.

As a result of the Spin-Off, there was an increase in the net operating loss deferred tax asset of $1,075 million. As of December 31, 2023, the Company had net operating loss carryforwards of $6,526 million primarily related to France, Ireland, Brazil, Germany, and the Netherlands, which can be carried forward indefinitely. The gross net operating loss carryforwards resulted in a deferred tax asset of $1,241 million as of December 31, 2023. This amount excludes accruals of $149 million for unrecognized tax benefits the Company has recorded related to the underlying tax positions which generated the net operating losses and expected impacts to U.S. foreign tax credits of $444 million.

UNDISTRIBUTED EARNINGS.

Post Spin-Off, the Company’s previously undistributed earnings of certain of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, in 2023, an incremental deferred tax liability of $21 million was recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings. However, the Company generally considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon an unforeseen future reversal (e.g., capital gain distribution or disposition to an unrelated third party) of approximately $7,729 million to be permanent in duration. Quantification of the deferred tax liability, if any, associated with indefinitely reinvested basis differences is not practicable.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

SEGMENT AND GEOGRAPHICAL INFORMATION - Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 19,552	$ 18,341	$ 17,585
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	8,228	7,819	7,060
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	2,560	2,325	2,510
All other countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 8,764	$ 8,197	$ 8,015

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

LEASES (Tables)

12 Months Ended

Dec. 31, 2023

Leases [Abstract]

Schedule of Operating Lease Assets and Liabilities

Our operating lease liabilities are recognized within All other current liabilities and All other liabilities in the Consolidated and Combined Statements of Financial Position, as detailed below.


Operating Lease Assets and Liabilities
	As of
	December 31, 2023		December 31, 2022
Operating lease ROU assets	$	356	$	313
Current operating lease liabilities	110		104
Non-current operating lease liabilities	273		243
Total operating lease liabilities	$	383	$	347

Schedule of Lease Expense and Supplemental Information


Operating Lease Expense
	For the years ended December 31
	2023		2022		2021
Long-term (fixed)	$	121	$	115	$	114
Long-term (variable)	106		98		67
Short-term	2		4		4
Total operating lease expense	$	229	$	217	$	185


Supplemental Information Related to Operating Leases
	For the years ended December 31
	2023			2022			2021
Operating cash flows used for operating leases	$	130		$	113		$	128
Right-of-use assets obtained in exchange for new lease liabilities	154			98			94
Weighted-average remaining lease term (in years)	4.7			4.4			4.7
Weighted-average discount rate	4.4		%	3.8		%	3.3		%

Schedule of Maturity of Lease Liabilities


Maturity of Lease Liabilities
	2024		2025		2026		2027		2028		Thereafter		Total
Undiscounted lease payments	$	124	$	100	$	79	$	48	$	23	$	52	$	426
Less: imputed interest													43
Total lease liability as of December 31, 2023													$	383

Schedule of Net Investment in Financing Leases


Net Investment in Financing Leases
	As of
	December 31, 2023		December 31, 2022
Total minimum lease payments receivable	$	236	$	248
Less: deferred income	(30)		(30)
Discounted lease receivable	206		218
Estimated unguaranteed residual value of leased assets, net of deferred income	11		12
Investment in financing leases, net of deferred income	$	217	$	230

Schedule of Contractual Maturities


Contractual Maturities

Due In	2024		2025		2026		2027		2028		Thereafter		Total
Net minimum lease payments receivable	$	80	$	61	$	41	$	25	$	15	$	14	$	236

FINANCING RECEIVABLES - Schedule of Financing Receivable (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses, current	$ (3)	$ (4)
Current financing receivables, net	97	97
Allowance for credit losses, noncurrent	(5)	(6)
Non-current financing receivables, net	178	196
Loans, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	29	29
Non-current financing receivables, gross	37	44
Investment in financing leases, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	71	72
Non-current financing receivables, gross	$ 146	$ 158

LEASES - Supplemental Information Related to Operating Leases (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating cash flows used for operating leases	$ 130	$ 113	$ 128
Right-of-use assets obtained in exchange for new lease liabilities	$ 154	$ 98	$ 94
Weighted-average remaining lease term (in years)	4 years 8 months 12 days	4 years 4 months 24 days	4 years 8 months 12 days
Weighted-average discount rate	4.40%	3.80%	3.30%

RECEIVABLES (Tables)

12 Months Ended

Dec. 31, 2023

Receivables [Abstract]

Schedule of Receivables


Current Receivables
	As of
	December 31, 2023		December 31, 2022
Current customer receivables(1)	$	3,339	$	3,112
Non-income based tax receivables	166		174
Other sundry receivables	118		100
Sundry receivables	284		274
Allowance for credit losses	(98)		(91)
Total current receivables – net	$	3,525	$	3,295


Long-Term Receivables
	As of
	December 31, 2023		December 31, 2022
Long-term customer receivables	$	55	$	80
Sundry receivables	73		68
Non-income based tax receivables	26		28

Allowance for credit losses(1)	(30)		(31)
Total long-term receivables – net(2)	$	124	$	145

(1) Write-offs of long-term receivables were not material for the years ended December 31, 2023 and 2022.

(2) Long-term receivables are recognized within All other assets in the Consolidated and Combined Statements of Financial Position.


Financing Receivables
	As of
	December 31, 2023		December 31, 2022
Loans, net of deferred income	$	29	$	29
Investment in financing leases, net of deferred income	71		72
Allowance for credit losses	(3)		(4)
Current financing receivables – net(1)	97		97
Loans, net of deferred income	37		44
Investment in financing leases, net of deferred income	146		158
Allowance for credit losses	(5)		(6)
Non-current financing receivables – net(1)	$	178	$	196

Schedule of Allowance for Credit Losses Related to Current Receivables

Activity in the allowance for credit losses related to current receivables for the years ended December 31, 2023, 2022, and 2021 consisted of the following:


Balance at December 31, 2020	$	93
Additions charged to costs and expenses	12
Write-offs	(10)
Foreign currency exchange and other	12
Balance at December 31, 2021	107
Additions charged to costs and expenses	2
Write-offs	(13)
Foreign currency exchange and other	(5)
Balance at December 31, 2022	91
Additions charged to costs and expenses	16
Write-offs	(11)
Foreign currency exchange and other	2
Balance at December 31, 2023	$	98

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Derivative [Line Items]
Cash flow hedge loss to be reclassified within 12 months	$ 21
Derivative, potential effect of rights of offset to assets and liabilities	41
Benefit from fair value adjustment of contingent consideration	17	$ 65	$ 0
Estimated fair value
Derivative [Line Items]
Borrowings	9,959	8,521
Carrying value
Derivative [Line Items]
Borrowings	$ 9,442	$ 8,249
Cash flow hedges
Derivative [Line Items]
Derivative, contract term	2 years
Derivative, remaining maturity	12 months
Net investment hedges
Derivative [Line Items]
Derivative, contract term	5 years
Derivative, remaining maturity	52 months

LEASES - Schedule of Maturity of Finance Leases (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
2024	$ 80
2025	61
2026	41
2027	25
2028	15
Thereafter	14
Total	$ 236	$ 248

BORROWINGS - Narrative (Details)		3 Months Ended	12 Months Ended
BORROWINGS - Narrative (Details)	Jan. 03, 2023 USD ($)	Dec. 31, 2023 USD ($) series	Dec. 31, 2023 USD ($) series	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Interest expense, long-term debt			$ 616,000,000	$ 54,000,000
Weighted average interest rate			6.03%	5.97%
Guarantor obligations, maximum exposure		$ 114,000,000	$ 114,000,000
Guarantee obligation, carrying value		4,000,000	4,000,000	$ 4,000,000
Commercial contracts
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure		751,000,000	751,000,000	657,000,000
Equipment residual value obligation
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure		39,000,000	39,000,000	43,000,000
Senior notes \| Senior unsecured notes
Debt Instrument [Line Items]
Debt, principal amount		$ 8,250,000,000	$ 8,250,000,000
Number of debt series \| series		6	6
Debt repurchase price, percentage			101.00%
Debt repayments			$ 0
Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Line of credit outstanding		$ 0	$ 0	$ 0
Line of credit \| Revolving credit facility \| 5-Year Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term			5 years
Maximum borrowing capacity		2,500,000,000	$ 2,500,000,000
Line of credit \| Revolving credit facility \| 364-Day Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term			364 days
Maximum borrowing capacity		1,000,000,000	$ 1,000,000,000
Line of credit \| Unsecured debt \| Floating rate Term Loan Facility due January 2, 2026
Debt Instrument [Line Items]
Debt, term			3 years
Maximum borrowing capacity		2,000,000,000	$ 2,000,000,000
Proceeds from lines of credit	$ 2,000,000,000
Debt repayments		$ 850,000,000

RELATED PARTIES - Schedule of Related Party Transactions (Details) - Majority shareholder - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Costs for centralized services
Related Party Transaction [Line Items]
Transaction amount	$ 42	$ 56
Costs associated with employee medical insurance
Related Party Transaction [Line Items]
Transaction amount	122	132
Costs for corporate and shared services
Related Party Transaction [Line Items]
Transaction amount	$ 457	$ 455

SHARE-BASED COMPENSATION - Narrative (Details) shares in Millions	12 Months Ended
	Dec. 31, 2023 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized for issuance	41
Stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period	10 years
Stock options \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Stock options \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years 6 months
RSUs \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
RSUs \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years 6 months
PSUs \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
PSUs \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years 6 months

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

REVENUE RECOGNITION - Summary of Contract and Other Deferred Assets (Details) - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Contract assets	$ 600	$ 584
Other deferred assets	400	405
Contract and other deferred assets	1,000	989
Non-current contract assets	72	37
Non-current other deferred assets	96	82
Total contract and other deferred assets	$ 1,168	$ 1,108

REVENUE RECOGNITION (Tables)

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Abstract]

Summary of Contract and Other Deferred Assets


Contract and Other Deferred Assets
	As of
	December 31, 2023		December 31, 2022
Contract assets	$	600	$	584
Other deferred assets	400		405
Contract and other deferred assets	1,000		989
Non-current contract assets(1)	72		37
Non-current other deferred assets(1)	96		82
Total contract and other deferred assets	$	1,168	$	1,108

(1)Non-current contract and other deferred assets are recognized within All other assets in the Consolidated and Combined Statements of Financial Position.

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES (Tables)

12 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Schedule of Product Warranties

An analysis of changes in the liability for product warranties follows.


Product Warranties
	For the years ended December 31
	2023		2022		2021
Balance at beginning of period	$	193	$	161	$	157
Current-year provisions	216		238		228
Expenditures	(218)		(199)		(221)
Other changes	1		(7)		(3)
Balance at end of period	$	192	$	193	$	161

Schedule of Unrecognized Contractual Obligations


Other Unrecognized Contractual Obligations
	2024		2025		2026		2027		2028		Thereafter		Total
Other Unrecognized Contractual Obligations	$	308	$	195	$	142	$	79	$	72	$	79	$	875

POSTRETIREMENT BENEFIT PLANS - Composition of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2023	Jan. 01, 2023	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets		$ 18,908
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets		$ 18,908
Pension Plans \| Principal Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	$ 14,700		$ 0
Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	14,700
Pension Plans \| Other Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	4,518		382
Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	4,518		425
Level 1 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	1,820
Level 1 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	290		60
Level 2 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	6,318
Level 2 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	2,205		157
Level 3 \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	626		61
Level 3 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	595
Level 3 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	31		61
Net Asset Value \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	5,967
Net Asset Value \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	1,992		147
Global equity securities \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	2,609
Global equity securities \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	467		67
Global equity securities \| Level 1 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	954
Global equity securities \| Level 1 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	51		33
Global equity securities \| Level 2 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	0
Global equity securities \| Level 2 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	1		0
Global equity securities \| Level 3 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	0
Global equity securities \| Level 3 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	0		0
Global equity securities \| Net Asset Value \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	1,655
Global equity securities \| Net Asset Value \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	415		34
Debt securities (including cash and cash equivalents) \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	8,121
Debt securities (including cash and cash equivalents) \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	2,977		205
Debt securities (including cash and cash equivalents) \| Level 1 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	866
Debt securities (including cash and cash equivalents) \| Level 1 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	239		24
Debt securities (including cash and cash equivalents) \| Level 2 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	6,309
Debt securities (including cash and cash equivalents) \| Level 2 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	2,203		150
Debt securities (including cash and cash equivalents) \| Level 3 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	0
Debt securities (including cash and cash equivalents) \| Level 3 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	0		0
Debt securities (including cash and cash equivalents) \| Net Asset Value \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	946
Debt securities (including cash and cash equivalents) \| Net Asset Value \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	535		31
Real estate \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	912
Real estate \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	508		25
Real estate \| Level 1 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	0
Real estate \| Level 1 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	0		0
Real estate \| Level 2 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	0
Real estate \| Level 2 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	0		0
Real estate \| Level 3 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	382
Real estate \| Level 3 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	20		12
Real estate \| Net Asset Value \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	530
Real estate \| Net Asset Value \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	488		13
Private equities and other investments \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	3,058
Private equities and other investments \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	566		128
Private equities and other investments \| Level 1 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	0
Private equities and other investments \| Level 1 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	0		3
Private equities and other investments \| Level 2 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	9
Private equities and other investments \| Level 2 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	1		7
Private equities and other investments \| Level 3 \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	213
Private equities and other investments \| Level 3 \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	11		49
Private equities and other investments \| Net Asset Value \| Pension Plans \| Principal Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	2,836
Private equities and other investments \| Net Asset Value \| Pension Plans \| Other Pension Plans \| Recurring
Defined Benefit Plan Disclosure [Line Items]
Fair value of assets	$ 554		$ 69